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ABSTRACT 
 
Research on self-assembling gemini surfactants and other amphiphiles for potential 
gene delivery applications in research as well as in clinical practice, and as alternatives 
to viral gene delivery vectors, is beginning to focus more on ‘structure–activity 
relationships’ to address the current low gene delivery efficiencies of amphiphiles. Some 
underlying structure–activity relations are beginning to emerge. But, as a better 
understanding of the factors that govern the transfection abilities of amphiphile 
molecules emerges, development of improved non-viral vectors with clinical potential 
may also emerge. 
The research conducted for this thesis was aimed at the design, synthesis and in 
vitro investigation of gemini surfactants as one of a family of novel amphiphiles being 
investigated for gene therapeutic applications. The properties of these compounds can be 
controlled as well as allowed to vary naturally. Gemini surfactant-based gene delivery 
systems were prepared and characterized for transfer of Luciferase plasmid 
(pMASIA.Luc) to both COS-7 and PAM 212 cells. Characterization was accomplished 
using microscopy, dynamic light scattering (DLS) and zeta (ζ) potential analysis. In vitro 
gene expression and toxicities were evaluated in COS-7 cell and PAM 212 keratinocyte 
cultures. 
The level of in vitro transfection in general was found to correlate strongly with the 
structure of the gemini surfactants. Among the 12-spacer-12 surfactants, incorporation 
of a pH-sensitive aza (N-CH3) group, which is also steric hindrance-imposing, in the 
spacer chain yielded increased transfection, particularly for the 12-7N-12 surfactant. In 
 iii
comparison, the incorporation of the more pH-sensitive imino (N-H) group in the 12-
7NH-12 surfactant yielded the highest increase in transfection among the 12-spacer-12 
surfactants. The deleterious effect of steric hindrance due to the aza group is more 
evident when comparing the transfection efficiency of 12-5N-12 (1 × aza, higher) vs. 12-
8N-12 (2 × aza, lower transfection). Another highlighted structural feature is provided 
by the fact that both the 12-7NH-12 and 12-7N-12 surfactants had higher transfection 
efficiencies than 12-5N-12 and 12-8N-12 surfactants; the first pair has trimethylene 
spacing, which constitutes an optimal separation between nitrogen centres, while the 
second pair has shorter dimethylene spacings. 
After expanding the structure of surfactants, transfection efficiencies were found to 
increase in response to increase in hydrocarbon tail length, but were much lower for 
surfactants with no amino functional groups, those that lacked the optimal trimethylene 
spacing, or those having both of these limitations in the gemini surfactant spacer. The 
18-7NH-18 surfactant had the highest overall transfection in both COS-7 and PAM 212 
cells. Gemini surfactant-based gene delivery systems capable of adopting both 
polymorphic structural phases and which could undergo pH-induced structural transition 
demonstrated high transfection efficiencies. Gemini surfactants with both characteristics 
(e.g., 12-7NH-12-based complexes are both polymorphic and pH-sensitive) had higher 
transfection than gemini surfactants with only one (e.g., 12-3-12-based complexes are 
only polymorphic). 
Overall, the m-7NH-m surfactants, the most efficient surfactants studied, had 
transfection efficiencies similar to that of the commercial Lipofectamine Plus™ reagent 
and imposed no higher toxicity on cells relative to the less efficient surfactants. Thus, 
the design of the m-7NH-m surfactants to enhance their transfection abilities also 
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ensured that their toxicity to cells were kept minimal. Overall, the design, synthesis and 
in vitro transfection screening of gemini surfactant candidates has revealed that the m-
7NH-m surfactants have the highest transfection efficiencies; they have emerged as 
suitable candidates for non-viral gene delivery in vivo or at higher levels. Gene delivery 
investigations for six of the gemini surfactant candidates are being reported for the first 
time.  
 
 
 v
ACKNOWLEDGEMENTS 
 
My appreciation is first to my supervisor, Dr. Marianna Foldvari, for her 
professional and moral support and guidance. By the same measure I also thank the 
members of my advisory committee, Drs. Ronald Verrall, Adil Nazarali and Jane 
Alcorn, for their guidance. Dr. Gordon McKay travelled to voluntarily chair my first two 
committee meetings, and I owe him much thanks. 
I thank Dr. Shawn Wettig from whose expertise I learnt the design and synthesis of 
gemini surfactants. He also provided other technical assistance, and was closely 
associated with my advisory committee, offering solid guidance. Colleagues of our 
research group, including Dr. Ildiko Badea (who currently conducts and manages her 
own research as a professor) and Mukasa Bagonluri, are also very much appreciated for 
their technical assistance. Martin Abu facilitated my settling in Saskatoon for these 
studies and I am highly appreciative of his support. 
The following institutions are duly recognized: Saskatchewan Structural Science 
Centre (Saskatoon, SK), Transmission Electron Microscopy Laboratory (College of 
Veterinary Medicine, Saskatoon, SK) and the National Synchrotron Light Source 
(Brookhaven National Laboratory, NY) for the use of instruments/equipment. The 
research was funded with grants from the Canadian Institutes of Health Research and the 
Natural Sciences and Engineering Research Council of Canada. The workspace and 
other facilities were also provided by the College of Pharmacy and Nutrition (University 
of Saskatchewan, Saskatoon, SK). 
 
 vi
DEDICATION 
 
To my wife and crony, Beata Kaatori, and my parents, who are my roots. 
 
 vii
TABLE OF CONTENTS 
PERMISSION TO USE ..................................................................................................i 
ABSTRACT.................................................................................................................. ii 
ACKNOWLEDGEMENTS ...........................................................................................v 
DEDICATION ..............................................................................................................vi 
TABLE OF CONTENTS............................................................................................ vii 
LIST OF TABLES .........................................................................................................x 
LIST OF FIGURES ......................................................................................................xi 
LIST OF ABBREVIATIONS.................................................................................... xiii 
1. INTRODUCTION........................................................................................................1 
1.1. Human Genes to Combat Diseases: an Overview ..................................................1 
1.2. Current Gene Therapy.............................................................................................2 
1.3. Gene Delivery and Transfection .............................................................................3 
1.3.1. Viral Gene Delivery Systems...........................................................................5 
1.3.2. Bacterial Gene Delivery Vectors .....................................................................6 
1.3.3. Non-viral Gene Delivery Vectors ....................................................................7 
1.3.4. Cellular Gene Delivery using Non-viral Vectors.............................................9 
1.4. Clinical Opportunities for Gene Therapy..............................................................12 
1.4.1. Gene Delivery via the Topical Route.............................................................13 
1.4.2. Keratinocyte Gene Delivery and Dermal Gene Therapy ...............................14 
1.4.3. DNA Vaccines for Genetic Immunization.....................................................17 
1.5. Genes and Biomaterials for Gene Therapy ...........................................................18 
1.5.1. DNA-based Therapeutic Materials ................................................................19 
1.5.2. Advantages of DNA-based Therapeutics.......................................................22 
1.5.3. Gemini Surfactants for Gene Delivery...........................................................23 
1.5.4. Condensation of DNA in Gene Delivery .......................................................27 
2. PURPOSE OF RESEARCH .....................................................................................30 
2.1. Current Perspectives on the Hurdle of Non-viral Gene Delivery .........................30 
2.2. Rationale for the Focus of this Research...............................................................31 
2.3. Hypotheses ............................................................................................................31 
2.4. Objective of Research ...........................................................................................32 
2.4.1. Specific Objectives ........................................................................................33 
2.5. Outline of Proposed Research...............................................................................33 
3. MATERIALS AND METHODS ..............................................................................36 
3.1. Gemini Surfactants................................................................................................36 
3.1.1. Synthesis ........................................................................................................37 
3.1.2. Gemini Surfactants Prepared – The Library ..................................................40 
3.1.3. Determination of Krafft Temperatures...........................................................42 
3.1.4. Surface Tension Measurements .....................................................................42 
3.1.5. Specific Conductivity Measurements ............................................................43 
3.2. Characterization: Gemini Surfactant-based Transfection Systems.......................43 
 viii
3.2.1. Gemini Surfactant, Lipid Vesicles and Plasmid Solutions ............................44 
3.2.2. Determination of pKa Values .........................................................................44 
3.2.3. Measurement of Particle Sizes .......................................................................45 
3.2.4. Measurement of Zeta Potential ......................................................................45 
3.2.5. Physical State of Transfection Systems by TEM...........................................46 
3.3. Cell Preparation and Transfection.........................................................................46 
3.3.1. Cell Preparation..............................................................................................46 
3.3.2. PAM 212 Cell Ultrastructural Study by TEM ...............................................47 
3.3.3. Transfection Mixture Preparation ..................................................................48 
3.3.4. Transfection and Quantitation of Protein Expression ....................................48 
3.3.5. Determination of Transfected Cell Viabilities ...............................................51 
3.4. Statistics ................................................................................................................52 
4. RESULTS ...................................................................................................................53 
4.1. Analytical Confirmation of the Synthesized Gemini Surfactants .........................53 
4.2. Characteristics of the Gemini Surfactants.............................................................53 
4.2.1. Gemini Surfactant Krafft Temperatures.........................................................53 
4.2.2. Surface Tension Analysis...............................................................................57 
4.2.3. Specific Conductivity Analysis......................................................................62 
4.2.4. pKa Values of the Amine-substituted Gemini Surfactants .............................67 
4.3. Characteristics of Gemini Surfactant/DNA Transfection Systems.......................69 
4.3.1. Particle Size....................................................................................................69 
4.3.2. Zeta Potential Analysis ..................................................................................78 
4.3.3. Physical State of Transfection Complexes.....................................................81 
4.4. Ultrastructural Examination of PAM 212 Cells....................................................84 
4.5. Evaluation of Gene Expression.............................................................................86 
4.5.1. Transfection with 12-spacer-12 Gemini Surfactants......................................86 
4.5.2. Advanced Multi-surfactant Series Transfections ...........................................89 
4.5.2.1. Transgene Expression: Effect of Time....................................................90 
4.5.2.2. Transgene Expression: Effect of +/- Charge Ratio .................................92 
4.5.2.3. Transgene Expression: Effect of Gemini Surfactant Structure ...............95 
4.5.2.4. DNA Transfection: COS-7 vs. PAM 212 Cells ....................................103 
4.5.3. Evaluation of Transfection-related Toxicological Effects ...........................105 
5. DISCUSSION ...........................................................................................................111 
5.1. Design Scheme and Properties of the Gemini Surfactants .................................111 
5.2. Transfection Abilities of the 12-spacer-12 Surfactants.......................................119 
5.3. Transfection with Multi-series Gemini Surfactants ............................................127 
5.3.1. The Gemini Surfactant Series and Structures ..............................................127 
5.3.2. Structure – Activity Relationship.................................................................128 
5.4. Transfection Complexes: Particle Characteristics vs. Transfection....................133 
5.5. Non-Transfectant-related Factors Affecting Transfection..................................137 
5.6. Toxicological Evaluation ....................................................................................139 
5.7. Concluding Remarks...........................................................................................141 
5.7.1. Important Structural Features Emerging from Transfection Studies ...........142 
5.7.2. Morphology of Transfection Complexes or Nanoparticles..........................142 
5.7.3. Toxicological Effects ...................................................................................143 
 ix
5.7.4. Future Directions of Research......................................................................143 
6. REFERENCES.........................................................................................................146 
7. APPENICES .............................................................................................................172 
 
 
 
 x
LIST OF TABLES 
 
Table 3.1.2-1.  Structure of the gemini surfactant candidates .........................................41 
Table 4.2.1-1. Krafft temperatures (TKraftt) for the gemini surfactants............................56 
Table 4.2.2-1. Critical micelle concentration (CMC) and head group area (a0) of the 
gemini surfactants determined from surface tension measurements........................61 
Table 4.2.3-1.  Critical micelle concentration (CMC) and degree of micelle ionization 
(α) of the gemini surfactants determined from specific conductivity. .....................66 
Table 4.2.4-1.  pKa values of amine-substituted gemini surfactants ...............................68 
Table 5.1-1. Distance between nitrogen centres for the gemini surfactants..................117 
Table 5.2-1. Transfection and cell viability levels for the 12-spacer-12 surfactants ....120 
Table 5.2-2. Membrane charge densities (σM), scattering peak positions (q) and d-
spacing for the plasmid–gemini surfactant–DOPE nanoparticles (complexes) 
obtained from SAXS measurements (all previously published [272; 273]). .........125 
Table A-I: CH&N elemental analysis results for the gemini surfactants .....................172 
Table A-II: 1H NMR data for the gemini surfactants ...................................................174 
Table A-III: Electrospray ionization mass spectroscopic (ESI-MS) data for the gemini 
surfactants ..............................................................................................................177 
Table B-I: Conductance vs. temperature data; TKrafft determination .........................180 
Table B-II: Specific conductance (κ) vs. concentrtion data; CMC determination .......184 
Table C: Log C vs. surface tension (γ) data; CMC determination................................187 
 xi
LIST OF FIGURES 
 
Figure 1.3.4-1. Model summary of cellular delivery of DNA with surfactant vectors....10 
Figure 1.5.1-1. Structure of DNA. ...................................................................................21 
Figure 1.5.3-1. General structural schemes of gemini surfactants. ..................................25 
Figure 3.1.1-1. Outline of synthetic process for the target gemini surfactants. ...............39 
Figure 3.3.4-1. The luciferase reaction. ...........................................................................50 
Figure 4.2.1-1. Determination of Krafft temperature for the gemini surfactants.............55 
Figure 4.2.2-1. Surface tension vs. log C plots for the gemini surfactants. .....................58 
Figure 4.2.3-1. Specific conductance vs. concentration plots for the gemini surfactants.
..................................................................................................................................65 
Figure 4.3.1-1. pH dependence of the size of gemini surfactant aggregates formed in 
aqueous solution.......................................................................................................72 
Figure 4.3.1-2. pH dependence of the size of transfection complexes formed from 
gemini surfactant–plasmid–DOPE mixtures............................................................76 
Figure 4.3.2-1. Effect of pH on the zeta potential of transfection complexes formed from 
gemini surfactant–plasmid–DOPE mixtures............................................................80 
Figure 4.3.3-1. Transmission electron micrographs showing complexes derived from 
plasmid–gemini surfactant–lipid mixtures...............................................................83 
Figure 4.4-1. Transmission electron micrographs of PAM 212 cells ..............................85 
Figure 4.5.1-1. Transfection efficiency and cytotoxicity results in COS-7 cells.............88 
Figure 4.5.2.1-1. Luciferase reporter gene expression in PAM 212 cells measured as a 
function of post-transfection duration......................................................................91 
Figure 4.5.2.2-1. Luciferase reporter gene expression in PAM 212 cells measured as a 
function of the gemini surfactant:DNA charge ratio (i.e., the +/− charge ratio). ....94 
Figure 4.5.2.3-1. Transfection efficiencies in PAM 212 cells transfected with PGL 
complexes prepared from gemini surfactants belonging to three different series. ..98 
Figure 4.5.2.3-2. Transfection efficiencies in PAM 212 cell – comparison of underlying 
surfactant structures. ..............................................................................................102 
 xii
Figure 4.5.2.4-1. Comparison of gemini surfactant-mediated transfection in COS-7 and 
PAM 212 cells for m-3-m, m-7-m and m-7NH-m surfactants. .............................104 
Figure 4.5.3-1. Comparison of cell viabilities in COS-7 and PAM 212 cells transfected 
using m-3-m, m-7-m and m-7NH-m surfactants. ..................................................107 
Figure 4.5.3-2. Dose-dependent toxicities for gemini surfactants in PAM 212 cells. ...109 
Figure 5.4-1. Illustration of the proposed ‘endosomal release or escape’ of complexed 
DNA during cellular transfection with pH-sensitive gene delivery molecules......135 
Figure 5.7.4-1. Schematic difference between m-(NH)X+1-m (left) and peptide-based 
(right) gemini surfactants. ......................................................................................144 
Figure D-I. Luciferase reporter gene expression in COS-7 cells measured as a function 
of the gemini surfactant:DNA charge ratio (i.e., the +/− charge ratio)..................189 
Figure D-2. Dose-dependent toxicities for gemini surfactants in COS-7 cells..............190 
 
 xiii
LIST OF ABBREVIATIONS 
 
12-3-12 1,3-propanediyl-bis(dimethyldodecylammonium) dibromide 
12-7-12 1,7-heptanediyl-bis(dimethyldodecylammonium) dibromide 
12-5N-12 1,5-bis(dodecyl)-1,1,3,5,5-pentamethyl-3-aza-1,5-pentanediammonium 
dibromide 
12-7N-12 1,9-bis(dodecyl)-1,1,5,9,9-pentamethyl-5-aza-1,9-nonanediammonium 
dibromide 
12-8N-12 1,10-bis(dodecyl)-1,1,4,7,10,10-hexamethyl-4,7-diaza-1,10-dodecane-
diammonium dibromide 
12-7NH-12 1,9-bis(dodecyl)-1,1,9,9-tetramethyl-5-imino-1,9-nonanediammonium 
dibromide 
16-3-16 1,3-propanediyl-bis(dimethylhexadecylammonium) dibromide 
16-7-16 1,7-heptanediyl-bis(dimethylhexadecylammonium) dibromide 
16-7NH-16 1,9-bis(hexadecyl)-1,1,9,9-tetramethyl-5-imino-1,9-nonanediammonium 
dibromide 
18-3-18 1,3-propanediyl-bis(dimethyl-octadecylammonium) dibromide 
18:1-3-18:1 1,3-propanediyl-bis(dimethyl-cis-oleylammonium) dibromide 
18-7-18 1,7-heptanediyl-bis(dimethyl-octadecylammonium) dibromide 
18-7NH-18 1,9-bis(octadecyl)-1,1,9,9-tetramethyl-5-imino-1,9-nonanediammonium 
dibromide 
18:1-7NH-18:1 1,9-bis(cis-oleyl)-1,1,9,9-tetramethyl-5-imino-1,9-nonanediammonium 
  dibromide 
Ab   antibiotic-antimycotic 
AMP   adenosine monophosphate 
ATP   adenosine triphosphate 
bp   base-pair, in reference to DNA 
CH&N carbon, hydrogen and nitrogen 
CMC   critical micelle concentration 
CMV   cytomegalovirus 
CO2   carbon dioxide 
Dc-chol 3ß-[N-(N',N'-dimethylaminoethane)-carbamoyl]cholesterol hydrochloride 
oC   degrees Celcius 
DLS   dynamic light scattering 
DMEM Dulbecco's Modified Eagle's Medium 
DOGS  dioctadecyl amino glycyl spermine 
DOPE  1,2-Dioleyl-sn-glycerophosphatidylethanolamine  
DOSPA 2,3-dioleyloxy-N-[2(sperminecarboxyamido)ethyl]-N,N-dimethyl-1-
propaniminium bromide 
DOTMA N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride 
ESI-MS  electrospray ionization mass spectrometry 
GFP   green fluorescent protein 
FBS   fetal bovine serum 
HCl   hydrogen chloride 
IFN   interferon 
 xiv
keV   kilo electronvolts 
log C   logarithm of concentration, to base ten 
MEM  Minimum Essential Medium 
mL   millilitre 
mM   millimolar concentration 
μL   microlitre 
m-s-m  N,N’-bis(alkyldodecyl)-α,ω-alkanediammonium dirbromide surfactant, 
  with alkyl tail length = m and alkyl spacer length = s 
NaOH  sodium hydroxide 
nm   nanometre 
PEI   polyethylenimine 
%   percent 
PG   plasmid–gemini complex 
PGL   plasmid–gemini–DOPE system 
pKa   negative logarithm of the equilibrium constant (Ka) for an acidic species 
pMASIA.Luc plasmid containing the luciferase gene from firefly 
PPi   pyrophosphate 
RH   hydronamic radius, denoting particle size 
SAXS   small-angle X-ray scattering 
TEM  transmission electron microscopy 
UV   ultraviolet 
w/v   weight per volume 
XP   xeroderma pigmentosum 
 
 1
1. INTRODUCTION 
1.1. Human Genes to Combat Diseases: an Overview 
Since the first proof of principle of gene therapy, that is, a disease caused by a 
known genetic defect can be treated or cured by delivering the correct copy of a 
defective gene via a specially designed vector to directly correct the gene-related 
pathological condition [1], decades of research have focused on realizing the clinical 
treatment of genetic diseases [2]. Along with the treatment of genetic defects, the 
treatment of acquired diseases can be effected by provoking a disruptive effect on the 
disease pathophysiology by delivering a genetic material [3]. In another type of 
application, gene therapy or modification could also involve instituting the function of a 
required alien gene in a biological host regardless of whether or not the host is diseased. 
For instance, genetic immunization is based on the delivery of DNA encoding for a 
protein-antigen from a pathogen to healthy cells to induce both cell-mediated and 
humoral immune responses. The vectors for carrying genes to target cells might be used 
to deliver not only genes but also other nucleic acid agents (‘drugs’), such as antisense 
oligonucleotides or mRNA to diseased cells for therapeutic purpose [4]. The focus of 
research has mainly been (1) developing the drugs (nucleic acids), and (2) transferring 
developed drugs to diseased cells or tissues in patients via vectors. Available 
technologies for design and engineering of nucleic acids have made it possible for 
plasmids containing various transgenes [5] to be constructed and produced on a large 
 2
scale [6]. This has put to rest the question of availability of nucleic acid drugs. However, 
the latter question of delivery or transfer of therapeutic genes via vectors is still a 
technological hurdle [7]. Neither of the two early classes of vectors, viral (natural) and 
non-viral (synthetic) [2], can be considered as representing a perfect choice for nucleic 
acid delivery [8]. Various groups have within the past decade tested the ability of 
bacteria to transfer genes to mammalian cells (in vitro and in vivo) [9-14], and the recent 
report by Loessner et al [15] demonstrates the somewhat effective transfer of genes by  
bacterial vectors. Thus, a third category of vectors, bacterial gene delivery vectors (the 
latest) [16], has been named.   
1.2. Current Gene Therapy 
Following the success of the first clinical trial of human gene therapy in 1990 (at 
NIH, USA) in which a 4-year-old girl was treated for fetal severe combined 
immunodeficiency (SCID) caused by adenosine deaminase (ADA) deficiency, the way 
was opened for other potential genetic-level treatments. Treatment at the genetic level, 
which by implication eliminates the cause of the disease [17; 18], was earlier examined 
for such diseases as cystic fibrosis [19-21], haemophelia [22] and hypercholesterolemia 
[23]. But as the base of potential therapy widened other inclusions have been made, such 
as sickle cell anemia, hepatitis [24; 25], cardiovascular disorders, neurological disorders 
such as Parkinson’s disease and Alzheimer’s disease, cancer  and AIDS [5; 26; 27]. The 
recently approved first ever adenoviral gene therapy treatment, Gendicine (by SioBiono 
GeneTech, 2003, China), for the treatment of head and neck squamous cell carcinoma 
(HNSCC) is considered a ground-breaking success that could allow for the treatment of 
a wide-spectrum of cancers [5; 28; 29]. In September 2005, the State Food and Drug 
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Administration of China approved a second drug based on gene therapy, Endostar, for 
treatment of cancerous tumours in the lungs and other organs [30]. In addition to 
application to diseases, some gene therapy protocols have diversified into genetic 
immunization or DNA vaccines, heralded as the third vaccine revolution [31; 32]. 
Despite the promise of gene therapy, current difficulties in regards to safe and 
effective transfer of available nucleic acid drugs to mammalian cells, whether cytosolic 
delivery or the introduction of DNA into the cell nucleus (transfection) [33], has not 
allowed gene therapy to fully evolve as a new treatment or disease-prevention [34]. 
Among all the technologies generalized as non-viral (artificial) approaches, molecular 
carrier systems (synthetic) capable of self-assembling [35; 36] and DNA condensation 
[37], such as gemini surfactant-based systems, show promise as prime candidates for 
gene delivery [33]. They represent safer alternatives to viral vectors [33], which have 
sparked safety concerns and provoked an urgent search for safe, non-viral vectors for 
nucleic acid delivery [38; 39]. 
1.3. Gene Delivery and Transfection 
The susceptibility of DNA and other nucleic acids to nuclease degradation and the 
rather unmatched abundance of nucleases usually in the pathway of in vitro- or in vivo-
administered genes generally call for a delivery vector/system that will provide an initial 
packaging. The packaging vectors not only protect the genes through the delivery 
process [17], but also preserve the activity of the nucleic acid drugs [5]. In particular, 
when a transgene is proposed to arrive at the nucleus (transfection), the requirement of a 
delivery system for packaging is emphasized by the fact that the transport processes 
involved in transfection can be deleterious to naked or unpacked genes. The processes 
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leading to eventual nuclear entry are migration from entry port to target cells, 
internalization or entry of ‘drug’ into cells (through endocytosis [40], fusion or other 
possible means), endosomal escape of free or vector-associated genes, and, finally, 
migration from cytosol to the nucleus [5]. In cases where transgene progression can be 
realized for DNA released into the cytosol, its migration from the cytosol to the nucleus 
is not needed. A combination of such transport phases gives rise to a complex 
pharmacokinetic profile [41; 42] to which a significant amount of research is dedicated. 
Even in cases of successful migration to the nucleus, a large amount of the genetic 
‘drug’ is usually intercepted and degraded by cytoplasmic nucleases during migration to 
the nucleus [17]. 
Delivery systems also facilitate/mediate both cellular uptake and nuclear entry of 
therapeutic DNA, marking an improvement over naked DNA which, due to its large 
size, negative charge, and membrane barriers imposed by cells, shows weak cell entry 
[37]. In the absence of delivery systems naked DNA may show some amount of cellular 
internalization only after local administration, as seen after intramuscular, intratumoral 
or intradermal injections [43-45]. It is hoped that the ultimate development of gene 
delivery vectors that combine safety with high delivery efficiency will see the realization 
of full-scale clinical treatment and prevention of diseases [46; 47]. Non-viral vectors are 
attracting significant research interest [33; 48] mainly because they have better safety 
profiles than viruses [3; 18; 37; 49-51], which nonetheless, are the most encountered 
vectors in clinical trials because of their higher delivery efficiencies. Both viral and 
synthetic (non-viral) types of vectors currently suffer from disadvantages [3], as do the 
relatively new bacterial types [16], driving continued research on all these vector types. 
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1.3.1. Viral Gene Delivery Systems 
Until 1987, when a report of studies involving the use of amphiphile molecular 
carriers (cationic lipids in the specific case) to transfer genes into cells was first 
published by Felgner et al. [37], research into DNA transfection focused mainly on the 
use of viral vectors (engineered viruses). Viral vectors have been demonstrated to be the 
most effective vectors currently used for DNA transfection [33; 52-55], with 
adenoviruses giving better results as compared with retroviruses, poxviruses or herpes 
simplex viruses [26; 56-59]. Viruses possess a natural capability of infecting cells, with 
their specific biological “keys” (e.g., glycoproteins in a viral envelope [58]) allowing 
passage initially across the cell membrane, and then across the nuclear membrane (into 
the nucleus) via a speedy cytosolic passage along dynein-based active linear 
translocation microtubules. This achieves high gene expression in most of a transfected 
population of cells in vitro and opens a wide range of cell targets for viral delivery. 
However, several concerns with viral vectors have arisen. These include strong immune 
response in host cells due to viral proteins (preventing virus reuse), endogenous viral 
recombination, oncogenic effects, possible large-scale contamination of the engineered 
viruses and high cost of production [17; 34; 37; 43; 52; 60].  
Since the tragic death of an 18-year-old viral gene therapy research subject (in Sept 
1999, USA), who was being treated for partial ornithine transcarbamylase (OTC) 
deficiency [61], and the therapy-turned-setback situation in which two out of eleven 
children developed a blood disorder similar to leukemia following an adenoviral 
treatment against SCID by a French gene therapy team [39], viral gene therapy has come 
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under severe scrutiny, provoking a sense of urgency to search for safer alternatives to 
viral vectors [62]. 
1.3.2. Bacterial Gene Delivery Vectors 
Loessner et al.’s report of bacteria-mediated DNA transfer (for gene therapy and 
vaccination) [15] is one of the latest on the subject. Gene transfer from bacteria to 
mammalian cells [9-14], and even yeast [63] and plants [64], have been reported. 
Therapeutic benefits, such as vaccinations against infectious diseases, immunotherapy 
against cancer and topical delivery of immunomodulatory cytokines in inflammatory 
bowel disease, have been achieved via bacteria-mediated DNA transfer. Of the types of 
bacteria tested (human clinical trial) such as Salmonella [9; 12], Shigella [10] and 
Listeria [11], attenuated strain of the first affords tumour-targeted gene delivery, but also 
highlights potential problems including toxicity. For large-scale production, the 
observed limited colonization properties could imply the potential to cause low yields. In 
addition, questions about the mechanism of DNA transfer from bacteria to mammalian 
cells are yet to be settled: the first limiting step can occur at cell entry [16] or earlier. 
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1.3.3. Non-viral Gene Delivery Vectors 
The unpredictable immune response and inherent safety issues with the use of viral 
vectors have mainly necessitated non-viral vector development [65]. A number of 
physical techniques for introducing naked DNA into cells, including DNA co-
precipitation with calcium phosphate [66; 67], bioballistics (using gene gun) [68; 69], 
microinjection [70] and electroporation [71], have evolved in the search for non-viral 
means of gene delivery. Electroporation gene delivery is an approach in which DNA is 
driven across cell membranes by the application of controlled electric current. The above 
approaches have managed to show effectiveness in a few cases (in vitro), but the clinical 
application of, especially the last two, have been questioned [3]. Particularly for 
electroporation, which results in cell motility, there could be aggravated consequences 
due to voltage shoot up resulting from current control failure.  
The latest trend of non-viral vector development includes the use of supramolecular 
and macromolecular systems with positive charges. These include gemini surfactants 
[72-74], lipids [17; 37; 51; 75; 76], polyelectrolytes such as DEAE-dextran [77; 78], 
polyamine (or polyamidoamine) dendrimers [79; 80], polynorborane [81], and 
polyethyleneimine (PEI) [82]. Supramolecular systems of lipids or gemini surfactants 
(amphiphiles) are of particular interest because of their ability to self-assemble into 
vesicular structures, commonly described as liposomes [3]. Gemini surfactants in 
particular demonstrate advanced ability to self-assemble (form liposomes), a feature 
which is of primary importance for their application in gene therapy (packaging of DNA 
for cellular uptake). Molecular delivery systems (generally termed ‘lipofection agents’) 
have seen an increasing application in gene therapy clinical trials recently, accounting 
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for 18% of all trials in 2000 [83]. The number of individual trials involving lipofection 
agents has since more than doubled, even though this has not translated into a 
proportionate rise in the percentage of these trials relative to the total number of trials 
(compare refs [33; 83], [39], [84]). 
In principle, gemini surfactant-based gene delivery vectors are developed to 
circumvent the problems faced by viral vectors, which also includes low DNA carriage-
capacity. The vector design is targeted at forming particles that mimic virus-like 
infection behaviour, including cellular attachment and rapid internalization, followed by 
endosomal escape and nuclear localization, ultimately achieving high gene expression 
[85]. Impressive transfection efficiencies for a few tested gemini surfactants, with low 
toxicity in host cells (in vitro, transgene expressed in most transfected cells) have 
received major highlights in recent reviews [86]. Unlike viruses, amphiphile aggregates 
have virtually no limitation on the quantity of plasmid they can carry. While viral 
capsids have been able to contain 40,000 DNA base pairs at maximum [87], it has been 
possible for amphiphile aggregates to package multiple genes and regulatory sequences, 
ranging from hundreds of thousands of DNA base-pairs to one million base-pairs for 
cellular uptake [88; 89]. 
Gemini surfactants allow a broad range of modification of their structures, allowing 
for structural optimization of gemini surfactant candidates for gene delivery. This 
structural optimization is important in the formation of effective gemini surfactant-based 
gene delivery systems for transfer of DNA to cells. There is also the ease of large-scale 
manufacture of gemini surfactants or other non-viral molecular delivery agents, and the 
low cost compared with the propagative production of viral systems [90]. Emerging 
design of gemini based-gene delivery vectors demonstrates that the incorporation of 
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selected functional groups can be used to augment vector efficacy and provide targeted 
gene delivery to cells and tissues [33; 65]. Because of the need for safer alternatives to 
viral and bacterial vectors, and also because amphiphile molecules such as gemini 
surfactants form inherently safe vectors, a growing number of studies, including this 
research, are aimed at developing molecular vectors for gene delivery. 
1.3.4. Cellular Gene Delivery using Non-viral Vectors 
The mechanism of cellular gene delivery continues to be probed in an attempt to 
gain improved insight into the design of more efficient non-viral–DNA systems, 
(including those referred to as lipoplexes and polyplexes), which can interface with 
cellular processes to yield better transfection. For in vitro transfection, an established 
concentration of lipoplexes is added to cell cultures, followed by a duration of 
incubation of the cell–lipoplex mixture. The added lipoplexes can diffuse freely through 
the supernatant medium and become attached to cells and can be internalized by cells 
[40; 91]; in vitro transfection as a result is simpler. This is relative to in vivo delivery in 
which the broad range of interactions between lipoplexes and multiple cells types or 
molecules within a host organism can present several challenges [17]. In terms of in 
vitro transfection, preparation of cationic lipoplexes with positive surface charge is a 
significant practice that ensures electrostatic interaction with cells. The overall positive 
charge allows lipoplexes to bind to the negative sulfated proteoglycans on cell surfaces, 
with such attachments leading to internalization of lipoplexes [92], either by cell-
lipoplex fusion [93; 94] or endocytosis (engulfment) [17; 40]. Cellular internalization of 
lipoplexes by endocytosis places the endocytosed lipoplexes in endosomes (Figure 
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1.3.4-1) [95; 96]. Endocytosis is believed to account for the majority of DNA that enters 
cells [91; 97-99]. 
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Figure 1.3.4-1. Model summary of cellular delivery of DNA with surfactant vectors. 
Cellular internalization is an important step in gene delivery. As shown, internalization 
is achieved here through endocytosis [100]. 
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Endocytosis resulting from proteoglycan interactions [101; 102] can be effective in 
vitro. However, internalization can be increased several fold through ligand-receptor 
interactions, which can be elicited by attaching ligands to lipoplexes via polymeric 
tether. Fusion (cell-lipoplex fusion) makes a minimal contribution to internalization [37; 
103] (Figure 1.3.4-1), and permits the entry of only the contents of lipoplexes [104; 
105]. Fusion, also described as lipid-mediated poration, results from mixing or 
rearrangement of constituent amphiphile molecules (gemini surfactants, lipids) [17] 
from vesicle bilayer membrane of lipoplexes and the phospholipid bilayer membrane of 
cells. The result is a change in membrane conformation that leads to creation of an open 
channel or pore between a previously attached lipoplex and a cell [92]. 
Endosomal escape of endocytosed lipoplexes must occur before endosomes advance 
into a powerful hydrolytic state (low pH) or ultimately fuse with lysosomes. Though 
DNA is protected in lipoplexes, its degradation is inevitable unless there is endosomal 
escape (Figure 1.3.4-1) [40]. In reality, only a fraction of lipoplexes make it to the 
cytoplasm, the rest being destroyed in the destructive, hydrolytic phase involving 
endosomes and lysosomes [3]. As such, assisted endosomal escape by the use of gemini 
surfactant-based or other molecular delivery systems capable of bilayer-to-micelle or 
lamellar-to-inverted hexagonal (HII) transition is helpful [106-108]. After endosomal 
escape, dissociation of lipoplexes should allow nuclear entry of DNA. This entry of 
unbound, decondensed DNA competes with its rapid degradation by cytoplasmic 
nucleases. The timeliness of this step is key to getting increased transfection [17; 33]. In 
many cases, the amount of DNA making successful entry into the nucleus (through 
nuclear pores) is further reduced. 
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Though gene expression is achieved from the delivery of target-free DNA [109], the 
possibility of better gene expression from the use of targeted DNA exists. Cytoplasmic 
receptors (importins) responsible for the transport of oligopeptides (and other proteins) 
to and from the nucleus (nuclear localization) are constantly shuttling across the nuclear 
membrane [65]. This offers an opportunity to tag recognition molecules (such as 
oligopeptide moieties) to DNA. The tagged DNA can then be picked and expressly 
transported to the nucleus, allowing DNA to escape degradation by cytoplasmic 
nucleases. Enhanced gene expression via nuclear localization signals has been reported 
[110; 111]. Nuclear entry can also be increased in dividing cells, as there is transient 
opening of their nuclei. This, however, may not be easily employed for routine delivery 
of DNA. 
1.4. Clinical Opportunities for Gene Therapy 
Of the many areas into which gene therapy research has diversified, such as gene 
(therapy) delivery to the lungs [112-114], kidney [115], heart [5], muscles [116], and to 
cell categories such as macrophages [11; 117], and the haematopoietic system [118; 
119], the opportunity provided by topical delivery in particular holds the key to many 
prospects. Topical gene delivery, a mode of transfer of DNA to skin cells and hair 
follicles, is gaining increasing popularity for a variety of applications ranging from 
alopecia treatment to DNA vaccination [120]. Also for the skin, dermal delivery systems 
provide a means of transferring DNA, which can be taken up and expressed by follicular 
and dermal stem cells to obtain local or systemic effects [121; 122].  
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1.4.1. Gene Delivery via the Topical Route 
Opportunities for treatment of pathological conditions (localized or systemic) via 
transfer of genes to and across the skin are many [123; 124]. The skin is the largest 
tissue in the body [125], which makes it the most accessible, exploitable port of entry for 
therapeutic agents, including therapeutic genes and DNA vaccines [126]. Topical 
delivery to the skin is pain-free, eliminates the need for invasive procedures (such as 
microinjection, which typically causes pain), and minimizes cost related to the use of 
expensive, invasive technology or equipment (such as microinjection and gene gun). It 
provides a proximal route of delivery for localized skin conditions, which could 
potentially increase bioavailability compared with systemic administration in which non-
specific reactions and particle removal by the reticuloendothelial system can 
significantly reduce bioavailability [127]. 
Given the opportunities of genetic treatment and genetic immunization (Sections 
1.4.2, 1.4.3, ahead) that can be elicited in the skin, delivery systems are being sought 
that will allow improved permeation by way of effective penetration through the 
outermost stratum corneum into and beyond the inner layers of skin. Use of penetration 
enhancers is sometimes resorted to because the skin naturally presents a tight chemical-
assisted physical barrier against invading pathogens and particles [126]. The stratum 
corneum is a major barrier against percutaneous adsorption, and yet is also the main 
pathway for penetration after topical administration [128]. Permeation through the skin 
is enhanced by gemini surfactants (and lipids), which primarily function as delivery 
systems. These compounds are able to loosen or fluidize the lipid matrix of the stratum 
corneum which are made of double-layered lipid membranes [129]. The hair follicle, 
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which is appendaged to the skin, can be selectively targeted for delivery as has been 
shown by Hoffmann and Li. The authors observed that liposome-follicle-targeting 
delivery allowed delivery of exogenous melanin to hair follicles in hair-producing 
histocultured skin [122]. The same authors previously showed that phosphatidylcholine-
containing liposomes can deliver DNA directly into the hair follicles of histocultured 
skin [130]. 
1.4.2. Keratinocyte Gene Delivery and Dermal Gene Therapy 
PAM 212 keratinocytes, a cell line developed from BALB/C mice, were used in this 
research as model skin cells for which gene delivery applications could be targeted. The 
introduction and expression of exogenous genetic material in cultured keratinocytes, 
which undergo terminal differentiation and mimic many of the biochemical and genetic 
properties of the intact epidermis, have enabled researchers to culture epithelial 
autografts used for treating burn patients. The expression of appropriate transgenes in 
keratinocytes can also enable transduction-mediated correction of mutant keratinocytes 
from patients with lamellar ichthyosis. Such corrected keratinocytes when transplanted 
to nude mice results in the formation of normal epidermal tissue [131]. Transduction-
mediated gene expression in keratinocytes also provides the opportunity to deal with 
various abnormal skin conditions. 
A variety of genetic or acquired conditions occur in humans in which the normal 
function of skin is altered, calling for gene-mediated correction of such conditions. Gene 
transfer to the skin has been employed to assess genetic treatment of skin cell carcinoma 
(cancer or tumour in skin)  [124], scleroderma [132], acute and chronic skin wounds 
[133],  and xeroderma pigmentosum (XP) [134]. Malignant melanoma and squamous 
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cell carcinoma are two cancer types that affect the skin. Most skin cancers have been 
traced to mutant genes, and UV radiation is considered the commonest risk factor [134], 
with its damaging effect on DNA. However, providing the functional copies of relevant 
genes [135] to especially XP individuals, who are hypersensitive to sunlight and are 
predisposed to skin cancer [136] (~1,000-fold increased risk), prevents the development 
of cancer at sun-exposed areas, primarily the skin (e.g., squamous cell carcinoma) [137-
139]. In XP patients, who typically have inactivating mutations in one of seven genes 
designated as XPA – XPG, nucleotide excision repair of sunlight-damaged DNA is 
impaired [140]. The functional copy of XPA gene when transferred to the skin (basal 
keratinocytes) expresses the XPA protein, which plays a role in initial damage 
recognition needed for nucleotide excision repair, and stabilizes the multiprotein repair 
complex assembled at the site of DNA damage [140]. Successful repair and stabilization 
ultimately stops the initiation of squamous cell carcinoma. In the absence of genetic 
treatment, the surest way for XPA patients to be safe is to stringently avoid all ultra-
violet B radiation from their very early childhood [141-144].  
Similarly for scleroderma, a skin condition which arises from overproduction and 
deposition of collagen by fibroblasts [145], transfer of T-cell-derived interferon-γ (IFN-
γ) gene to fibroblasts and the consequent reduction of fibroblast collagen synthesis as 
well as repression of fibroblast proliferation (observed in vitro) indicates the possibility 
to genetically treat scleroderma via expression of IFN-γ protein [132]. Indeed, Jimenez 
et al. [146] reported an improvement in the skin from an early treatment of scleroderma 
via transfection-assisted expression of exogenous IFN-γ gene. Badea et al. [132] have 
recently shown similar enhancement in skin condition using gemini surfactant-based 
dermal delivery for the interferon gene. Acute and chronic skin wounds are yet other 
 16
types of skin defects for which potential treatment lies in gene therapy. A group of 
proteins including platelet-derived growth factors [133] and vascular endothelial growth 
factors [133] promote and accelerate wound healing. But the commonly noted drastic 
reduction of the physiological half-life of purified or recombinant peptides after 
application to affected skin limits protein-mediated treatment of these defects [147]. The 
transient cutaneous transgene expression of these proteins marks an improvement over 
the use of synthetically derived proteins. Transgene expression relies on the cellular 
machinery of the host to locally manufacture the needed proteins, eliminating problems 
associated with shortened half-life of topically applied proteins [120]. Transgene 
delivery to the skin thus holds a viable alternative for the treatment of skin wounds and 
ulcers.  
Advances in gene therapy have gone beyond the skin to include hair follicles, which 
are a complex appendage of the skin. Hair serves important functions for humans, both 
cosmetically and by scalp protection, and the hair follicles produce sweat gland products 
that help to balance body temperature and release pheromones [148]. However, loss of 
hair pigment and hair itself (e.g., during aging), and conditions including albinism and 
severe hair loss either caused by alopecia areata or chemotherapy, can be of concern to 
those affected. There have been few treatments for the underlying causes of hair changes 
during aging or as a result of the aforementioned disorders, and gene therapy is expected 
to settle all such problems [120]. Following Li and Hoffman’s [122] earlier 
demonstration of selective gene therapy of hair follicle in mice via topical application of 
liposomes-entrapped lacZ reporter gene, Alexeev et al. [149] advanced the approach by 
using an RNA-DNA (chimeric) oligonucleotide to correct albino mutation of the mouse 
tyrosinase gene. Chimeric oligonucleotides when placed in hair follicle melanocytes are 
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able to correct albino point mutations by using the cellular machinery for homologous 
recombination and mismatch DNA repair [150]. The correction restores tyrosinase 
activity and activates concomitant melanin synthesis, resulting in the production of 
pigmented hair shafts in albino mice. The effect lasted for three months. The same 
chimeric oligonucleotide was previously shown by Alexeev et al. to correct the albino 
mutation in cultured melanocytes, rendering clonal, heritable melanin production, as 
exhibited in the in vivo study mentioned above [151]. 
Genetic corrections of not only unpigmented hair (albinism) but also conditions of 
loss of hair such as alopecia universalis or baldness have been researched. Sato et al. 
[150; 152] showed that antigen development leading to production of hair shaft could be 
stimulated in C57BL/6 mice via transfer of the sonic hedgehog (shh) gene. With the 
cloning of the human hairless gene [153], which is responsible for alopecia universalis, a 
stage has been set for the genetic correction of hairlessness in humans [120]. 
1.4.3. DNA Vaccines for Genetic Immunization 
The skin is a site at which important cellular and molecular-level immunologic 
responses to foreign species and tissue-specific antigens originate [125; 154]. This 
provides the basis for development of DNA vaccines, targeting the skin or for 
administration via the skin in order to mitigate disease states prophylactically. DNA-
mediated immunization involves delivery of plasmid DNA (i.e., DNA vaccine) encoding 
for a protein-antigen (from a pathogen) into cells of the skin (such as keratinocytes). 
Genetic immunization takes advantage of the fact that host cells produce appropriate 
antigens in situ which, when presented to the immune system including T lymphocytes 
(by antigen-presenting cells), induce specific cytotoxic T lymphocyte response via MHC 
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class I-restricted pathway. As well, antigens released extracellularly are linked to the 
induction of humoral response and helper T lymphocytes (Th) via MHC class-II 
restricted antigen presentation. Keratinocytes can be transfected to produce antigens of 
interest, which can be presented to CD4+ T or CD8+ T cells, also directly [155; 156]. 
Langerhans cells are capable of migration and are able to present antigens to lymphoid 
tissues to induce immune response from T lymphocytes. Antigen-specific immune 
responses induced by DNA vaccines give protection against infectious diseases caused 
by viruses, bacteria, and parasites. Other diseases such as cancer, allergy and 
autoimmunity are also targeted for DNA vaccination [157; 158]. DNA vaccines 
encoding antigens as well as cytokines can express the two types of molecules 
concomitantly for enhancement of immune response. IFN-γ (a cytokine), for example 
plays an active role in cellular immunogenicity, is observed to arrest progress of mice 
lymphoma and destroy existing tumours [159]. Fan et al [160] have shown that topical 
application of DNA encoding the hepatitis B surface antigen (HBsAg) elicits an antigen-
specific immune response. This depends on the presence of normal hair follicles, 
suggesting that follicular cells could be made targets of DNA vaccination to take 
advantage of their special protein synthesis. 
1.5. Genes and Biomaterials for Gene Therapy 
The nature of clinical benefits and applications to basic science research that can 
emerge from gene delivery is diverse. Added to this, research has focused on the 
development of DNA-based products (e.g., plasmids) and biomaterials, including gemini 
surfactants, lipids and polymers for use as gene delivery systems. The molecules of gene 
delivery systems have functional groups or other structural components that can be 
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modified to improve the functional effectiveness of the biomaterials they constitute. 
These biomaterials yield better safety, allow ease of manufacture and structural 
manipulation, encapsulate and preserve the activity of therapeutic DNA. They thus 
represent ideal models for realizing ultimate drug delivery in humans. However, current 
hurdles associated with them include low gene delivery efficiency. 
1.5.1. DNA-based Therapeutic Materials 
Since the double helix structure of DNA (Figure 1.5.1-1) was elucidated in the 
1950s through the combined research of Watson and Crick [161; 162] and others such as 
Wilkins and R. Franklin [163-165], a large proportion of scientific research has evolved 
based on DNA. Some of this research has focused on concepts such as gene therapy, 
which is expected to have a greater impact in the fight against diseases. The two 
complementary polynucleotide strands of DNA, which run head-to-toe [166; 167], are 
held on to each other by hydrogen bonds. Each strand is a long polymer of nucleotides 
(i.e., a polynucleotide chain). The nucleotide units are in turn made of a sugar 
(deoxyribose), a phosphate and one of five kinds of nucleobases (per nucleotide). 
Nucleotides on adjacent single strands are held to each other through hydrogen bonding 
creating the double strand helix. The pairings are predetermined such that only the 
following possible pairings are allowed: adenine–thymine, thymine–adenine, cytosine–
guanine and guanine–cytosine. A fifth base, uracil is rarely found in DNA, except as a 
result of chemical degradation of cytosine, or in some viruses, notably PBS1 phage 
DNA, where uracil completely replaces the usual thymine in its DNA [166-168].  
DNA, most of which is found in the cell nucleus and the rest in mitochondria (in the 
case of eukaryotic cells), contains genetic information that is passed down from a parent 
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to its progeny. The correct (and precise) sequence of base pairs ultimately determines 
the specific sequences of amino acids in peptides, enzymes and other proteins, and is 
essential for every gene to function normally [166; 167]. On rare occasions, incorrect 
pairing does occur, or the full sequence for a particular gene can be missing. Such 
genetic anomalies lead to deficient gene function or entire loss of gene function, both of 
which entail serious health consequences. Imperfections in DNA, referred to as 
mutations, are due not only to incorrect base pairing, for instance during synthesis of a 
new DNA strand, but can also occur after chemical damage by mutagens or UV damage 
[166]. Cells may or may not be able to successfully repair mutant genes by themselves.  
When mutation leads to conditions such as adenosine deaminase (ADA) deficiency, 
a correction of the condition to normalcy can be accomplished by introducing normal 
exogenous DNA or transgenes, referred to as therapeutic DNA, usually into the nucleus 
of affected cells. For instance, in adenosine deaminase (ADA) deficiency the normal 
ADA gene (the therapeutic DNA coding for the enzyme adenosine deaminase) can be 
transferred to white blood cells or bone marrow cells [169] for protein synthesis and thus 
correction of the deficiency. The structure, size (weight) and charge of DNA constitute 
important parameters that can either present challenges or be manipulated to advantage 
in application-based DNA research. Of the three slightly different geometries of DNA, 
the "B" form described by Watson and Crick is thought to be predominantly native to 
cells. It is 2 nm wide and extends 3.4 nm per 10 bp of sequence (Figure 1.5.1-1). The 
actual size ranges from tens of base-pairs to over thousands of base-pairs, and depends 
on the particular piece of genetic material and the regulatory sequences present [166]. 
For instance, there are approximately 220 million bp in human chromosome number 1, 
making it the largest chromosome in humans [170; 171]. Whereas DNA can be in many 
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cases linear (such as during replication), the ends of a piece of double-helical DNA can 
be joined so that it forms a circle, as in plasmid DNA. The phosphate groups account for 
the negative charge of DNA. 
 
  
 
  
 
 
Figure 1.5.1-1. Structure of DNA. 
To the left of the figure is shown the double helix of DNA, portraying the major and 
minor groove. To the right is the chemical structure showing connections between 
phosphates, deoxyribose sugar groups and various nucleobases. Hydrogen-bonded base-
pairs are also shown. Adopted from www.wikipedia.com in accordance with GNU 
General Public License policy [166]. 
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1.5.2. Advantages of DNA-based Therapeutics 
Because of the specificity that underlines the action of a gene, therapeutic agents 
modelled on the structure of DNA offer rare advantages over currently used low 
molecular weight pharmaceuticals [5]. For instance, whereas the later typically show 
less specificity, their DNA-based counterparts have high specificity and selectivity for 
recognition of their molecular targets, which means reduced incidence of drug toxicity, 
fewer negative side-effects, and safer drugs [157]. In addition, a therapeutic transgene 
after insertion into the genome of a cell can express a protein persistently, meaning long 
therapeutic half-life relative to synthetic, therapeutic proteins, which typically have 
shortened half-lives. Proteins synthesized in situ from therapeutic DNA are without the 
toxicities associated with high levels of intravenously administered proteins, and 
mammalian post-translational modifications of in situ produced proteins eliminate other 
challenges (such as incompatibility) associated with making recombinant proteins in 
non-mammalian hosts [157]. 
For instance, although live attenuated virus vaccines have existed before DNA 
vaccines and have been extremely effective against a variety of diseases in both the past 
and present (including the elimination of small pox), the risk of their reversion to the 
wild-type, though probably a remote possibility, cannot be dismissed. In the special case 
of HIV, viral vaccine development must occur with great caution because of the threat 
that the virus-based vaccine could revert to the wild type responsible for the disease. 
Against this backdrop, DNA vaccines are emerging as an ideal class of vaccines. Their 
manufacture can be fairly less resource-demanding relative to traditional live viruses that 
require significant effort for proper pathogen attenuation and design of cellular 
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production systems [157]. For diseases with multiple virus strains such as HIV or 
influenza, their viral vaccines have to be reformulated to antigens for evolving strains. 
Not only is this resource demanding or poses a problem for the yearly supply of 
vaccines, but such vaccines also give no protection against epidemic strains that may 
arise in the very near future. Most notable is the novel pandemic strain of influenza in 
the infamous 1919 Spanish Influenza that killed millions of people worldwide. In 
contrast, it has been demonstrated that a DNA vaccine made from the genetic sequence 
of one influenza virus strain can protect against a subtype, and this is a relieving 
indication that DNA offers the opportunity to make vaccines for diseases with multiple 
strains [157]. 
1.5.3. Gemini Surfactants for Gene Delivery 
Gemini surfactants, or simply bis-surfactant molecules, are attracting increasing 
interest in research as non-viral gene delivery systems. The term “gemini,” meaning 
“twin,” has been traced to Menger who originally coined the term in 1991 to describe 
bis-surfactants [35] (Figure 1.4.3-1). Bis-surfactants were generally not new around that 
time; some studies on bis-surfactants occurred well in advance of Menger’s work [172-
176]. But there was a renaissance, triggered by Menger’s work, in the synthesis and 
material property studies of these types of surfactants due to new potential applications 
including gene therapy. The specific gemini surfactant molecules, synthesized and 
studied by Menger, were made by coupling two individual surfactant molecules by a 
rigid spacer. The individual surfactants used for making gemini surfactants, whether 
now or then, usually have a polar/ionic headgroup and a nonpolar hydrocarbon moiety 
or tail [35; 90; 177; 178]. Over time, non-rigid spacers [90; 177; 179-182], many of 
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which are symmetrical [33] (but may be asymmetrical), were also used for gemini 
surfactant synthesis. Using the effective tool of synthesis, gemini surfactants exhibiting 
special and enhanced properties (including vesicle formation) relative to the early ones 
have been synthesized and reported in the literature. 
 25
 
 
 
 Ionic (polar)
head groups
Spacer Hydrophobic tailHydrophobic tail
 
 
H2m +1Cm N (CH2)s N
CH3
CH3CH3
CH3
CmH2m +1
 
 
Figure 1.5.3-1. General structural schemes of gemini surfactants. 
(A) General structure, showing how any two monomer surfactants can be connected 
using a spacer group. (B) Structure of the m-s-m gemini surfactants. Two traditional 
monomeric surfactants with Cm alkyl tails are connected at their quaternary ammonium 
heads via a polymethylene chain containing s methylene units. That is, m = number of 
carbons in the hydrocarbon or alkyl tail, s = number of methylene units in the spacer 
chain. 
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Of the properties of gemini surfactants (dimers), their greatly enhanced ability to 
spontaneously aggregate [35; 36; 183] (~1000-fold superiority over monomer 
surfactants [33]) into complex structures including micelles, bilayers and vesicles put 
them at the front line of drug delivery. Their extremely low critical micelle 
concentration (CMC) [33; 35; 36] allow these surfactants to effectively package or 
encapsulate DNA, and this is an important first in gene delivery. Low CMC values are 
also essential for minimizing the amount of gemini surfactant used to achieve gene 
delivery, which is in turn essential for ensuring an optimal safety profile of any foreign 
compound used in a biological host, as well as ensuring reduced cost [33]. 
The gemini surfactants encountered in gene delivery are generally symmetric, with 
their headgroup being made of quaternary ammonium, or primary, secondary or tertiary 
amines groups. Such kinds of headgroups (cationic or protonable) present the necessary 
features for binding to the negative phosphate groups in DNA, so as to neutralize and 
condense DNA [33]. The simplest gemini surfactants (according to the general structure 
in Figure 1.5.3-1) which can be used for gene delivery have a divalent (dicatonic) head 
made of two quaternary ammonium groups and two hydrocarbon tails (usually C8 – C18). 
Such a combination of head and tail ensures the presence of the cationic character 
necessary for neutralizing and compacting DNA, and the presence of the hydrophobic 
moiety to initiate co-aggregation with DNA to form vesicle-DNA complexes. Advances 
in organic synthesis allow for making gemini surfactants [90] with multivalent 
headgroups [73] for improved DNA compaction, implying that synthetic expertise could 
be used to modify and tailor properties of gemini surfactants for application in gene 
delivery. 
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1.5.4. Condensation of DNA in Gene Delivery 
The first important characteristic of an effective molecular gene delivery system is 
its ability to spontaneously interact with DNA. Cationic delivery systems have evolved 
with the ability to efficiently neutralize, condense and encapsulate DNA into complexes 
whose sizes range from less than 100 nm to about 1000 nm, depending on the molecular 
system and other factors [184; 185]. Such interactions allow the shape and size of 
macromolecular DNA to be changed into a form (i.e., into complexes) readily taken up 
by cells, without loss of biological function of the genetic material [186; 187]. The 
complexes formed between cationic polymers and DNA, and referred to as polyplexes, 
generally have smaller sizes due to more efficient DNA condensation by the polymers 
[188; 189]. Complexes formed between DNA and the relatively smaller cationic lipids 
or surfactant molecules (these complexes are termed lipoplexes), on the other hand, can 
have fairly large sizes. For both lipoplexes and polyplexes, the size of complexes 
displays some dependence on the cationic molecular agent-to-DNA charge ratio [105; 
190-194]. As noted earlier, the neutralization, condensation and encapsulation of DNA 
is achieved through a combination of interactive forces. These include electrostatic 
forces (between phosphate groups of DNA and positive charges from a cationic 
molecular transfection system) and hydrophobic–hydrophobic as well as van de Waal’s 
interactions, which allow for self-association of the hydrophobic moieties of gene 
delivery molecules to form micelles or vesicles [33; 195]. 
The positive charge in cationic lipids or surfactants are usually concentrated on the 
polar headgroups, more commonly termed cationic headgroups, while the positive 
charge of cationic polymers are incorporated along with the repeating units of the 
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polymer chain. Because of the important role of the cationic headgroups, many 
investigations have focused on the number of positive charges and their chemical 
structure (which predominantly fall into the following categories: quaternary 
ammonium, or primary, secondary or tertiary amines). Univalent cationic lipids, such as 
DOTMA (the first to be used for transfection [37]) and sphingosine [196], contain one 
quaternary ammonium and one primary amine, respectively, for interaction with DNA. 
However, such lipopolyamines or multivalent lipids as DOGS and DOSPA contain 4 
and 5 amine or ammonium groups, respectively, which give them the ability to interact 
with and condense DNA more efficiently, and to transfect cells more efficiently [95; 
197; 198]. As a result, both DOGS and DOSPA are commercially available. Within the 
context of efficient interaction with and condensation of DNA, cationic gemini 
surfactants present cationic headgroups, which at minimum are divalent. This is because 
gemini surfactants contain two separate monomeric surfactants chemically linked 
through a spacer (see general structure, Figure 1.4.3-1), a concept that has also been 
extended into ‘gemini lipids’ [199; 200]. By virtue of the wide scope of structural 
variation permitted by the polar or cationic headgroup, a significantly large number of 
gemini surfactants have been developed and investigated based on the rationale of 
enhancing interactions with DNA, improving the interaction profile in biological hosts 
and ultimately increasing transfection efficiency. Wettig et al. [86] have recently 
reviewed and classified gemini surfactants that were investigated for DNA transfection 
in various reports into four comprehensive categories: (1) m-s-m [132; 201-204], (2) 
carbohydrate-based [33; 52; 205-209], (3) peptide-substituted [33; 73; 210; 211] and (4) 
disulfide-containing gemini surfactants [212-216]. Similar to lipids, the improved 
interaction of DNA with developed gemini surfactants containing multiple amine or 
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quaternary ammonium groups or both kinds of groups, combined, gives efficient DNA 
condensation as well as increased transfection. 
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2. PURPOSE OF RESEARCH 
2.1. Current Perspectives on the Hurdle of Non-viral Gene Delivery 
The path or assisted path of a gene, transported by molecular delivery systems, from 
the route of administration to the nuclei of target cells is complex. Whether or not there 
is eventual nuclear delivery, and the efficiency of delivery is dependent on a rather large 
number of factors [33; 191; 217]. As a result, the efficiency of gene delivery using 
molecular delivery systems still ranges from very low to modest, especially relative to 
viral-mediated gene delivery. As a way to improve the delivery efficiencies of molecular 
systems, considerable attention is being paid to the factors that come into play as a 
genetic material is ‘cargoed’ to the cytoplasm or further into nucleus of a cell via a 
molecular system. These factors can be grouped into two main categories. The first is 
the type of target cells (or tissue), and the second relates to the properties of the 
molecular system. From the view point of synthetic and material science, the properties 
of molecules can be tailored to allow them to mediate gene delivery at significantly 
higher efficiencies [33; 65; 195] using carefully conceived molecular design approaches. 
In fact, non-viral gene delivery has already evolved from an early generation of 
molecules, which achieved very low transfection efficiency, to the recent generation of 
molecules, which yield remarkably improved efficiency. 
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2.2. Rationale for the Focus of this Research 
Gemini surfactants, as a focus of this research aimed at developing non-viral vectors 
for gene therapy, have a general structure that presents an unlimited versatility in their 
design and synthesis. This gives a significant opportunity in the search for clinically 
efficient gemini surfactant molecules for routine gene therapy applications. For gemini 
surfactants to pass a test of optimal utility in gene therapy, the surfactant molecules must 
meet important requirements; these include the ability to efficiently mediate gene 
delivery and to exert minimal or no toxic effects on their biological hosts. This calls for 
the use of rational design schemes for generating and testing gemini surfactants. 
Through rational design, gemini surfactants are progressively modified with reference to 
chosen compound templates, making a defined structural modification per step. This 
allows certain properties to be conferred on the surfactants for subsequent testing in 
biological hosts. The larger goal of the design process is to improve the particle 
properties of gemini surfactant-based DNA transfection complexes. This would improve 
their interaction characteristics with host cells and lead to efficient DNA transfection. 
2.3. Hypotheses 
The various non-viral gene delivery molecules that are currently studied in research, 
such as gemini surfactants, must be able to achieve a number of critical functions, above 
which any molecular gene delivery agent will be able to attract attention to its potential. 
Thus, among other important things these molecular agents should be able to 
spontaneously interact with DNA and create effects including: 
• compaction of DNA into nanometre-scale particles, 
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• electrostatic binding of the compact nanoparticles to cells, and 
• after passage of nanoparticles into cells, the gene delivery molecules should 
dissociate from the DNA to allow subsequent protein expression either after 
nuclear translocation of DNA or after recognition of its presence in the 
cytoplasm by cellular protein expression machinery. 
Hypothesis: 
It is therefore hypothesized that for the purpose of improving cellular gene delivery, 
• Imino-substitution in gemini surfactants induce endosomal escape 
This hypothesis relates to the release of DNA encapsulated within the gemini surfactant 
vesicles. An indicator to signify (or validate) release of DNA during cellular transfection 
will be a higher level of transfection efficiency imino-substituted gemini surfactants 
relative to an appropriate ‘negative gemini surfactant control’. 
2.4. Objective of Research 
This research is focused on the overall objective of developing new gemini 
surfactant-based non-viral gene delivery systems for gene therapy applications. First, a 
library of gemini surfactants will be created from a process of gemini surfactant design 
and synthesis. Second, these surfactants, after preparation into transfection systems and 
characterization, will be applied in transgene delivery experiments and the level of gene 
expression evaluated. This ultimately allows the transfection abilities of constituent 
surfactants to be assessed. To ensure that emerging gemini surfactants with high 
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transfection abilities also have low/acceptable level of toxicity, transfection-related 
toxicity experiments were run alongside transgene delivery experiments. 
2.4.1. Specific Objectives 
To achieve the overall goal of this research, the major objective has been restated 
into specific objectives. These include: 
 
1. Rational design, synthesis and characterization of gemini surfactants, 
2. Preparation and characterization of gemini surfactant-DNA nanoparticles, i.e., 
transfection complexes, 
3. Transfection pre-screening in COS-7 cells and quantitative gene expression 
studies of plasmid DNA delivered to PAM 212 cells, and 
4. Toxicology studies of COS-7 and PAM 212 cells involved in transfection pre-
screening and quantitative gene expression studies, respectively. 
2.5. Outline of Proposed Research 
1. Preparation of gemini surfactants for creation of surfactant library 
a. Synthesis 
b. Isolation and purification 
c. Structural confirmation and purity assessment  
 
2. Preparation and characterization of gemini surfactant-DNA nanoparticles 
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a. Preparation of gemini surfactant-based DNA transfection mixtures 
(complexes) using gemini surfactants obtained from a rational design 
scheme (Table 3.1.2-1) 
b. Determination of physicochemical properties of gemini surfactant-DNA 
nanoparticles: 
i. Determination of size and zeta potential 
ii. Determination of particle morphological distribution 
 
3. Transfection of COS-7 cells in a pre-screening phase using 12-spacer-12 
surfactants (Table 3.1.2-1) 
a. Quantitation of luciferase gene expression in COS-7 cells after       
transfection with gemini surfactant-based transfection mixtures 
containing luciferase plasmid 
 
4. PAM 212 cell ultrastructural studies and stereological examination 
a. Electron microscopic examination of the cells, including size and 
morphologies adopted by the cells 
 
5. Transfection of PAM 212 cells using three different gemini surfactant series (m-
3-m, m-7-m, m-7NH-m) – advanced transfection phase 
a. Quantitation of luciferase gene expression in PAM 212 cells after       
transfection with gemini surfactant-based transfection mixtures 
containing luciferase plasmid:  various composition of mixtures, time 
study of gene expression 
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6. Toxicology studies on COS-7 and PAM 212 cells 
a. Measurement of cell viabilities of transfected cells for assessment of the 
level of cellular toxicity caused by transfection 
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3. MATERIALS AND METHODS 
3.1. Gemini Surfactants 
The gemini surfactants investigated in this study were each enlisted to fit within a 
rational design scheme that will enable the determination of organic structural units or 
moieties as well as the architectural arrangement of these units/moieties within a 
molecule that is necessary for achieving effective DNA transfer to cells. Equally 
importantly, any features (architectural, structural units/moieties) that derail the ability 
of a molecule to transfer DNA to cells, if noted, will be indicated. Out of a library of 
over 30 gemini surfactants designed and synthesized for testing of their transfection 
abilities, 14 surfactants, each of which falls into at least one of four categories below, 
were investigated over the course of this study. 
 
 Surfactant series Members 
1. 12-spacer-12 12-3-12, 12-5N-12, 12-8N-12, 12-7N-12, 12-7NH-12 
2. m-7NH-m 12-7NH-12, 16-7NH-16, 18-7NH-18, 18:1-7NH-18:1 
3. m-3-m 12-3-12, 16-3-16, 18-3-18, 18:1-3-18:1 
4. m-7-m 12-7-12, 16-7-16, 18-7-18 
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3.1.1. Synthesis 
1. Synthesis of the five 12-spacer-12 surfactants used in this research (namely the 12-3-
12 [218], 12-5N-12, 12-8N-12, 12-7N-12 and 12-7NH-12 [219] surfactants) was 
carried out in work done prior to this research. However, to cater for arising needs, 
synthesis of the 12-7NH-12 surfactant, which also belongs to the m-7NH-m series, 
was repeated in this study, making it available in sufficient quantities (synthesis is 
described below). In both previous work and work under this study, the syntheses of 
all gemini surfactants followed the general scheme described by Menger and Littau 
[35; 36]. Figure 3.1.1-1 (below) exemplifies the routine procedure for generating 
gemini surfactants in this research, with specific reference to the 18-3-18 surfactant. 
2. Following previous synthesis of the 12-7NH-12 gemini surfactant [219] belonging to 
the m-7NH-m series, the 12-7NH-12 surfactant was resynthesized. The higher 
members (having longer tails, i.e., m = C16, C18, Coleyl representing oleyl chain) were 
synthesized as follows: the surfactants resulted from the reaction of 1 equivalent of 
3,3’-iminobis(N,N-dimethyl-propyl amine) (Aldrich) with 2.1 equivalents of the 
appropriate tail group in acetonitrile or anhydrous acetonitrile in the case of 
unsaturated tail species. The species 1-bromohexadecane (C16), 1-bromooctadecane 
(C18) and 1-bromo-cis-9-octadecene (Coleyl) (all from Aldrich) were used as tail 
groups. Prior to its use, 1-bromo-cis-9-octadecene was obtained by conversion of the 
corresponding cis-9-octadecen-1-ol into the bromide compound using a previously 
described conversion method [220]. The conversion was by addition of solid 
Ph3PBr2 (10.62 g, 24.18 mmol, 96% purity, Aldrich), over the course of 10 min, to a 
solution of cis-9-octadecen-ol (5.74 g, 18.62 mmol, 85% purity, Spectrum) and 
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pyridine (2.33 g, 29.78 mmol, 99.8% purity, Aldrich) in anhydrous acetonitrile (36 
mL) maintained at 0 oC. The complete mixture was stirred for 1 h (disappearance of 
alcohol checked by TLC) and was filtered through a short pad of silica gel. The 
recovered filtrate was rinsed with l:10 ether/pentane (200 mL). A final mass of 4.64 
g (14.00 mmol, 75% yield) of pure 1-bromo-cis-9-octadecene was obtained upon 
further work up. 
3. Previous synthesis of the m-3-m surfactants carried out prior to this research made 
available the 12-3-12 [221], 16-3-16 [222] and 18:1-3-18:1 [223] surfactants. These 
previous syntheses were accomplished via a bis-Menshutkin reaction of 1 equivalent 
of tetramethyl-1,3-propanediamine with 2.1 equivalents of the appropriate alkyl 
bromide (saturated or unsaturated). Thus, for the synthesis of 18-3-18 surfactant, 
which was carried out in this research, 1 equivalent of 1,3-dibromopropane (Aldrich) 
was reacted with 2.1 equivalents of N,N-dimethyloctadecylamine (Akzo Nobel) 
using the bis-Menshutkin method. 
4. The m-7-m surfactants were synthesized from reaction of 1 equivalent of 1,7-
dibromoheptane (Aldrich) with 2.1 equivalents of either N,N-
dimethyloctadecylamine (Akzo Nobel) or N,N-dimethyl-n-hexadecylamine (TCI 
America) or N,N-dimethyldodecyldecylamine (Aldrich). 
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Figure 3.1.1-1. Outline of synthetic process for the target gemini surfactants.  
Formation of the 18-3-18 gemini surfactant from the constituent reactants was achieved 
through quaternization reaction between 2 mol of dimethyloctadecylamine (i.e., the alkyl 
tails) and 1 mol of dibromo-1,3-propane (i.e., spacer group). The reactants can 
alternatively be selected such that the alkyl tail is an alkyl bromide while the propyl 
spacer chain bears the two terminal tertiary amine groups to be quaternized. 
1. Combine reactants: 
tail (1) + spacer (2) 
2. Add solvent, stir bar. 
Attach reaction flask to a 
condenser, and suspend in 
an oil bath 
3. Run cold H2O through 
condenser, turn on stirring, 
flow N2 gas over mixture, 
and heat at 90-100 oC; all 
lasting 24 h 
4. Detach flask and cool to 
room temp, or to -20 oC if 
products do not crystallize
5. Filter the solid, and purify 
by recrystallizations ≥ 3x 
6. Oven dry, 40 oC, 2-4 h, 
and/or freeze dry, 12 h 
7. Analysis: 1H NMR, % CH&N,
ESI-MS 
8. Characterization –  
CMC, ao , α, TKrafft 
Synthetic process – exemplified for 18-3-18 surfactant 
BrBrC18H37N +2
1 2 C18H37
N+ N+ 2Br-
C18H37
,
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3.1.2. Gemini Surfactants Prepared – The Library 
The reactions leading to the formation of final surfactants (Table 3.1.2-1, below) 
were all carried out under reflux for 24 h or more in acetonitrile, but not exceeding 72 h. 
The product compounds crystallized out as white solids upon cooling of each reaction. 
The white solids were recovered by filtration, followed by purification by several 
recrystallizations from acetonitrile or a mixture of acetonitrile/diethyl ether (anhydrous 
acetonitrile, in the case of unsaturated surfactants). Additional purification for the 
unsaturated surfactant 18:1-7NH-18:1 was done by soxhlet extraction in anhydrous 
diethyl ether for 72 h for removal of trace impurities.  
Structures of the purified surfactants were confirmed by 1H NMR spectroscopy 
(CDCl3, 500 MHz Bruker) and electro-spray mass spectrometry, while their purities 
were verified by aqueous surface tension measurements and elemental analysis. The 
surface tension (γ) vs. log C plots for all surfactants showed the absence of a minimum, 
in the plateau region above the CMC, indicating all surfactant products were highly 
pure. These purity assessments are particularly important regarding the need to use 
pharmaceutically pure grade materials in biological hosts. 
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Table 3.1.2-1.  Structure of the gemini surfactant candidates 
1. 12-spacer-12 series   
N+ N+
C12H25C12H25
spacer
 
Spacer group 
 
 
Symbol 
 
12-3-12 
 
N
 
12-5N-12 
 
N
N
 
12-8N-12 
 
N
 
12-7N-12 
 
H
N
 
12-7NH-12 
2. m-7NH-m series   
N+
H
N
N+
RR  
 
R group 
n-C12H25 
n-C16H33 
n-C18H37 
n-C18H35 
Symbol 
12-7NH-12 
16-7NH-16 
18-7NH-18 
18:1-7NH-18:1 
3. m-3-m series   
N+ N+
RR  
R group 
n-C12H25 
n-C16H33 
n-C18H37 
n-C18H35 
Symbol 
12-3-12 
16-3-16 
18-3-18 
18:1-3-18:1 
4. m-7-m series   
N+ N+
RR  
R group 
n-C12H25 
n-C16H33 
n-C18H37 
Symbol 
12-7-12 
16-7-16 
18-7-18 
The molecular properties were varied from surfactant to surfactant through variation of the nature of both 
the spacer and alkyl tail groups. The resultant surfactant library was assessed in terms of transfection 
abilities. 
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3.1.3. Determination of Krafft Temperatures 
To guide the solution preparation process, determination of the Krafft temperatures 
was carried out as a step prior to the determination of critical micelle properties. 
Saturated surfactant-in-water solutions (prepared at ≥ 1% w/v, for surfactants with m = 
16, 18, 18:1) were prepared by adding excess gemini surfactant to water. Conductivities 
of the saturated solutions were then measured as a function of increasing temperature, 
using a Weyne-Kerr precision component analyzer (Model 6425), to determine the 
Krafft temperature. The initial temperature was set to ≤ 10 oC for each set of 
conductivity vs temperature measurements to determine the Krafft temperature. 
Determination of critical micellar properties of the gemini surfactants, including critical 
micelle concentrations (CMC), was carried out once gemini surfactants solutions were 
prepared using the Krafft temperatures as dissolution guidelines. 
3.1.4. Surface Tension Measurements 
Surface tension measurements were performed using a Kruss (Model K10T) 
tensiometer, applying the du Nouy ring technique. The measured surface tension values 
(γ) were corrected using the method of Harkins and Jordan [224]. Experimental 
temperatures were maintained at 25.0 ± 0.1oC (for m = 12) and 45.0 ± 0.1oC (for m = 16, 
18, 18:1) using a VWR Scientific (Model 1160A) circulating water bath. The stock 
gemini surfactant solutions were titrated into 15 mL of water and the surface tension was 
measured after each addition.  
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3.1.5. Specific Conductivity Measurements 
Specific conductivities were measured using a Weyne-Kerr precision component 
analyzer (Model 6425) operating at 1.5 kHz in conjunction with a Tacussel electrode as 
employed in previous analysis [221]. The current operating cell constant of the electrode 
was found to be 1.52 cm-1. Experimental temperatures (T oC) were maintained at 25.0 ± 
0.1oC (for m = 12) and 45.0 ± 0.1oC (for m = 16, 18, 18:1) using a Haake (Model F3) 
circulating water bath. The specific conductance was measured after each addition of an 
aqueous solution of concentrated surfactant to 15 mL water under nitrogen atmosphere, 
allowing the solution to equilibrate.  
Generally, preparation of gemini surfactant stock solutions prior to both surface 
tension and specific conductivity measurements was done using a combination of 
appropriate dissolution techniques including one or any combination of stirring, 
sonication and warming in warm water bath. Samples were then finally kept to 
equilibrate (overnight) at temperatures not less than the Krafft temperature for each 
gemini surfactant. 
3.2. Characterization: Gemini Surfactant-based Transfection Systems 
Solutions for individual gemini surfactants as well as the corresponding gemini 
surfactant–plasmid–lipid transfection mixture systems (or formulations, used for 
transfection) were prepared and subjected to physicochemical analyses. These analyses 
allow the determination of critical properties of these materials that influence or govern 
the efficiency of non-viral transfections, and so allow correlations to be determined 
between physiochemical properties and level of transfection. 
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3.2.1. Gemini Surfactant, Lipid Vesicles and Plasmid Solutions 
Aqueous solutions at various concentrations, including notably 1.5 and 2 mM which 
are well above the CMC values for all gemini surfactants, were prepared and filtered 
through 0.2 µm Acrodisc® filters (Pall Gelman, Ann Arbor, MI, USA). Lipid vesicles 
were prepared as follows: 1,2-Dioleyl-sn-glycerophosphatidylethanolamine (DOPE) 
(Avanti Polar Lipids, Alabaster, AL, USA) and α-tocopherol (Spectrum, Gardena, CA, 
USA) in 1:0.2 weight ratios were dissolved in 100% ethanol (Commercial Alcohols Inc., 
Brampton, ON, Canada) and deposited as a thin film on a round-bottomed flask. The 
lipid film was vacuum-dried (12 h) to remove traces of solvent, followed by 
resuspension in 9.25% w/v isotonic sucrose (Spectrum) solution (pH 9) via sonication to 
yield a 1 mM solution. The final solution was filtered through 0.45 µm Acrodisc® filters 
giving DOPE vesicles with average size of 124 ± 5 nm (n = 3).  
Two plasmids were used in this research. Luciferase plasmid (pMASIA.Luc), 
commonly employed to take advantage of bioluminescence analysis for the assessment 
of transfection levels, was propagated and purified in our laboratory prior to this 
research using established methods [225]. Similarly, the plasmid pGTmCMV.IFN-GFP 
was previously constructed in our laboratory [132], with optimized utility for analyses 
relating to cell transfection. Both plasmids were routinely used as 0.1 µg/µL solutions. 
3.2.2. Determination of pKa Values 
pKa values for nitrogen centres in the gemini surfactants having aza- or imino-
substituents in their spacers were measured using a Beckman pH meter (Model 350) 
with a glass calomel electrode (Beckman Model 511083). Solutions (2 mM) of the 
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gemini surfactants were prepared in 1 mM NaOH to ensure complete deprotonation of 
the nitrogen, initially, and then titrated with 0.5 mM HCl at room temperature. 
3.2.3. Measurement of Particle Sizes 
Particle sizes (hydrodynamic radius, RH) for gemini surfactant aggregates (in 
solution) as well as gemini surfactant-based transfection mixtures were determined as a 
function of pH using a ZetaSizer NanoZs working in conjunction with an MPT-2 auto-
titrator (Malvern Instruments, Worcestershire, UK). The samples, each in a volume of 
10 mL and having the required concentration, were placed in the titration cell of the 
auto-titrator and titrated (in 0.2–0.5 pH unit increments) with 0.1 M NaOH and 0.1 M 
HCl over the desired pH range – basic to acidic pH. The surfactant-only samples were 
made at pre-titration concentration of 2 mM, which is above the critical micelle 
concentration in all cases. Titrations for the transfection mixtures (prepared as described 
in Section 3.3.3.) were performed for those mixtures with a DNA:surfactant charge ratio 
of 1:10. The solvent medium for the surfactant-only samples was either double-
distilled/deionized water (used for the 12-spacer-12 surfactants) or aqueous 9.25% w/v 
sucrose solution (for only the remaining surfactants) whilst the solvent medium for all 
transfection mixtures was aqueous 9.25% w/v sucrose solution. 
3.2.4. Measurement of Zeta Potential 
Determination of zeta potentials used the same instrumental set up, sample volumes 
and concentrations as for size determinations (Section 3.2.3). However, the analysis was 
performed for fresh samples, with the instrument switched to a zeta potential standard 
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operation procedure mode. The titrations were performed by varying pH and measuring 
the corresponding values of zeta potential. 
3.2.5. Physical State of Transfection Systems by TEM 
The physical state of both the gemini surfactant solutions and the equilibrated 
transfection complexes, formed from aqueous mixtures of plasmid and gemini 
surfactants, was studied using transmission electron microscopy (TEM). Each sample to 
be visualized was prepared by placing a small drop of about 10 µL of pre-made 
surfactant solutions or transfection mixtures on a carbon coated and glow discharged 
200 mesh copper grid. After blotting off excess liquid, a thin layer of the sample was 
allowed to dry and absorb onto the grids. Negative staining of absorbed sample was 
performed using 1% w/v phosphotungstic acid. Images of surfactant aggregates and the 
transfection nanocomplexes were obtained using a Philips Model 410LS transmission 
electron microscope operating at 60 keV. 
3.3. Cell Preparation and Transfection 
3.3.1. Cell Preparation 
The incubation conditions, i.e., 5% CO2/95% air atmosphere, 37 oC, were kept 
constant through the entire cell culture period, while sterility principles were followed 
over the entire duration. PAM 212 cells used for the experiments were routinely cultured 
in Minimal Eagle’s Medium (MEM) supplemented with 10% fetal bovine serum (FBS) 
and antibiotic-antimycotic (Ab) at 1 unit/mL. COS-7 African Green monkey kidney 
fibroblast cells, also used herein, were cultured in Dulbecco's Modified Eagle's Medium 
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(DMEM) supplemented with FBS and Ab in the same manner as done for MEM. In each 
case, cells were harvested from substrate after 85% confluence to initiate a transfection 
experiment or a cellular ultrastructural study.  
3.3.2. PAM 212 Cell Ultrastructural Study by TEM 
The confluent cells were detached from the growth substrate and washed with 
serum-free medium. Pellets of the cells, obtained from centrifugation of cells during 
washing process, were processed for electron microscopic visualization while working 
in a fume hood. Cells were fixed in 2.5% glutaraldehyde in sodium cacodylate buffer 
(pH 7.3) at 4 oC for 2 h. The supernatant fixative was aspirated, and cells washed three 
times in the same buffer (without glutaraldehyde). Secondary fixation of cells was done 
in 2% aqueous osmium tetroxide at 4 oC for 1 h. Washing was repeated using distilled 
water. The cells were embedded in molten agar and the agar allowed to solidify at room 
temperature. The agar-embedded specimens were cut into small cubes and stained with 
2% aqueous uranyl acetate at 4 oC for 2 h. The specimens were dehydrated in acetone 
(using an increasing gradient) and embedded in a low-viscosity Spurr resin, followed by 
oven-polymerization at 60 oC for 24 h. Ultra-thin sections, approximately 60-90 nm 
sections, were cut from polymerized specimen blocks and immobilized on 300 mesh 
copper grids (pre-cleaned in 2% NaOH). Sections were stained in 2% aqueous uranyl 
acetate, followed by a second staining in Reynold’s lead citrate. The cells were finally 
viewed and imaged using a Philips Model 410LS transmission electron microscope 
operating at 60 keV. 
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3.3.3. Transfection Mixture Preparation 
For preparing the non-viral transfection formulations, it is estimated that 1 µg of 
plasmid DNA (i.e., 3 nmol of phosphate) combines with 1.5 nmol of dicationic 
molecule, such as the gemini surfactant (i.e., 1.5 nmol x 2 ammonium nitrogens) being 
studied to give a gemini surfactant:plasmid DNA  charge ratio (ρ+/-) of 1:1. Using this 
guide, separate transfection mixtures representing ρ+/- = 0.5:1, 1:1, 2.5:1, 5:1 and 10:1 
were routinely used for cell transfection. For each preparation (representing a ρ+/- value), 
0.2 µg of plasmid was mixed with the appropriate aliquot (in nmol) of gemini surfactant 
solution (1.5 mM), which was pre-diluted into 5 µL for each surfactant to eliminate 
volume disparities. The binary mixtures were incubated at room temperature for 15 min, 
after which 50 µL of the DOPE vesicles (1 mM) was added, then a final incubation of 30 
min at room temperature. This order of addition of the reagents (i.e., addition of gemini 
surfactant to DNA, followed DOPE) has previously been demonstrated by our 
laboratory to give optimal transfection complexes compared with other ways of addition 
such as addition of the gemini surfactants to DOPE first, and then combining with the 
plasmid. The finished transfection mixtures were added to cells dropwise. 
3.3.4. Transfection and Quantitation of Protein Expression 
On the day before each transfection, 2 x 104 cells/well were seeded in 96-well plates 
(Corning Inc., Corning, NY, USA), keeping the cell types in their respective media. 
Volumes were kept to 100 µL per well (for 96-well plates) unless otherwise stated. One 
hour prior to transfection, cells were rinsed and covered with fresh serum-free culture 
medium. This was to avoid rapid degradation of DNA when transfection mixtures are 
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added to cells. The cells were then transfected with transfection mixtures representing a 
plasmid dose of 0.2 µg/well, which were prepared according to different preparation 
formulas (i.e., with different ρ+/- values: 10:1, 5:1, 2.5:1, 1:1, 0.5:1). Transfection 
mixtures that were to be added to cells were prepared using pMASIA.Luc, while the 
mixtures for particle size and zeta potential analysis were prepared using the 
pGTmCMV.IFN-GFP plasmid. This was to retain sufficient quantities of the 
pMASIA.Luc plasmid for routine transfections. The transfection nanoparticles formed 
from the complexation of the pGTmCMV.IFN-GFP plasmid using the gemini 
surfactants are expected to be the same and so be representative of the properties of 
transfection nanoparticles formed from the pMASIA.Luc plasmid. The properties are 
expected to be same, as the two plasmids are approximately equal in size and as the 
nanoparticles for the two plasmids were obtained by identical preparation steps. For size 
and zeta potential measurements, the transfection mixtures were prepared up to the 
required sample volume of 10 mL. 
After 5 h incubation, the cell medium was replaced with fresh culture medium 
supplemented using original supplementing formula. To allow informed comparisons 
with results obtained in other studies using other molecular kinds of vectors, parallel 
transfections were run using the non-viral commercial transfection standard 
Lipofectamine Plus™ (Invitrogen Life Technologies, Carlsbad, CA, USA). The 
Lipofectamine Plus™ preparation for a plasmid dose of 0.2 µg/well followed the 
manufacturer’s protocol. Each transfection experiment was done in triplicate. The 
resulting luciferase expression was quantified 12 − 72 h later, using the Promega Steady-
Glo™ Luciferase Assay system and luminescence measurements (Reporter microplate 
luminometer, Turner Biosystems, Sunnyvale, CA, USA). 
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The use of Steady-Glo™ Luciferase Assay system allows the quantitation of 
luciferase protein (an enzyme) produced from transfection of the luciferase gene (in the 
form of the plasmid pMASIA.Luc) into cells. By the mode of operation of this 
determination method, a prepared cell lysis reagent system containing excess luciferin is 
added to luciferase enzyme produced in situ in transfected cells. This results in the 
action of luciferase as a catalyst for the reaction between luciferin and oxygen, a 
luminescent reaction (known as the luciferase reaction, Figure 3.3.4-1) with a quantum 
yield of 0.9, the highest for any known luminescent reaction [226]. Since luciferin and 
oxygen (atmospheric) are in excess, the intensity of luminescence produced and 
measured by a photo-detecting apparatus such as the Reporter microplate luminometer, 
is proportional to the quantity of luciciferase protein produced in transfected cells. 
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Figure 3.3.4-1. The luciferase reaction.  
Mono-oxygenation of luciferin is catalyzed by luciferase in the presence of Mg2+, ATP 
and molecular oxygen. This reaction provides the basis for use of luciferin-containing 
assays (such as Promega’s Steady-Glo™ Luciferase Assay system) for determining the 
level of luciferase expression in cells transfected with luciferase gene-containing 
plasmid pMASIA.Luc. The involvement of cellular ATP in the luciferase reaction 
provides the basis for determing the viabilities of transfected or treated cells (Section 
3.3.5-1). 
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3.3.5. Determination of Transfected Cell Viabilities 
The experimental PAM 212 cells were prepared and transfected as described above 
(Section 3.3.1, 3.3.3). However, to determine the cell viabilities, that is to assess the 
transfection-related cytotoxicities, the transfected cells were assayed using the Promega 
CellTitre-Glo® luminescent cell viability assay system. The assay preparation followed 
the manufacturer’s instructions and the emanating luminescence was monitored using a 
Reporter microplate luminometer (Turner). 
The luminescent signal for determination of cell viability allows measurement of the 
amount ATP from metabolically active or viable cells and is based on the luciferase 
reaction (Figure 3.3.4-1). In principle, viable cells in culture maintain amounts of ATP 
that correlates with the number of viable (or living) cells. However, when cell death is 
caused through a process such as transfection, cells lose the ability to synthesize ATP, 
and endogenous ATPases destroy any remaining ATP, resulting in a dramatic decline in 
the levels of ATP. In view of this, the cell viability assay system was employed to 
inhibit endogenous ATPases and provide both luciferin and luciferase and other reagents 
necessary to measure ATP using luminescence produced from the luciferase reaction. 
Within a prepared assay, further ATP synthesis is ceased and the ATP molecules are 
released into the extracellar space (through lysis of cell membranes) for reaction with 
reagents (luciferin, luciferase). To ensure complete measurement of the ATP, cell 
viability assays must contain sufficient luciferin and luciferase as constituent reagents in 
order for all ATP molecules to react and generate luminescence that is proportional to 
the amount of ATP (Figure 3.3.4-1). 
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3.4. Statistics 
Statistical analysis was performed by one-way ANOVA (with either SPSS 13.0 
software, or using MS Excel statistical functions). Comparisons were made using 
Tukey’s multiple comparison test, non-parametric analysis (Kruskal-Wallis test) and 
Pearson’s correlation. Significant differences between the experimental groups were 
established at the p < 0.05 level of significance, and also at p < 0.01 for a number of 
cases where significant difference exists at only the lower probability level. 
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4. RESULTS 
4.1. Analytical Confirmation of the Synthesized Gemini Surfactants 
The results of independent analyses of the structure and purity of the surfactant 
products obtained from synthesis carried out in this research are given in Appendix A. 
These results, namely data from CH&N elemental, 1H NMR and Electrospray Ionization 
Mass Spectrometric (ESI-MS) analyses, strongly confirm that the desired compounds 
were produced and well purified, there being no starting materials or intermediate 
monoquartenary species present. 
4.2. Characteristics of the Gemini Surfactants 
Important transfection-related characteristics for aqueous solutions of the gemini 
surfactants were obtained by measuring certain physicochemical properties of the 
gemini surfactant-water systems. The results are presented below. 
4.2.1. Gemini Surfactant Krafft Temperatures 
Generally, when a saturated gemini surfactant-in-water suspension containing 
excess undissolved surfactant is heated with concurrent measurement of conductivity, it 
reaches a point in temperature (i.e., the Krafft temperature, TKrafft) at which the solubility 
of the surfactant increases sharply. This sharp increase, which also marks the onset of 
aggregation, is signaled by a rapid increase in the conductivity of the heated sample 
 54
[227]. The surge in conductivity results in an inflection in the conductance vs. 
temperature curve. These curves are given in Figure 4.2.1-1. Krafft temperatures for the 
gemini surfactants estimated from slopes of the lines before and after the inflection are 
tabulated in Table 4.2.1-1. The inflection points of reference are indicated by arrows. 
It is important to note that while the 18-3-18, 18-7-18 and 18-7NH-18 surfactants 
show the typical rapid increase in conductance (i.e., sharp increase in solubility) with 
heating, resulting in more distinctive inflection at their Krafft temperatures (Figure 
4.2.1-1B, C), the other surfactants such as 16-7-16, 16-7NH-16, 18:1-3-18:1 and 18:1-
7NH-18:1 displayed less distinctive inflection points (note, the inflections referred to are 
indicated by arrows) (Figure 4.2.1-1A, D). The less distinctive Krafft point inflection for 
the latter group of gemini surfactants occurs particularly for 16-7-16 and 16-7NH-16 as 
a result of their fairly high solubilities at temperatures well below their Krafft 
temperatures. The high solubilities coupled with relatively small increases in solubility 
in response to rise in temperature resulted in conductance vs. temperature curves that 
show a gradual rise in solubility just before the Krafft temperature instead of the usual 
steep rise in solubility as shown for the 18-3-18 surfactant (Figure 4.2.1-1C). 
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Figure 4.2.1-1. Determination of Krafft temperature for the gemini surfactants.  
The point of inflection for each curve (indicated by an arrow) shows the point at which 
complete clarification of the saturated aqueous gemini surfactant–water system was 
observed. Using conductivity (G) vs. temperature (T) plots, TKrafft is determined from the 
intersection of the regression lines for each curve. The plotted data are also given in 
Appendix B. 
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Table 4.2.1-1. Krafft temperatures (TKraftt) for the gemini surfactants. 
Molecular weight  TKrafft Surfactant (g mol-1)  (oC) 
12-spacer-12 Various weights  DNP   
        
m-3-m        
16-3-16 740.9  42.0a 
18-3-18  797.0  45.3 
18:1-3-18:1 793.0  28.8 
        
m-7-m        
16-7-16 797.0  38.9 
18-7-18  853.1  39.3 
    
m-7NH-m    
16-7NH-16 798.0  38.4 
18-7NH-18 854.1  39.3 
18:1-7NH-18:1 850.07  30.2 
DNP: determination not pursued; TKrafft for the gemini surfactants with C12 chains falls 
below room temperature 
aFrom ref. [228] 
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Krafft temperature determination for the gemini surfactants with C12 chains was not 
pursued; aqueous solutions of these surfactants did not become saturated upon addition 
of a large excess of the solute surfactants, implying the Krafft temperatures are lower 
than room temperature. On the other hand, Krafft temperature for the gemini surfactants 
with long, saturated carbon chains were quite higher than room temperature. High Krafft 
temperatures, which are usually a minimum of 39 ± 2 oC for long, saturated carbon 
chains (≥ C16), are a source of potential problems in the preparation of aqueous 
surfactant solutions, including those with low solubilities. 
The introduction of unsaturated carbon chains allowed the reduction of Krafft 
temperatures for the oleyl-tailed surfactants 18:1-3-18:1, 18:1-7NH-18:1 relative to their 
saturated C18 tail-bearing analogues (Table 4.2.1-1). The presence of hydrophilic groups, 
which generally boost solubilities of organic molecules in water, can also allow 
reduction of Krafft temperatures. The incorporation of an NH group, a small hydrophilic 
unit, did not replicate this trend in the surfactants studied. In the subsequent analysis of 
aqueous surfactant solutions, the solutions were prepared by dissolving the surfactant 
solutes at temperatures higher than the Krafft temperatures of the surfactants. 
4.2.2. Surface Tension Analysis 
Surface tension vs. log concentration for aqueous gemini surfactant solutions are 
given in Figure 4.2.2-1, below. All the curves indicated the absence of a minimum in the 
plateau region just above the CMC, giving additional indication of highly pure 
surfactants. Critical micelle concentration (CMC) values, determined from regression 
analysis of the pre- and post-micellar region of each curve, are given in Table 4.2.2-1.  
 58
40
45
50
55
60
65
-4 -3.5 -3 -2.5
log C
γ / 
m
N
 m
-1
12-7-12
40
45
50
55
60
65
70
-5.7 -5.3 -4.9 -4.5
log C
γ / 
m
N
 m
-1
16-7-16
16-7NH-16
 
 
  
30
35
40
45
50
55
60
65
70
-5.8 -5.3 -4.8 -4.3
log C
γ / 
m
N
 m
-1
18-3-18
18-7-18
40
45
50
55
60
65
70
-5.8 -5.3 -4.8 -4.3
log C
γ / 
m
N
 m
-1
18-7NH-18
18:1-7NH-18:1
 
 
Figure 4.2.2-1. Surface tension vs. log C plots for the gemini surfactants. 
Linear fits are indicated by lines; CMC values are calculated from intersections. The 
plotted values are also given in Appendix C. 
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The minimum head group area (a0), occupied per surfactant molecule at the aqueous 
solution/air interface, was calculated from the surface excess concentration, Γmax, 
according to Equation 4.2.2-1 
18
2 1
0
A max
10a (unit : nm molecule )
N
−= Γ  4.2.2-1 
where NA is the Avogadro number, and Γmax is derived from the Gibbs adsorption 
isotherm (Equation 4.2.2-2) 
max
1 d
2.303nRT dlogC
⎛ ⎞γΓ = − ⎜ ⎟⎝ ⎠    4.2.2-2 
In Equation 4.2.2-2, R is the gas constant and T is the absolute temperature. The value 
for n, which is the number of species at the interface resulting from the dissociation of 
the surfactants, was set to 3 for the calculations in this research. This is based on the 
consideration that dimeric surfactants such as the type studied herein consist of one 
dimeric surfactant ion and two univalent counterions. Calculations using n = 2 are 
usually for ionic surfactants made up of one univalent surfactant ion and one counterion. 
Nonetheless, a value of n = 2 for dimeric surfactants is sometimes encountered in the 
literature, because proponents of n = 2 assume that one of the two charged groups on the 
surfactant ion is neutralized by a bound counterion [172-174; 229]. Consequently, while 
several studies have used n = 3 [182; 230-232], others have used n = 2, 3 [233; 234] for 
calculation of a0 for gemini surfactants. In presence of a swamping electrolyte n is 
simply assigned a value of 1. Setting n = 1 indicates that the ionic strength of aqueous 
solution remains unchanged as surfactant concentration is varied [235]. 
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Two general trends are observed with respect to the CMC. First, CMC values 
determined for the gemini surfactants, in agreement with trends reported in the literature 
including a work published by Zana [178], were seen to decrease as the length of the 
alkyl tail is increased for constant spacer length. This trend is shared by single-head-and-
single-alkyl tail or monomer surfactants for which earlier studies of surface-active 
behaviour were focused. The distinguishing factor is that CMC values for gemini 
surfactants are orders of magnitude lower than for corresponding monomer surfactants 
of equal alkyl tail length. The second trend arises for gemini surfactants having a 
constant alkyl chain length and a spacer varying in both its length and elemental 
constitution, in a manner that eliminates simple comparison based on length. Where the 
spacer is a straight chain made of C and H only, 7-methylene-long spacers resulted in 
lower CMC values relative to 3-methylene-long spacers. But this is not to suggest any 
linearity between the length of spacer and CMC values. This issue is further discussed in 
Chapter 5.  
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Table 4.2.2-1. Critical micelle concentration (CMC) and head group area (a0) of the 
gemini surfactants determined from surface tension measurements. 
CMC  a0 Surfactant (×10-3 mol L-1)  (nm2 molecule-1) 
12-spacer-12        
12-3-13a 0.89 ± 0.08  1.11 ± 0.04 
12-5N-12b 1.14 ± 0.04  1.30 ± 0.03 
12-8N-12b 1.10 ± 0.10  1.95 ± 0.13 
12-7N-12b 0.87 ± 0.13  2.06 ± 0.20 
12-7NH-12b 1.29 ± 0.07  1.56 ± 0.04 
        
m-3-m        
16-3-16c 0.030 ± 0.002  1.21 
18-3-18  0.013 ± 0.001*  0.82 ± 0.4* 
18:1-3-18:1d 0.0151 ± 0.0004  0.72 ± 0.05 
        
m-7-m        
12-7-12 0.85 ± 0.07  1.24 ± 0.06 
16-7-16 0.016 ± 0.009*  1.19 ± 0.08* 
18-7-18  0.011 ± 0.001*  1.26 ± 0.09* 
    
m-7NH-m    
16-7NH-16 0.16 ± 0.05*  1.44 ± 0.07* 
18-7NH-18 0.013 ± 0.001*  1.36 ± 0.22* 
18:1-7NH-18:1 0.044 ± 0.007*  1.22 ± 0.11* 
a0 was computed by taking n = 3 in Equation 4.2.2-2  
*Experiment at 45 oC. All other values were at 25 oC including the values from 
   the cited refs 
aFrom ref. [218; 236] 
bFrom ref. [219] 
cFrom ref. [222] 
dFrom ref. [223] 
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4.2.3. Specific Conductivity Analysis 
 The specific conductance (κ) vs. concentration (C) plots for the gemini 
surfactants are given in Figure 4.2.3-1. The values of CMC and the degree of micelle 
ionization (α) derived from the κ vs. C plots are listed in Table 4.2.3-1. Different 
mathematical methods are available for calculating CMC values from specific 
conductance vs. concentration curves. A simple one is the calculation by way of 
regression analysis of two intersecting linear regions above and below the CMC. But to 
objectively determine CMC values a different approach is needed [237], regardless 
whether or not experimental points distinctively show intersecting lines. As well, any 
errors due to manipulation of the data must be eliminated. In the determination herein, a 
nonlinear curve fit of the conductivity–concentration raw data has been used, in which 
case the first derivative of the κ vs. C curve is assumed to follow a Boltzmann-type 
decreasing sigmoid as follows: 
1 2
2 (c CMC) / dC
A Ad A
d 1 e −
−κ = + +     4.2.3-1 
where κ is the specific conductivity, c (lower case) is the total concentration of 
surfactant, A1 and A2 are the lower-premicellar and upper-postmicellar limits of 
sigmoid, respectively. The CMC value is the centre of the sigmoid, and d is the so-called 
time constant, which is directly related to the independent variable range at which the 
abrupt change of the dependent variable occurs. The variation of the variable κ as a 
function of the surfactant concentration C, is then described by the integral of Equation 
4.2.3-1 [238], given by 
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(c CMC) / d
0 1 2 1 CMC/ d
1 eA c d(A A ) ln
1 e
−
−
⎛ ⎞+κ = κ + + − ⎜ ⎟+⎝ ⎠
  4.2.3-2 
where κ0 (the integration constant) is the specific conductivity of the surfactant-free 
solvent-water. The ratio of the two parameters A2/A1 gives the value of the degree of 
micelle ionization α, with values listed in Table 4.2.3-1. The CMC values determined 
from conductivity analysis (Table 4.2.3-1) exhibit a decreasing trend as the hydrocarbon 
chain length is increased. This trend was earlier observed using surface tension analysis and 
is a generally known trend. 
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Figure 4.2.3-1. Specific conductance vs. concentration plots for the gemini surfactants. 
Data are graphed as sigmoids from which CMC values are determined as described 
(Equation 4.2.3-2). The plotted data are also given in Appendix C. 
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Table 4.2.3-1.  Critical micelle concentration (CMC) and degree of micelle ionization 
(α) of the gemini surfactants determined from specific conductivity. 
CMC  α Surfactant (×10-3 mol L-1)  (no units) 
12-spacer-12        
12-3-13a 0.98 ± 0.04  0.23 ± 0.02 
12-5N-12b 0.97 ± 0.02  0.31 ± 0.01 
12-8N-12b 1.22 ± 0.10  0.38 ± 0.01 
12-7N-12b 1.17 ± 0.04  0.45 ± 0.02 
12-7NH-12b 1.21 ± 0.04  0.42 ± 0.01 
        
m-3-m        
16-3-16c 0.026 ± 0.001  0.35 ± 0.02 
18-3-18  0.028 ± 0.002*  0.32 ± 0.05* 
18:1-3-18:1d 0.0234 ± 0.0004  0.42 ± 0.06 
        
m-7-m        
12-7-12 0.865 ± 0.005  0.334 ± 0.03 
16-7-16 0.040  ± 0.01*  0.41 ± 0.16 * 
18-7-18  0.026 ± 0.001*  0.44 ± 0.04* 
    
m-7NH-m    
16-7NH-16 0.050 ± 0.001*  0.59 ± 0.06* 
18-7NH-18 0.025 ± 0.002*  0.56 ± 0.02* 
18:1-7NH-18:1 0.038 ± 0.008*  0.58 ± 0.06* 
*Experiment at 45 oC. All other values were at 25 oC including the values from the 
   cited refs 
aFrom ref. [218] 
bFrom ref. [219] 
cFrom ref. [222] 
dFrom ref. [223] 
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4.2.4. pKa Values of the Amine-substituted Gemini Surfactants 
pKa values, obtained from pH titrations for the amine-substituted gemini surfactants, 
are listed in Table 4.2.4-1. pKa analysis was not pursued for the amine-free gemini 
surfactants due to the expected lack of basic properties. Overall, the pKa values obtained 
make the surfactants weak bases. Nonetheless, the pKa value of a weak base gives an 
indication of the degree of ionization of a base; i.e., the basic strength. Lower pKa values 
imply greater ability of the aza (N-CH3) or imino (NH) groups on the surfactants to be 
protonated or ionized in aqueous medium and thus imply higher basic strength. The 
reverse is also true. With respect to cellular gene delivery, low pKa values allow for pH 
buffering of endosomes during downward pH transition of these compartments. This can 
help protect and favour release of DNA from gemini surfactant/DNA complexes taken 
up by cells. In general, the protection and assisted release of DNA are considered to lead 
to improved transfection [239].  
The pKa values alone would suggest that 12-8N-12 and 12-7N-12 surfactants, with 
the lowest and second lowest pKa values among the amine-substituted gemini 
surfactants, would be better in protecting and favouring the release of DNA. But any 
conclusion that these two surfactants will emerge as better tranfection agents relative to 
the other amine-subsituted gemini surfactants stands to be validated experimentally. 
Moreover, the level of importance of low pKa values is relative to the effect of 
potentially more important factors including the demonstrated effectiveness of 
surfactant–DNA interactions (Table 5.1-1) and the pH-sensitivity of transfection 
complexes formed upon the mixing of DNA with the gemini surfactants (Section 4.3.1). 
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Table 4.2.4-1.  pKa values of amine-substituted gemini surfactants 
Surfactant pKa Surfactant pKa 
12-5N-12b 5.2 ± 0.4 12-7NH-12b 5.0 ± 0.4 
12-8N-12b - pKa1 4.1± 0.4 16-7NH-16 5.04 ± 0.3 
12-8N-12b - pKa2* – 18-7NH-18 5.06 ± 0.3 
12-7N-12b 4.5 ± 0.2 18:1-7NH-18:1 4.99 ± 0.2 
*Second ionization not observed under experimental conditions 
bFrom ref. [219] 
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4.3. Characteristics of Gemini Surfactant/DNA Transfection Systems 
4.3.1. Particle Size 
Figure 4.3.1-1 (A – E) shows the changes in size of surfactant aggregates as a 
function of pH. The m-7NH-m surfactants clearly show a significant change in 
aggregate size on going from basic to acidic pH, as a result of protonation of their imino 
groups. Aggregates of the 12-7NH-12 surfactant exhibited a narrow transition in size 
(from ~2.5 to 3.7 nm radius, Figure 4.3.1-1A, also shown in ref [201]) compared with 
the vesicle-to-micelle transition observed for sugar-based gemini surfactants [52; 206; 
207; 240; 241]. This observed structural change, induced by a transition from neutral to 
acidic pH, nonetheless holds potential importance when it comes to aiding the release of 
DNA once gemini surfactant-DNA complexes have been incorporated within the cell. 
The change in aggregate size was more pronounced for the 16-7NH-16, 18-7NH-18 and 
18:1-7NH-18:1 surfactants. It is important to note the difference in hydrocarbaon tail 
length between these three higher m-7NH-m surfactants and the 12-7NH-12 surfactant. 
The hydrocarbon tails of the three higher m-7NH-m surfactants are extended by 4 to 6 C 
atoms (C4 to C6) relative to the 12-7NH-12 surfactant. This confers stronger aggregation 
characteristics to the three longer-tailed surfactants as evidenced by the lower CMC 
values of the m = 16, 18, 18:1 surfactants relative to the m = 12 surfactant. Such 
variation in surfactant structure helps to highlight important structural components in 
molecules that are designed for gene delivery. 
The fact that the four m-7NH-m surfactants showed structural transition, inspite of 
the variation in hydrocarbon tail length (m = 12, 16, 18, 18:1, Figure 4.3.1-1A, B and C, 
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respectively) indicates the consistent pH-sensitivity of these surfactants. This is similar 
to the pH-sensitive behaviour reported for other systems [207; 242] for which the 
resulting size vs. pH curves, in some cases, can be said to assume a sigmoidal shape. 
The degree of structural change was, however, different between the 12-7NH-12 
surfactant and the higher members of the series (16-7NH-16, 18-7NH-18 and 18:1-7NH-
18:1). For the 12-7NH-12 surfactant, the particle size was seen to increase with 
acidification of the system beyond neutral pH up to a maximum at which particle size 
stayed constant with further acidification (decrease in pH). The accompanying change in 
particle size for aggregates of the 12-7NH-12 surfactant from ~2.5 to 3.7 nm (Figure 
4.3.1-1A) represents an overall increase of 1.2 nm. In contrast, surfactant aggregates for 
the three higher members showed a more pronounced response to the downward 
adjustment of pH; aggregates showed size increase by 2.5 to 5 nm (Figure 4.3.1-1B, C). 
The particle size increase for the 16-7NH-16 and 18-7NH-18 surfactant aggrgates 
occurred sharply as pH was decreased below a value of 6, reaching a plateau at pH 3 or 
2. The increase in particle size for the 18:1-7NH-18:1 surfactant aggregates was gradual 
and continuous over a wide pH range starting from 11 to around 3.5. This gave rise to an 
arc-shaped curve (Figure 4.3.1-1C) that somewhat departs from the classic sigmoidal 
shapes observed for the other surfactants within the m-7NH-m series (m = 12, 16, 18) 
(Figure 4.3.1-1A, B). The ‘arc-like’ structural change, nonetheless, clearly signifies the 
pH-senitive tendancy of the 18:1-7NH-18:1 surfactant, implying this surfactant does not 
fall short of the potential to aid the release of DNA once gemini surfactant–DNA 
complexes have been incorporated within a cell. 
The difference between the 12-7NH-12 surfactant and the three higher analogues is 
likely due to the qualitative difference in alkyl tail length between the 12-7NH-12 
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surfactant and the three longer-tailed analogues. The difference hydrocarbon in tail 
length also stands to explain why aggregates for the three higher analogues were 
generally larger than aggregates for the 12-7NH-12 surfactant. Overall, the structural 
changes observed, which were pronounced for the three higher m-7NH-m surfactant 
members and less pronounced for the 12-7NH-12 surfactant, hold the potential to aid the 
release of complexed DNA.  
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Figure 4.3.1-1. pH dependence of the size of gemini surfactant aggregates formed in 
aqueous solution. 
Initial concentration of aqueous gemini surfactants in each case was 2 × CMC. pH was 
adjusted using standard acid (HCl) and base (NaOH) solutions. The results presented in 
part A are also published in ref [201]. 
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Investigations for pH-dependent changes in particle size of surfactant aggregates for 
the rest of the surfactants involved in this study were also carried out. The aggregate size 
for these other surfactants, shown in Figure 4.3.1-1A (top three on the legend), Figure 
4.3.1-1D (m-3-m series) and Figure 4.3.1-1E (m-7-m series), remain essentially 
unchanged. The lack of structural changes for these surfactants is in contrast with 
structural changes for the m-7NH-m surfactants and creates the scenario for one to look 
forward to a comparison of the two opposing traits in terms of transfection efficiency. 
However, in expectation that the structural changes will aid the release of complexed 
DNA, a higher level of transfection efficiency can be presumptuously assigned to the m-
7NH-m surfactants over the other surfactants.  
The aggregation of gemini surfactants (or other amphiphilic molecules) and the 
change in structural conformation of the aggregates from one structural phase to another, 
are generally gorvened by certain factors. These factors include the molecular structure 
of the gemini surfactant, the surfactant concentration within an aqueous solution 
(absolute concentration or as factor of the CMC), the ionic strength, pH and temperature 
of the solution. Keeping all these variables constant and varying only pH allowed the 
pH-sentivities already described for the gemini surfactants to be investigated. As one of 
the controlled variables, the gemini surfactant concentration was set to twice the CMC 
value (2 × CMC) of the gemini surfactants at the start of each pH-dependent size 
analysis. This was done to ensre proportionate aggregation for all the gemini surfactants. 
Under this condition, the diameter of micellar aggregates formed by each gemini 
surfactant can be expected to fall within the length of the fully extended tails of the 
gemini surfactant, with the possibility of experimental deviation. Though the use of a 
common concentration value, such as 2 mM, for all the gemini surfactants is sufficient 
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to generate surfactant aggregates for size analysis, it represents an aggregation condition 
that is not proportionate across all the gemini surfactants. For instance, whereas the 2 
mM concentration is generally two-fold greater than the CMC values for surfactants 
with C12 tails, this concentration is far more greater than the CMC values for the 
surfactants with C16 and C18 tails; e.g., 2 mM is more than 100-fold greater than CMC 
value of the 18-3-18 surfactant which has the lowest CMC value. Further investigations 
could, in future, be carried out to compare the results of size analysis at a constant 
surfactant concentration (e.g., 2 mM) and at 2 × CMC value for each surfactant. 
The influence of the molecular structure of the gemini surfactants on the surfactant 
aggregates was observed in two ways. First, in terms of the already described ability of 
aggregates of the m-7NH-m surfactants to undergo structural changes at acidic 
conditions due to their possession of pH-sensitive imino group. Second, in terms of the 
generally observed increase in aggregate size in response to increase in the hydrocarbon 
tail length of the surfactants (an expected trend). The larger (increasd) aggregate sizes 
for surfactants with longer hydrocarbon tails can be seen among the the m-7NH-m 
surfactants, but is particularly more obvious with the m-3-m and m-7-m surfactants. A 
better comparison of the surfactant aggregate size can be done at neutral or non-acidic 
pH. At neutral pH, the aggregates of gemini surfactants with C12 tails fall within a close 
size rang ~2.2 ± 0.2 nm. The surfactants with longer hydrocarbon tails (m = 16, 18) 
yielded larger aggregates, except the oleyl-tailed surfactants (m = 18:1) whose 
aggregates are closer in size to those of the C12-tailed surfactants. The small aggregate 
size for the oleyl-tailed surfactants is attributable to the mono-unsaturation in the oleyl 
tails. 
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In carrying out further work on the structural changes of gemini surfactants systems, 
investigations were focused on m-7NH-m surfactants. The pH dependence of both 
particle size and zeta potential (see Section 4.3.2) was determined for ternary plasmid-
gemini surfactant-lipid (PGL) transfection complexes prepared using these surfactants 
and the lipid DOPE. As shown in Figure 4.3.1-2 (A, B), these complexes exhibited a 
pH-dependent structural transition in their particle size. The initial change begins at 
about neutral pH, with the size of particles increasing as pH becomes more acidic, until a 
plateau occurs at pH lower than 4.5. The least change/increase in size (12.5 nm) within 
the pH range 7 to 4.5 was observed for the P-18:1-7NH-18:1-L complexes, while the 
rest showed an increase between 40 and 80 nm. 
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Figure 4.3.1-2. pH dependence of the size of transfection complexes formed from 
gemini surfactant–plasmid–DOPE mixtures. 
The titrations were carried out for transfection systems with the optimal +/- charge ratio 
(i.e. ρ+/- = 10:1) in the case of each gemini surfactant to transfect cells. The results 
presented in part A are also published in ref [201]. 
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With regards to the observed structural changes for both the surfactant aggregates 
and transfection complexes for the m-7NH-m surfactants, it is worth noting the 
similarity in the pattern of structural change between the aggregates and the complexes. 
For instance, for the 12-7NH-12 surfactant, both the complexes (Figure 4.3.1-2A) and 
surfactant-only aggregates (Figure 4.3.1-1A) showed an increase in their particle size in 
response to decreasing pH. The rest of the m-7NH-m surfactants (namely, m = 16, 18, 
18:1) yielded aggregates and complexes with similar behaviour. That is, for these three 
higher surfactants (of the m-7NH-m series), the transfection complexes showed an 
increase in particle size as pH was decreased (Figure 4.3.1-2B), a trend also observed for 
the particle size of the surfactant aggregates (Figure 4.3.1-1B&C). These observations 
suggest that the transfection complexes (i.e., for all four m-7NH-m surfactants) which 
undergo (Figure 4.3.1-2A&B) enlargement in response to acidification, do so as a result 
of pH-induced expansion of the aggregated surfactant component of the transfection 
complexes. The disreuptive effect of such structural expansion is believed to then lead to 
release of DNA from its spheres of entrapment. Release of DNA is important for 
presenting cells with freed DNA for gene expression. The spheres of entrapment, upon 
endocytosis, include entrapment within the gemini surfactant–DNA complexes and 
within the outer endosomal membrane. 
These pH-induced changes in the particle size of both the aggregates and 
transfection complexes, and the structural changes they indicate can be explained as 
follows. For the surfactants-only aggregates, the increament in particle size (for the m-
7NH-m) as pH becomes increasingly acidic may suggest a swelling of the aggregates 
resulting from protonation and repulsion between aggregate-forming gemini surfactant 
molecules. This bears a similarity to observed changes from vesicular to cylindrical, 
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ellipsoidal or the so-called ‘ribbon’ entities [243], in which case the aggregate size 
increases at acidic pH. This is in contrast to the behaviour of other systems for which 
there is a reduction of the aggregate size as pH becomes increasing acidic; this is usually 
explained in terms of a vesicle-to-micelle transition [207]. It should, however, be noted 
that because the size analysis performed herein is not a ‘diagnostic’ analysis that 
determines the exact type of structural change, the changes observed for these 
surfactants could as well indicate other types of conformational changes. With regard to 
the transfection complexes, the increase in particle size is possibly the result of the 
dissociation of DNA from its carrier gemini surfactant molecules, an event that would 
allow the complexed DNA to unpack and decondense. The importance of such 
unpacking and decondensation of DNA after cellular uptake of complexed DNA lies in 
the premise that any nuclear entry should involve the freed DNA as this will permit 
ready protein expression. Further studies could, in future, be carried out to determine the 
exact type of structural changes, which in a general form, were detected in this research 
using pH-dependent size analysis. 
4.3.2. Zeta Potential Analysis 
Zeta (ζ) potential of the transfection complexes, like particle size, also displayed 
pH-dependence (Figure 4.3.2-1A, B), similar to previously reported systems [207]. For 
all the complex systems analyzed, the ζ-potential increases in response to decrease of pH 
within the basic range, which is consistent with the expected decrease in counterion (i.e., 
hydroxide) binding to the complex. The ζ-potential behaviour for the 12-7NH-12 
surfactant-containing system, in the neutral to acidic pH range, was rather unique when 
compared with the behaviour for the three other m-7NH-m surfactants (m = 16, 18, 
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18:1). As the pH was decreased from a basic pH medium above pH 7, a rise in the ζ-
potential curve for the 12-7NH-12 surfactant was observed, and this gave way to a 
plateau region beginning at around pH 7. This plateau region was followed by a sharp 
decrease in ζ-potential at a pH of about 5.5, becoming another plateau at lower pH 
(Figure 4.3.2-1A). Such behaviour could be linked to the pH-induced structural change 
for the 12-7NH-12 surfactant systems, which was also observed within the neutral to 
acidic pH range (Figure 4.3.1-1A, Figure 4.3.1-2A). For the systems containing the 16-
7NH-16, 18-7NH-18 and 18:1-7NH-18:1 surfactants, increase in ζ-potential occured as 
the pH was decreased from a basic pH medium above pH 7. However, the ζ-potential 
generally plateaued or started to plateau as pH fell from pH 7 into the acidic pH range 
(Figure 4.3.2-1B). 
As expected, the complexes for all four m-7NH-m surfactants were positively 
charged at neutral pH (pH = 7), with ζ-potential in the range of +40 – +45 mV (Figure 
4.3.2-1). Indeed the overall positive charge at neutral pH is a result of the residual 
concentration of cationic gemini surfactants after DNA was neutralized and complexed 
with excess gemini surfactant at a gemini surfactant:DNA charge ratio of 10:1. The 
electrostatic interaction between the negatively charged phosphate groups of DNA and 
the positive charges of cationic agents has itself been routinely verified using ζ-potential 
analysis. The premise is that a reduction in the ζ-potential of positively charged gemini 
surfactant vesicles should occur after addition of negatively charged DNA (ζ-potential 
herein found to be -43 mV), and final charge of the mixture (in mV) should still be 
higher than the ζ-potential of the surfactant-free DNA [244; 245]. 
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Figure 4.3.2-1. Effect of pH on the zeta potential of transfection complexes formed 
from gemini surfactant–plasmid–DOPE mixtures. 
The titrations were carried out for transfection systems with the optimal +/- charge ratio 
(i.e. ρ+/- = 10:1) in the case of each gemini surfactant to transfect cells. Results in part  A 
are also published in ref. [201]. 
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4.3.3. Physical State of Transfection Complexes 
The physical state of transfection complexes freshly prepared from the m-7NH-m 
surfactants at the +/- optimal charge ratio of 10:1 was further examined using TEM 
(Figure 4.3.3-1). The complex nanoparticles which showed an overall positive charge 
(Figure 4.3.2-1) and revealed themselves as discrete particles, in the size range of 
approximately 150 – 250 nm. This particle size range is particularly noteworthy because 
of the similarity in size of transfection complexes between TEM and pH-dependent size 
analysis (size range 120 – 225 nm, Figure 4.3.1-2). Such particle size agreement 
between analytical methods such as the pH-dependent size analysis (a method operating 
based on dynamic light scattering, DLS) and TEM is not commonly seen in the literature 
though it helps to independently confirm particle size of transfection complexes. 
The physical appearance of the particles showed a very similar nature for complexes 
derived from the m-7NH-m surfactants  regardless of the alkyl tail length (m = 12, 16, 
18, 18:1). Some particles were observed to have either fused/aggregated into larger ones, 
reminiscent of previously reported observations [40; 187; 190; 246], or remained as 
single spherical entities, also consistent with previously reported studies on particles [40; 
190; 247]. Apart from size, the particles were also heterogeneous in shape, with their 
uneven surfaces being consistent with DNA molecules being sandwiched between lipid 
bilayers [191; 248; 249]. Free DNA was not observed, which is clearly due to its 
complete neutralization, condensation and encapsulation at the optimal +/- charge ratio 
at which the gemini surfactant is present in excess. Also, unlike those in previous reports 
[40; 101; 189; 250-252], structures in the form of strands or ‘spaghetti’ were not 
observed. In the light of the heterogeneity observed for the complex nanoparticles, it 
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would be reasonable to think that such heterogeneity may well indicate the tendencies 
displayed by certain transfection complexes in which they adopt a number of multiple 
structural phases including lamellar, hexagonal and cubic phases. This hypothesis could, 
in future, be evaluated from small-angle X-ray scattering (SAXS) studies of the 
complexes and examination of the scattering pattern in relation to the physical state of 
complexes revealed using TEM. 
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Figure 4.3.3-1. Transmission electron micrographs showing complexes derived from 
plasmid–gemini surfactant–lipid mixtures. 
Representative selection of electron micrographs of the complex particles derived from 
the plasmid–m-7NH-m gemini surfactant–lipid mixtures at pH of 7.6 ± 0.4. The gemini 
surfactant:DNA charge ratio for the mixtures was 10:1. mag. 2400x 
300 nm 300 nm 
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4.4. Ultrastructural Examination of PAM 212 Cells 
The high resolution afforded by transmission electron microscopy (TEM) was 
employed in conjunction with TEM sample preparation techniques (described in Section 
3.3.2) to study the morphology and size or other structural adaptations of the cells. The 
two electron micrographs in Figure 4.4-1 demonstrate a preservation of the cellular 
matrix and allow stereological analysis using these ultrastructural images. Morphometric 
measurement of several imaged cells indicates the diameter of cells falls within a range 
of 6-10 µm. This is assuming cells are spherical. In reality, cells were of unequal size 
and exhibited mixed morphologies, including nearly spherical and oval shapes. 
Cell size has the potential to be important in the ability of a cell line to take up 
particles presented to the cells as a transfection preparation. A second factor of prime 
importance, in terms of efficient transfection, is the size of non-viral DNA complexes 
themselves being transferred into the cells. For instance, correlation has been drawn in 
some cases between the small size of complexes and transfection activity [253]. On the 
other hand, attempts seeking to explore the effects of cell size have yet to appear in the 
literature. The physical features, including size and morphology, of the PAM 212 cells 
used in this research were examined in an attempt to proceed into transfection studies 
with a deeper understanding of the cells’ structural dimensions.  
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Figure 4.4-1. Transmission electron micrographs of PAM 212 cells 
(A) This electron micrograph shows the extracellular background (Esp). Varying 
morphologies, ranging from imperfect round to elongated shapes, are revealed by the 
cells labeled C1, C2, C3 and C4; mag. 2400x. (B) A segment of a cell depicting the 
nucleus (N), and the nuclear membrane (arrowheads). Adjacent to the nuclear membrane 
are tonofilaments (arrows); mag. 24000x 
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4.5. Evaluation of Gene Expression 
Assessment of the transfection abilities of the surfactants studied in this research 
was conducted in two phases involving two cell lines overall. COS-7 cells were used as 
a standard transfection cell line to perform an initial screening of surfactants for 
advanced testing in PAM 212 cells. Results of the two transfection phases are presented 
below, in Sections 4.4.2.1 and 4.4.2.2, respectively. 
4.5.1. Transfection with 12-spacer-12 Gemini Surfactants 
Figure 4.5.1-1 shows both transfection efficiencies and cytotoxicity results for 
transfection complexes prepared using the 12-spacer-12 surfactants. The experiments 
featured plasmid-gemini surfactant (PG) and plasmid-gemini surfactant-DOPE (PGL) 
complexes, which are binary and ternary systems, respectively. Increasingly, large 
numbers of non-viral delivery systems involving gemini surfactants are being 
investigated for use as transfection agents. A recent evaluation of 12-s-12 surfactants by 
Badea et al. [132] showed the highest transfection occurred with the 12-3-12 surfactant 
among the 12-s-12 series. For comparison, the 12-3-12 surfactant has been included in 
this study. Previously published results indicate that the plasmid-gemini surfactant 
complexes, prepared with the exclusion of DOPE, yielded weak or no transfection, while 
addition of DOPE to these complexes significantly increased the transfection 
efficiencies [39; 132; 192; 254; 255]. The results in Figure 4.5.1-1A indicate that for 
both PG and PGL systems, the imino-substituted 12-7NH-12 surfactant yielded the 
highest transfection. In this case the PG system yielded modest results, and not 
surprisingly, the PGL system yielded a 13-fold increase in transfection over the PG 
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system. Increase in transfection afforded by the addition of DOPE has been explained in 
terms of the ability of DOPE to stabilize cationic liposomes and to induce the 
destabilization of the endosomal membrane upon contact between liposome-DNA 
complexes and endosomes. Once destabilized, the endosomes release complexed DNA 
to permit its entry into the nucleus and to allow transcription to take place [254; 256] or 
to permit expression of the DNA while it is still in the cytosol. 
The transfection efficiencies given by the aza- and imino-substituted surfactants are 
higher than efficiencies found for their previously reported unsubstituted counterparts 
[132], which do not bear any aza- and imino-substitution. These surfactants, prepared 
and used as amine-substituted PGL systems, also recorded greater transfection 
efficiencies over the plasmid-DOPE system, which yielded negligible results (Figure 
4.5.1-1A). This is due to the absence of a cationic component to compact and neutralize 
DNA for better cellular uptake. No significant difference was observed for the 12-3-12 
surfactant and 3-β-[N-(N`,N`-dimethylaminoethane)-carbamoyl] cholesterol (DC-Chol). 
By way of its high transfection efficiency, no significant difference in transfection was 
observed between the 12-7NH-12 surfactant and commercial Lipofectamine Plus™ 
transfection agent. 
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Figure 4.5.1-1. Transfection efficiency and cytotoxicity results in COS-7 cells. 
(A) Transfection with plasmid-gemini surfactant complexes (PG, black bar), and gemini 
surfactant-DNA-DOPE nanoparticles (PGL, white bars); ρ+/- = 10:1 (n = 6, error = SD). 
Results for DC-Chol with (white) and without DOPE (black), plasmid with (white) and 
without DOPE (black), and Lipofectamine Plus™ (shaded), used as controls are also 
shown.  
(B) Mean cell viability (n = 4, error bars = SD) of COS-7 cells transfected with plasmid 
gemini surfactant-DOPE nanoparticles (white bars) n = 4, bars = SD). Data are also 
presented for untransfected cells and cells transfected with plasmid only (black bars) n = 
4, bars = SD), and cells transfected with Lipofectamine Plus™ (gray bar). Determination 
of both transfection efficiency and cell viability was done 24 h after transfecting cells. 
Columns connected by a solid line show no significant difference, those connected with 
a dashed line show a significant difference (p < 0.01). Results in this figure are also 
published in ref. [201]. 
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As part of the assessment of surfactant suitability for use in biological hosts, 
transfection efficiencies were closely compared with transfection-related cytotoxicities 
resulting from the use of gemini surfactants and Lipofectamine Plus™ (Figure 4.5.1-
1B). The surfactants 12-5N-12, 12-8N-12 and 12-7N-12 caused similar toxicity in 
transfected COS-7 cells as in the Lipofectamine Plus™ reagent (p > 0.05). Both these 
surfactants and Lipofectamine Plus™ reduced the viability of cells to approximately 
80% of the non-transfected control or cells transfected with plasmid alone. The parent 
12-3-12 surfactant recorded minimal toxicity and was not more toxic than the non-
transfected control. Cell toxicity for the 12-7NH-12 surfactant was slightly higher 
(~70% cell viability) than for Lipofectamine Plus™ (p < 0.01), but not significantly 
different from the 12-5N-12 and 12-8N-12 surfactants (p > 0.05). Thus, compared with 
these two surfactants in the amine-substituted surfactant family, 12-7NH-12 achieved 
increased transfection without resulting in increased cytotoxicity. 
4.5.2. Advanced Multi-surfactant Series Transfections 
Following phase 1 transfections in Section 4.5.1 above, an advanced and expanded 
transfection phase (i.e., the ensuing section) was staged to study the best surfactants (or 
the structures) coming out of phase 1. These surfactants were contrasted with related but 
structurally different surfactant analogues for which one or more of the predicted 
transfection-enhancing features (based on rational molecular gene carrier design) are 
removed. Surfactants tested in the current transfection phase are grouped into three 
series; namely, m-3-m, m-7-m and m-7NH-m surfactants (Table 3.1.2-1). 
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4.5.2.1. Transgene Expression: Effect of Time 
Protein expression following successful transfer of a reporter gene into cells or 
tissue can either be permanent or transient, due to a permanent or transient genetic 
modification, respectively, caused in the host. With permanent gene expression, the level 
of protein expression plateaus following an increase in the pattern of protein expression, 
whereas in transient gene expression, protein levels will be expected to rise and decline 
with time. In the particular scenario of our experiments (with PAM 212 murine 
keratinocytes, pMASIA.Luc plasmid and our new group of gemini surfactants), the 
levels of protein expression were quantified at different time points. Transfection results 
for plasmid–gemini–DOPE (PGL) complexes representing ρ+/- = 10:1 for the m-3-m 
surfactants are illustrated in Figure 4.5.2.1-1. 
Luciferase expression rose from 12 h post-transfection to its highest level at 24 h 
post-transfection, and then declined through 48 h and 72 h post-transfection. Virtually 
no luciferase was expressed in cells transfected with two gemini surfactant-free controls; 
namely, plain plasmid solution (termed naked DNA) and plasmid combined with DOPE 
in a 0.1:18 weight ratio. Since the highest protein expression was detected at 24 h post-
transfection, quantitation of luciferase reporter gene expression in subsequent 
transfections was carried out 24 h after transfection. 
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Figure 4.5.2.1-1. Luciferase reporter gene expression in PAM 212 cells measured as a 
function of post-transfection duration. 
The PGL complexes prepared with ρ+/- = 10:1 featured the m-3-m surfactants. The 
transfections also involved three controls, namely, naked DNA (plasmid), 
plasmid/DOPE combination and Lipofectamine Plus reagent. The resulting protein 
produced within the cells was quantified after transfection at different time points: 12 h, 
24 h, 48 h, 72 h. n = 4, error bars = SD. 
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4.5.2.2. Transgene Expression: Effect of +/- Charge Ratio 
In addition to the influence of time (i.e., the post-transfection duration) on the level 
of expression of a reporter gene, which was shown in the previous section (Section 
4.5.2.1), gene expression in host cells is also governed by how well the genetic material 
is packaged and presented to cells. Efficient packaging is obtained by complete 
neutralization, condensation and encapsulation of DNA into nanoparticles using delivery 
molecules containing cationic headgroups or protonatable amine groups arranged to 
permit close-matching interaction with DNA. In addition, the nanoparticles need an 
optimal +/- charge ratio to propel the nanoparticle–cell attachment and subsequent 
cellular uptake. In short, the efficiency of non-viral gene transfer is dependent on the +/- 
charge ratio and, of more interest to us, the structural features of the delivery agent. As 
such it was important to unify or eliminate the effect of interfering variables, including 
charge ratios, to create optimal conditions under which the different structural schemes 
exhibited by our surfactants can be fairly compared.  
The first step for this was to determine the post-transfection duration leading to the 
highest level of gene expression (Figure 4.5.2.1-1). The next step was to determine the 
ρ+/- at which all the surfactants most effectively transfer DNA into cells (indicated by the 
level of gene expression). Thus, transfections were carried out involving five different 
charge ratio (ρ+/-) values; namely, 10:1, 5:1, 2.5:1, 1:1, 0.5:1. The m-3-m surfactants 
were featured in the transfections. Figure 4.5.2.2-1 shows that the transfection 
efficiencies (i.e., level of luciferase expression, 24 h post-transfection) was highest in 
cells transfected using PGL complexes with ρ+/- = 10:1. Complexes with lower ρ+/- 
values recorded lower efficiencies due to reduced cell-surface binding. This observation, 
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using the m-3-m surfactants, led us to also conduct ρ+/--dependent transfections for the 
two analogue surfactant families, i.e., m-7-m and m-7NH-m surfactants. As expected, 
the ρ+/- = 10:1 preparation formula consistently recorded the highest transfection 
efficiency in both the m-7-m and m-7NH-m surfactants (Figure 4.5.2.3-1). In previous 
investigations by our laboratory, transfection complexes with ρ+/- = 10:1 also transfected 
cells better than complexes with higher ρ+/- values, including ρ+/- = 20:1 and 40:1 [244]. 
Thus, gene expression was optimal when cells were transfected using complexes with 
ρ+/- = 10:1 and the gene expression was quantitated 24 h after transfection.  
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Figure 4.5.2.2-1. Luciferase reporter gene expression in PAM 212 cells measured as a 
function of the gemini surfactant:DNA charge ratio (i.e., the +/− charge ratio). 
The PGL complexes prepared with variable ρ+/- values including 10:1, 5:1, 2.5:1, 1:1 and 
0.5:1, featured the m-3-m surfactants. The resulting protein produced within the cells 
was quantified at 24 h-post transfection. n = 4, error bars = SD. 
Charge ratio (+/−) 
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4.5.2.3. Transgene Expression: Effect of Gemini Surfactant Structure 
The many variables employed in our ongoing development of optimal, potentially 
clinically effective gemini surfactant systems for carrying genes into cells include 
surfactant structural variation. So, the three series of gemini surfactants were compared 
under an advanced transfection phase using optimized conditions (ρ+/- = 10:1, 24 h post-
transfection analysis). As seen in Figure 4.5.2.3-1, levels of protein expression were, 
overall, the highest for m-7NH-m surfactants, making them better transfection agents (p 
< 0.01) than both the m-3-m and m-7-m surfactants, which follow in that order. The 
level of protein expression recorded by the m-7NH-m surfactants, when compared with 
the commercial Lipofectamine Plus reagent, indicates that the m-7NH-m surfactants are 
as good transfection agents as the commercial reagent (p < 0.01). 
The aim of studies conducted in this research was partly to determine the validity of 
the hypothesis that, imino-substitution in gemini surfactants induces endosomal escape, 
a proof of which include increased transfection efficiency. This research was to further 
establish the conditions necessary for imino-substitution in gemini surfactants to yield 
optimal effect. Together, the high transfection efficiency for the m-7NH-m surfactants 
and the low transfection efficiency for m-7-m surfactants (Figure 4.5.2.3-1), which serve 
as negative controls, uphold the hypothesis. Further more, transgene expression, which 
is highest 24 h post transfection, was consistently demonstrated to be optimal using 
transfection complexes with ρ+/- value of 10:1 as opposed to lower values. While noting 
these, it was important to conduct closer comparisons to adequately highlight key 
structural features of the surfactants such as imino-substituent and the level of 
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significance that can be attributed to them in the overall performance of gemini 
surfactant candidates. 
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Figure 4.5.2.3-1. Transfection efficiencies in PAM 212 cells transfected with PGL 
complexes prepared from gemini surfactants belonging to three different series. 
 
(A) Transfections featuring m-7NH-m surfactants. (B) Transfections featuring m-3-m 
surfactants. (C) Transfections featuring m-7-m surfactants. For all (i.e., A - C), the 
magnitude (in percentage) by which transfection efficiencies for complexes with ρ+/- = 
10:1 exceeds the transfection efficiencies for complexes with lower ρ+/- values 
(excluding 0.5:1) is indicated above the respective columns (taken as a group) for lower 
ρ+/-values. Note that the two surfactants with m = 18:1 in the m-3-m and m-7NH-m 
series were excluded in this figure in order to conduct fair comparisons between these 
two surfactant groups and the m-7-m group with no m = 18:1 surfactant. In all cases 
luciferase expression was quantified after 24 h of transfection. n = 4, error bars = SD. 
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Comparison among surfactants for which the hydrocarbon tail length is held 
constant (i.e., m-3-m, m-7-m, m-7NH-m, m = 12 or 16 or 18, at a time) revealed that 
every surfactant from the m-7NH-m group transfected cells better  than than the equal-
tail surfactant from both the m-3-m and m-7-m surfactant families (p < 0.01) (Figure 
4.5.2.3-2A, comparisons made for optimized results). Between the m-3-m and m-7-m 
surfactants (m = 12 or 16 or 18, at a time), the m-3-m surfactants were moderately more 
efficient. In fact, out of the three different tails, the m-3-m surfactant with m = 12 
emerged significantly more efficient than the m-7-m surfactant with the same tail lenth. 
Despite these differences in transfection efficiency, only seemingly minor differences 
exist between the structures of the three surfactant groups (i.e., m-7NH-m, m-3-m and 
m-7-m surfactants). First, the m-7NH-m surfactants have an imino (NH) substitution in 
their spacer in place of the central methylene (-CH2-) group, while the methylene group 
is maintained for the m-7-m surfactants. Second, the m-7NH-m surfactants have, 
inserted in their spacer, an imino group separated by trimethylene spacing from each of 
two ammonium nitrogens, whereas no imino group is present in the m-3-m surfactants 
whose ammonium nitrogens are also separated by trimethylene spacing (see detailed 
structures in Table 3.1.2-1). The m-7-m surfactants, besides not having an imino group, 
also lack the optimal trimethylene spacing by having a spacer (7-methylene units) that is 
double the optimal spacing. Thus, both the imino group and the trimethylene spacing are 
shown as critical structural factors for improving the transfection abilities of our gemini 
surfactants (this issue is further examined in the chapter 5). 
The individual surfactants within surfactant groups with the same spacer type (m-
7NH-m, four members; m-3-m, four members; m-7-m, three members) but with 
different hydrocarbon tail lengths or types were also closely examined. This included 
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comparison (under optimized conditions) of monounsaturated oleyl tails (m = 18:1), 
reported to boost transfection in some cases, with the saturated counterparts (m = 18). In 
one case, i.e., for the m-3-m series, the 18:1-3-18:1 surfactant with oleyl tails showed a 
better transfection efficiency than the 18-3-18 surfactant with saturated tails, though the 
difference was insignificant (Figure 4.5.2.3-2A). But within the m-7NH-m surfactant 
group, the transfection efficiency of the oleyl-containing 18:1-7NH-18:1 surfactant was 
rather lower than the saturated 18-7NH-18 analogue. Further comparisons (Figure 
4.5.2.3-2B) indicated that for the m-7NH-m surfactants, increase in transfection 
efficiency occurred as follows: m = 12 vs. m =16, m = 12 vs. m = 18 and m = 16 vs. m = 
18 (significant increase for the longer tails, p < 0.01). The remaining surfactant from this 
group, m = 18:1, which recorded the lowest efficiency (though the reverse was 
expected), was significantly less efficient (p < 0.01) than only the m = 18 and 16 
surfactants, which had the highest and next highest efficiencies, respectively, within 
their group. For the m-3-m surfactants (m = 12, 16, 18, 18:1), the increase (or 
difference) in transfection efficiency was insignificant (p < 0.01) when any two of these 
surfactants were compared. This no-significant-increase (difference) observation was 
also true for the m-7-m surfactants (m = 12, 16, 18). Thus, using surfactant tail length as 
a variable largely led to insignificant statistical differences in these experiments. 
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Figure 4.5.2.3-2. Transfection efficiencies in PAM 212 cell – comparison of underlying 
surfactant structures. 
(A) Level of transfection efficiency compared using modifications in gemini surfactans 
spacer group as the changing variable, the hydrocarbon tail is held constant. 
(B) Level of transfection efficiency compared using hydrocarbon tail as the changing 
variable, the type of spacer group is held constant.  
In all cases luciferase expression was quantified 24 h after cells were transfected using 
complexes with ρ+/- = 10:1. n = 4, error bars = SD. 
 
Legend 
Solid line indicates no significant difference (p < 0.01) between any columns (individual 
or group) connected by the solid line. 
Dashed line indicates a significant difference (p < 0.01) between columns (individual or 
group) connected by the dashed line. 
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4.5.2.4. DNA Transfection: COS-7 vs. PAM 212 Cells 
The expression of a reporter gene in eukaryotic cells depends, to a large extent, on 
the gene’s promoter region and cell type. Of interest in the present study was the effect 
of varying cell type. Therefore, COS-7 cells were introduced as a different cell line and 
the three groups of gemini surfactants were pre-assessed by way of transfection of COS-
7 cells, followed by the advanced-phase transfection of PAM 212 cells. COS-7 cells are 
a relatively more phagocytotic cell line and thus have a higher PGL complex uptake 
capacity. They often serve as a standard cell line for pre-screening non-viral vectors to 
be used in more advanced transfection experiments. The results of pre-screening in 
comparison with transfection results in our chosen experimental PAM 212 cells are 
shown in Figure 4.5.2.4-1. The COS-7 cells showed better transfectability (ability to be 
transfected) than our model PAM 212 cells. This is consistent with other transfectability 
comparisons in which COS-7 cells were easier to transfect than other cell lines [257]. As 
observed with PAM 212 cells, results of ρ+/--dependent transfections in COS-7 cells 
(Figure D-I, Appendix D) were the best for PGL complexes with ρ+/- = 10:1, and 
decreased as ρ+/- decreased. 
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Figure 4.5.2.4-1. Comparison of gemini surfactant-mediated transfection in COS-7 and 
PAM 212 cells for m-3-m, m-7-m and m-7NH-m surfactants. 
Origins of cell lines: COS-7, monkey kidney; PAM 212, epidermis of newborn BALB/C 
mice. The transfections were carried out using optimized conditions (PGL complexes 
with ρ+/- = 10:1; the luciferase expression was quantified after 24 h of transfection). 
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4.5.3. Evaluation of Transfection-related Toxicological Effects 
The efficacy of any medication or benefit of the ingredients therein is particularly 
important when comparing the therapeutic benefit realized on the one hand, with the 
toxicity effects on tissues or cells on the other hand. Ultimately, the efficacy/toxicity 
balance must fall within safe limits to not put the life of organisms being genetically 
treated in more danger and for a promoted molecular delivery system to successfully 
pass through regulatory steps. We therefore determined cytotoxicities in our 
transfections using the optimal conditions. The cytotoxicity results for transfections in 
both COS-7 and PAM 212 cells are shown in Figure 4.5.3-1. 
For both cell lines, the individual gemini surfactants recorded cell viability within 
the 75 – 80% range, which is statistically similar to the 80% cell viability level recorded 
by Lipofectamine Plus reagent. The cell viability of both the surfactants and 
Lipofectamine Plus reagent contrasts with the control surfactant-free transfections 
(Control, Plasmid, DOPE/plasmid, Figure 4.5.3-1) for which the cell viability was 100% 
due to the absence of any toxic surfactants or Lipofectamine components. Not 
withstanding the statistical similarity in the toxicity effects posed by the gemini 
surfactants, the m-7NH-m and m-3-m surfactants recorded the lower and upper edge of 
cell viability values, respectively, whereas the m-7-m surfactants were placed in 
between. Thus, the cytotoxicities generally increased in the following order: m-3-m < m-
7-m < and m-7NH-m surfactants. However, neither cell line was particularly more 
susceptible to toxic effects as there was no indicating trend to suggest cell type 
susceptibility. This is against the premise that COS-7 cells are more phagocytotic and 
may have taken up more gemini surfactant-containing complexes, thus expressing more 
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protein than PAM 212 cells under the same conditions (Figure 4.5.3-1). In short, despite 
the probability of higher intake of toxicity-causing transfection complexes, the COS-7 
cells did not show higher toxicity than the PAM 212 cells. This is likely due to the fast 
cell division (growth) mechanism that is in-built in COS-7 cells. The fast cell division 
mechanism would allow living cells to divide and quickly replenish cells dying as a 
result of transfection-related toxicity. The result will be a high survival rate as if to 
discount the higher particle uptake capacity of the COS-7 cells compared to the PAM 
212 cells. 
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Figure 4.5.3-1. Comparison of cell viabilities in COS-7 and PAM 212 cells transfected 
using m-3-m, m-7-m and m-7NH-m surfactants. 
Also included are results for non-transfected cells (Control), naked DNA (Plasmid), 
plasmid combined with DOPE (DOPE/plasmid) and Lipofectamine Plus™ reagent. 
Transfections were carried out using optimized conditions (i.e., PGL complexes with ρ+/- 
= of 10:1, with luciferase quantitation 24 h after transfection). n = 4, error bars = SD. 
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To evaluate the effect of different doses of gemini surfactants on the level of 
transfection-related toxicities, as a complementary investigation to the ρ+/--dependent 
gene expression (shown in Figure 4.5.2.2-1), cytotoxicities in both COS-7 and PAM 212 
cells were determined following cell transfections. The transfections were carried out 
using PGL complexes containing varying concentrations of gemini surfactants, and with 
ρ+/- values corresponding to the values in previous transfections (Figure 4.5.2.2-1). The 
results displayed in Figure 4.5.3-2 were obtained for the m-7NH-m surfactants, and is 
representative of the dose-dependent cytotoxicity trends also for the m-3-m and m-7-m 
surfactants. Since cell viability of transfected cells is inversely related to cytotoxicity (% 
Mortality = 100 - % cell viability), a decline in cell viability indicates an increase in 
cytotoxicity. As such, the observed increase in cell viability of transfected cells in 
response to reduction of the gemini concentration used for transfection corresponds to a 
decrease in cytotoxicity as the gemini surfactant concentration is decreased. 
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Figure 4.5.3-2. Dose-dependent toxicities for gemini surfactants in PAM 212 cells.  
Cells were transfected with PGL complexes prepared using varying concentration of m-
7NH-m surfactants (i.e., complexes had values of ρ+/- ranging from 10:1 to 0.5:1. The 
numbers in parentheses next to each ρ+/- value represent the amount of surfactant used 
for preparing complexes based on a uniform plasmid dose of 0.2 µg). Cell viabilities 
were quantified after 24 h of transfection. The figure inset shows the level of 
cytotoxicity or motility in transfected cells (% Mortality = 100 - % cell viability).  n = 4, 
errors bars = SD. 
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In our pre-screening tests for the surfactants, cell viability experiments were also 
carried out for COS-7 cells covering the three gemini surfactant groups and the five 
different gemini surfactant dose variations (i.e., using PGL complexes with variable ρ+/- 
values: 10:1, 5:1, 2.5:1, 1:1, 0.5:1). The results for these experiments (Figure D-2, 
Appendix D) were consistent with the surfactant concentration–toxicity proportionality 
trend, reiterated by the results of our present transfections of PAM 212 cells (Figure 
4.5.3-2).  
 
 111 
5. DISCUSSION 
5.1. Design Scheme and Properties of the Gemini Surfactants 
The research on gemini surfactants in general is currently being led by studies 
focusing on the m-s-m or N,N-bis(dimethylalkyl)-α,ω-alkanediammonium surfactants 
(Figure 1.4.3-1), an example of which is the 12-3-12 gemini surfactant having two C12 
alkyl tails (dodecyl tails, m = 12) and a trimethylene spacer (s = 3). Through 
modification of the m-s-m gemini surfactant structure, with many manipulations centred 
on the headgroup-spacer region (the hub of major modifications), other types of gemini 
surfactants have evolved. The application of gemini surfactants, in general, in gene 
therapy research is in part driven by the safety issues surrounding the more effective 
viral alternatives, and of significant surfactant research interest, also driven by the 
remarkable suitability of molecular characteristics displayed by gemini surfactants. For 
instance, the critical micelle concentration (CMC) of gemini surfactants is generally 
some orders of magnitude lower than it is for comparable monomer surfactants, making 
gemini surfactants greatly superior over monomer surfactants in the encapsulation of 
DNA for delivery to cells. Because lower CMCs permit lower concentrations of gemini 
surfactants to effectively encapsulate DNA for cellular delivery, toxicity levels are 
greatly minimized in biological hosts. 
The gemini surfactants studied herein include both normal m-s-m types and amine-
substituted gemini surfactants that are based on the m-s-m general structure. For the m-
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3-m, m-7-m and m-7NH-m series of surfactants, with a fixed spacer group for each 
series (Table 3.1.2-1), an increase in the alkyl tail length resulted in an increase in the 
Kraft temperature (Table 4.2.1-1) and a decrease in the CMC (Tables 4.2.2-1, 4.2.3-1), 
conformant with the linear decrease in the natural logarithm of CMC, which correlates 
with increase in alkyl tail length [258]. Two types of C18 hydrocarbon chains, which are 
the longest alkyl tails used for the gemini surfactants, resulted in different Kraft 
temperatures. Saturated C18 tails resulted in the highest Kraft temperatures, regardless of 
the nature of spacer group, while in contrast, unsaturated C18 tails (oleyl chains) reduced 
these Kraft temperatures by 9 – 16 oC (Table 4.2.1-1), underscoring the purpose of their 
use. As compared to saturated hydrocarbon tails, unsaturation in hydrocarbon tails 
introduces ‘bends’ in unsaturated tails. The bends results in poor stacking of the tails and 
lead to intermolecular forces that are much weaker than for saturated tails, consequently 
leading to reduced Kraft temperatures for surfactants with unsaturated tails. 
As noted earlier, the trend of CMC values resulting from variations in the gemini 
surfactant spacer groups differs from the generally inverse relationship between CMC 
values and length of alkyl tail. Changes in the CMCs as a result of variations in the 
gemini surfactant spacer groups are in themselves small compared with the effect of 
variation in the tail length. The CMC values, determined from both surface tension and 
specific conductivity analysis (Tables 4.2.2-1, 4.2.3-1, respectively), are slightly lower 
for the m-s-m gemini surfactants (m = constant) having s = 7 than for those with s = 3. 
This observation for the two different polymethylene spacers is consistent with results 
previously reported in literature in which the CMC goes through maximum at s = 4–5, 
observed in an investigation of polymethylene spacers ranging from 2–16 methylene 
units for 12-s-12 gemini surfactants [218]. The reasons for such behaviour and the 
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potential of spacer variations to induce a rich array of aggregate structures for drug 
encapsulation, made possible by a number of steric, electrostatic and hydrophobic 
interactions, has been recently reviewed [86]. The rise in CMC up to its maximum value 
at s = 4–5 has been explained in terms of the conformational changes that gemini 
surfactants with short spacers (1 ≤ s ≤ 4) have to undergo in order to pack the alkyl tails 
into the core of micelles. But as the spacer chain extends beyond s = 6, its hydrophobic 
character as well as folding into the core of the micelles increases, thus favouring 
micelle formation and decreasing the CMC [178; 179]. 
The amine-substitution of gemini surfactants, which exploits the small changes that 
spacer variations generally cause to the CMC, was employed to impart other 
physicochemical properties while maintaining fairly constant CMCs. Some of the 
properties relate to changes including the insertion of pH-active aza- (N-CH3) and 
imino- (N-H) groups in the polymethylene spacers of m-s-m gemini surfactant 
structures. This is demonstrated in the 12-spacer-12 and m-7NH-m surfactant groups 
(Table 3.1.2-1). The slight increase in CMC resulting from these more hydrophilic 
spacers (aza- and imino-substituted) relative to their equivalent length polymethylene 
counterparts can be linked to diminished or lack of spacer incorporation within the core 
of the micelle due to increased solubility, and this is less favourable to micelle formation 
[86]. 
The headgroup area (a0), another characteristic of gemini surfactants central to their 
interaction with DNA, was also varied through changes in the spacer group of 
surfactants. The values of a0 were higher for spacer species containing 8 or 7 atoms in 
the spacer chain and decreased as the spacer length decreased (Tables 4.2.2-1). The 
trend in literature indicates an increase in a0 with an increase in length of spacer chain up 
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to s = 10 - 12, at which point there is a maximum, and then a decrease in a0 beyond s = 
10 - 12 [218; 234]. The decrease of a0 after s = 10 - 12 is taken as evidence of the 
folding of longer spacers away from the water-side of the water-oil interface, which then 
brings the interconnected quaternary ammonium headgroups close to one another [86]. 
But whether a spacer is long or short, the ability of gemini surfactants to interact with or 
compact DNA is governed by the characteristics of the two distinct structural elements 
of gemini surfactants; namely, the headgroup-spacer region and the hydrophobic tail.  
The gemini surfactants studied herein (Table 3.1.2-1) can be rated in terms of the 
characteristics referred to above, which are, for the headgroup-spacer region: 
equilibrium N-to-N distance, value of a0, and available positive charges for neutralizing 
DNA phosphates; and for the hydrocarbon tail: tail length and whether it is saturated or 
unsaturated. A mathematical approach that relates these surfactant characteristics to the 
optimal morphology these surfactants form upon self-aggregation is given by Equation 
5.1-1 below, 
s
0
vN =
la
      5.1-1 
where v = volume of alkyl tail, l = length of alkyl tail, and a0 = surface area occupied by 
the head-group. The magnitude of Ns indicates the preferred curvature of the aggregate 
structure. An Ns value of 0.3 favours spherical micelle organization (highly curved), 
whereas Ns = 1 and Ns > 1 favours planar bilayer formation and inverted micelles, 
respectively. Efficient DNA compaction using gemini surfactants is achieved when the 
spacer length s is <4 or >10, but not for intermediate lengths, and the compaction is 
enhanced when increasing the alkyl tail length from C12 - C18 [259]. One report [202] in 
which the 16-6-16 surfactant gave a higher transfection in cells than both the 16-2-16 
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and 16-3-16 surfactants is somewhat contrary to the positive correlation between 
efficient DNA compaction and high transfection. In other words, for the m-s-m 
surfactants herein, the m-3-m series is expected to compact DNA better than the m-7-m 
series; a similar trend in their transfection could also be expected. The use of unsaturated 
alkyl tails (oleyl tails) for one of the m-3-m surfactants could be more beneficial since 
oleyl tails have been suggested to form mixed structures, including micellar, while, for 
instance, saturated C16 tails form lamellar structures alone [202]. 
The equilibrium N-to-N distance (dN-to-N) between nitrogen centres in the gemini 
surfactants (Table 5.1-1), especially for the gemini surfactants with aza- and imino-
groups incorporated within their spacers, have been examined and previously published 
by our laboratory [201]. When the N-to-N distances, calculated from energy minimized 
models of the surfactants molecules, are said to allow a closer match with adjacent 
phosphates on DNA spaced by 6.5 - 7.1 Å [260], more favourable electrostatic 
interactions can occur between the gemini surfactants and DNA [261]. A study 
examining the interaction of DNA with the polyamine spermine [261], which has a 
trimethylene spacing of 4.9 Å between its adjacent nitrogen centres [262-264], has 
shown the trimethylene spacing to be suitable for electrostatic interactions between 
DNA and the polyamine agent. Calculations of N-to-N distances have also been reported 
specifically for gemini surfactants. The calculations for gaseous 18-s-18 are reported to 
be 5.23 Å, 6.21 Å and 7.76 Å, for s = 3, 4, and 5, respectively [182]. Stronger 
transfections have been demonstrated for surfactants with short N-to-N distances, such 
as s = 3 and 4, supporting the hypothesis that these spacings allow surfactants to 
optimally interact with DNA [265]. The implications of these findings with respect to 
the gemini surfactants (Table 5.1-1) being studied in this research are as follows: the m-
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3-m, m-7NH-m and 12-spacer-12 group of surfactants, which have N-to-N distance of 
around 5.1 - 5.25 Å, are well placed for optimal interaction with DNA and transfection 
of cells [201]. The m-7-m surfactants, on the other hand, seem to have a spacer (10.08 
Å) that is longer than required for optimal interactions and culminates in weak 
transfection. The folding of spacers that leads to enhanced transfection efficiencies has 
been clearly observed only for very long spacers, e.g., s = 16 [132], suggesting that the 
spacer for the m-7-m surfactants might be incapable of such folding. 
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Table 5.1-1. Distance between nitrogen centres for the gemini surfactants 
Surfactants Atoms dN-to-N (Å) Model 
m-3-m series N1 – N2 5.25 
N+ N+
C12H25C12H25  
  
Others: m = 16, 18, 18:1   
  
 
12-5N-12 N1 – N2 3.90 
N1 – N3 7.52 
N+
N
N+
C12H25 C12H25  N2 – N3 3.88 
 
12-8N-12 N1 – N2 3.86 
N1 – N3 7.40 
N1 – N4 11.17 N
+ N N
N+
C12H25
C12H25
N2 – N3 3.86 
 N2 – N4 7.42 
 N3 – N4 3.86 
 
Note: Table continued on next page. 
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Table 5.1-1 (cont’d). 
Distance between nitrogen centres for the gemini surfactants 
Surfactants Atoms dN-to-N (Å) Model 
m-7NH-m series N1 – N2 5.08 
N1 – N3 10.15 
N+ N
H
N+
C12H25C12H25  
Others: m = 16, 18, 18:1 
N2 – N3 5.08 
 
12-7N-12 N1 – N2 5.14 
N1 – N3 10.18 
N2 – N3 5.14 
N+ N N+
C12H25 H25C12  
  
 
m-7-m series 
N+ N+
C12H25C12H25  
Others: m = 16, 18 
N1 – N2 10.08   
 
Calculated from Energy Minimized Model of Molecules using ChemOffice Chem 3D Pro Software. 
Molecules were energy minimized (MM2 force field) in the gas phase to a minimum root-mean-square 
gradient of 0.05. ref. [201]. 
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In summary, the design scheme applied to the gemini surfactants varied the 
surfactant alkyl tail length and the degree of alkyl tail saturation, with alkyl tail varieties 
including C12, C16, C18 (all saturated) and cis-oleyl tail (monounsaturated C18). The 
different spacers used for the gemini surfactants also varied in length (number of 
methylene units) and allowed for the type of amine-substituents in the spacer as well as 
the spacing between nitrogen centres in the gemini surfactant spacer to be varied. The 
solution properties of the gemini surfactants (Tables 4.2.2-1, 4.2.3-1) responded to 
applied modifications as expected. The differences among the gemini surfactants in 
terms of both the solution properties and structure of the gemini surfactants introduce 
differences in the levels of transfection efficiency achievable by the various compounds. 
The sections that follow examine transfection results in detail in order to answer the 
question of the correlation between transfection and properties of the investigated 
surfactants. 
5.2. Transfection Abilities of the 12-spacer-12 Surfactants 
Cellular gene delivery or transfection studies involving five 12-spacer-12 gemini 
surfactants, combined with complementary analysis of transfection-related 
cytotoxicities, marked the start of investigations of the transfection abilities of the 
gemini surfactants (Table 3.1.2-1). Results for the 12-spacer-12 surfactants in COS-7 
cells (Figure 4.4.2.1-1) provided an initial platform for correlating the efficiency of 
transfection to the characteristics of the gemini surfactants. The fact that the 12-7NH-12 
surfactant matched the commercial transfection agent Lipofectamine Plus™ in 
transfection efficiency, and is followed by the significantly less efficient surfactants in 
the order 12-7N-12, 12-5N-12, 12-8N-12, 12-3-12, makes the 12-7NH-12 surfactant the 
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focus of discussion. Table 5.2-1 summarizes transfection results (Luciferase expression - 
highest values at the bottom of table, cell viabilities) from the charts in Figure 4.4.2.1-1 
to illustrate the trend in transfection. 
 
Table 5.2-1. Transfection and cell viability levels for the 12-spacer-12 surfactants 
Surfactant 
or agent 
Luciferase 
expression  
(ng/2 × 104 cells) 
% Viable 
(treated cells) 
Plasmid 0.06 ± 0.01 100 ± 4 
12-3-12 0.80 ± 0.03 90 ± 4 
12-8N-12 1.01 ± 0.21 77 ± 2 
12-5N-12 1.41 ± 0.55 78 ± 5 
12-7N-12 2.30 ± 0.60 80 ± 2 
12-7NH-12* 0.40 ± 0.01 ND 
12-7NH-12 6.70 ± 0.50 70 ± 1 
Lipofectamine 
Plus™ 7.40 ± 1.12 82 ± 2 
Results for surfactants are for PGL preparations of the surfactants; however, 12-
7NH-12* is for a preparation without the lipid DOPE component. Values for 
plasmid are representative of both plasmid-only and plasmid-DOPE systems. ND: 
not determined 
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In relating the levels of transfection to the composition or characteristics of various 
transfection systems, it is important to first note that the addition of DOPE to the binary 
surfactant–plasmid systems (i.e., 12-7NH-12*, Table 5.2-1) caused a significant increase 
in transfection. Such a finding has been reported in previous studies [39; 132; 192; 254; 
255]. Explanations offered for this beneficial effect are that helper lipids such as DOPE 
are able to stabilize liposomes and facilitate the release of complexed DNA through 
membrane fusion and/or destabilization of the endosomal membrane [254; 256]. A 
similar boosting effect was also evidenced by the addition, or absence, of a cationic 
component in systems with plasmid, and either with or without DOPE (Table 5.2-1). A 
clear demonstration is the significant increase in transfection for all nitrogen-substituted 
PGL systems relative to the plasmid–DOPE system (≈Plasmid, Table 5.2-1; p < 0.05). 
This stresses the need for negatively charged macromolecular DNA to be neutralized, 
condensed and complexed or encapsulated into small (nanometre-scale) particles to 
improve uptake by cells. Indeed, if a high DNA condensation beyond an average 
minimum is needed for efficient transfection, then the more efficient condensation of 
DNA reported for the 12-7NH-12 surfactant [201] may provide some explanation for its 
high transfection efficiency (i.e., the surfactant’s PGL system). 
One of the foremost indications from transfection results for the 12-spacer-12 
surfactants is that amine-substitution is the factor responsible for the increased 
transfection for the four amine-substituted surfactants over the base 12-3-12 surfactant 
structure. But to create another level of interest, the amine-substituted gemini surfactants 
are in two types: the aza- and the imino-substituted surfactants. The most efficient aza-
substituted surfactant 12-7N-12 (one N-CH3), compared with family members, has a 
spacer that is two methylene units longer relative to 12-5N-12 (one N-CH3) and one 
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methylene unit shorter relative to 12-8N-12 (two N-CH3) (efficiencies being in that 
order). Clearly, the decline in transfection for 12-8N-12, which has double the number 
of aza substituents relative to its two family members, removes any expectation that 
transfection efficiency will correlate with a mere multiplicity of the aza substituents. 
Rather, other factors are necessary to adequately account for the observed difference. 
First, the increase in aza substituents for the 12-8N-12 surfactant creates an increased 
steric effect within the spacer group that affects the ability of the surfactant to form 
aggregates and/or bind DNA. Second, and as noted earlier (Table 5.1-1), optimal 
surfactant–DNA interactions are allowed by, for instance, an equilibrium inter-nitrogen 
spacing of 3-methylene units. This separation provides a closer match and electrostatic 
interaction between nitrogen groups on the surfactants and phosphate units on DNA. The 
condition is met by 12-7N-12 but not its two family members, which both have a rather 
short dimethylene spacing between their nitrogen centres. The trimethylene separation 
between the nitrogen centres in the imino-substituted surfactant 12-7NH-12 would, in 
part, account for the high transfection efficiency observed for this surfactant. 
The 12-7NH-12 surfactant presents a clear contrast to 12-7N-12 and the other aza-
substituted surfactants. Its increased transfection relative to 12-7N-12 may be in part due 
to decreased steric hindrance. A more important factor to account for the wide difference 
in transfection between the two surfactants is the increased pH activity owing to the 
imino substituent versus the aza substituent. By monitoring the changes in size of 
surfactant aggregates and the plasmid–gemini surfactant–lipid complexes as function of 
pH, a significant change in size for both the aggregates and the complexes was observed 
on going from a basic to acidic pH for samples involving the 12-7NH-12 surfactant 
(Figures 4.3.1-1A, 4.3.1-2A, respectively). The change results from the protonation of 
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the imino group. As earlier noted, even though the transition in size for the surfactant 
aggregates in particular is not as wide as the kind of vesicle to micelle transitions 
reported for sugar-based gemini surfactants [52; 206; 207; 240; 241; 266], the relevance 
to increased transfection is still clear. The transitions, due to their structural perturbation 
effect, aid in the endosomal release of DNA taken up by cells in the form of complexed 
DNA. The fact that the 12-7N-12 surfactant shows no change in the size of complexes 
containing it, and is also less efficient in transfection than the 12-7NH-12 surfactant, 
strongly supports the link between increased pH-activity and increased transfection. 
Unlike the 12-7N-12 surfactant, which only shows an increase in zeta potential with a 
decrease in pH (in response to decreasing amount of OH- ions available to bind to its 
complexes), 12-7NH-12-containing complexes exhibited a transition in zeta potential as 
pH turns more acidic, in addition to the noted pH-induced structural transition. Such pH-
sensitivity (shown by 12-7NH-12) and its potential to cause structural change, which 
will lead to increased transfection, can be placed in the context of previous reports. For 
example, pH-induced transitions from lamellar to the more fusogenic inverse hexagonal 
structure for DNA-carbohydrate gemini surfactant complexes are hypothesized to 
facilitate membrane fusion, and thus promote increased transfection at that level [52; 
205]. Similar pH-induced transitions could be expected for the Lipofectamine Plus™ 
system based on the structure of component DOSPA, as well as in other polyamine-
based molecules for gene delivery. 
The morphological characteristics of transfection complexes involving DNA and 
either lipids or gemini surfactants present another level for explaining transfection 
patterns. These characteristics of the 12-spacer-12 gemini surfactant–plasmid–DOPE 
complexes, including small-angle X-ray scattering (SAXS) data, are presented in 
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recently published work  [201]; a summary of the salient points are given in Table 5.2-2 
(below). Transfection complexes, in general, display various structural forms, including 
the more common lamellar structures [39; 256; 267], and also inverse hexagonal [39] 
and cubic structures [268]. Inverse hexagonal bilayer complexes had earlier been 
associated with increased transfection, but later reports have shown that other structures 
such as lamellar (including multilamellar [269]) yield high transfection provided their 
membrane charge density (σM) exceeds a critical minimum of 1.04 × 10-2 e/Å2 [39; 270]. 
But since the computed value of σM is less than the minimum value for all the 12-spacer-
12 surfactants except 12-3-12 and 12-5N-12 (Table 5.2-2), there has to have been other 
structural forms apart from lamellar to explain the efficient transfection, especially for 
the 12-7NH-12 surfactant. σM calculation is based on Equation 5.2-1; 
cl
M
nl nl cl cl
eZN
N A N A
σ = +     5.2-1 
where Z = 2 = valency of gemini surfactant, Anl and Acl are the headgroup areas for 
DOPE (= 46 Å2 [271]) and the gemini surfactants, respectively, and Nnl and Ncl are the 
number of moles of DOPE and the gemini surfactant. 
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Table 5.2-2. Membrane charge densities (σM), scattering peak positions (q) and d-
spacing for the plasmid–gemini surfactant–DOPE nanoparticles (complexes) obtained 
from SAXS measurements (all previously published [201]). 
Surfactant σM (× 10-2 e/Å2) q (Å-1) d-spacing (Å) 
12-3-12a 1.15 Previous Previous 
12-5N-12 1.05 0.107 (L), 0.173 (DNA), 
0.207 (L) 
58.6 
12-8N-12 0.780 0.105 (L), 0.119, 0.170 
(DNA), 0.210 (L) 
59.6 
12-7N-12 0.748 0.083, 0.097, 0.105, 0.117, 
0.134, 0.174 
59.6 
12-7NH-12 0.920 0.083, 0.094, 0.106, 0.116, 
0.171 
59.4 
aPreviously reported by our group [272; 273]: complexes for 12-3-12 form lamellar (L), 
inverse hexagonal and cubic structures. Calculation – d-spacing = 2π/q. Numbers in bold 
indicate main scattering peaks. 
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As indicated in Table 5.2-2, complexes formed with 12-3-12, 12-5N-12 and 12-8N-
12 surfactants exhibit a lamellar (L) phase (peaks, d-spacing given). However, 12-3-12 
has been noted in earlier reports to also form inverse hexagonal and cubic phase 
complexes, making it possible that the additional peak for 12-8N-12 is a sign of an 
additional phase. For both 12-7N-12 and 12-7NH-12, a main peak (bold) and several 
additional peaks exist. Research has yet to name the structural phases that these peaks 
correspond to. The presence of multiple scattering peaks for complexes of the 12-7N-12 
and 12-7NH-12 surfactants (increased transfection) is consistent with complexes for 12-
3-12, 16-3-16 and 18:1-3-18:1 for which multiple phases have been identified [272; 
273]. Thus, these three surfactants display structural polymorphism. Therefore, the 
suggestion that complexes of gemini surfactants capable of polymorphism fuse readily 
with endosomal lipids and assist the release of DNA [201] could explain the increased 
transfection for the 12-7N-12 and 12-7NH-12 surfactants. 
The importance of the level of transfection achieved by the 12-spacer-12 surfactants 
gains significant emphasis when factored together with cell toxicities caused by the 
surfactants (Table 5.2-1). The 12-7NH-12 surfactant was slightly more toxic to cells, 
reducing cell viability to 70%, relative to its equally efficient-transfection counterpart 
(agent) Lipofectamine Plus™, which resulted in 80% cell viability (p < 0.01). These cell 
viabilities are relative to the 100% viable control cells. The aza-gemini surfactants (12-
5N-12, 12-8N-12 and 12-7N-12), however, showed similar toxicity to the cells relative 
to Lipofectamine Plus, while the parent gemini surfactant 12-3-12 was also similar to the 
control. But, more importantly, the 12-7NH-12 surfactant was not significantly more 
toxic relative to its amine-substituted analogues (12-5N-12, 12-8N-12) (p < 0.01). This 
implies that the remarkable increase in transfection efficiency for the 12-7NH-12 
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surfactant does not result in a corresponding rise in cell toxicity. Thus, this surfactant 
has emerged as a suitable candidate or base structure for further modification and 
testing, with the anticipation that the resulting modified structures would be more 
efficient transfection agents. 
5.3. Transfection with Multi-series Gemini Surfactants 
5.3.1. The Gemini Surfactant Series and Structures 
As elaborated in Section 5.2, investigation of the 12-spacer-12 surfactants (with 
variable spacers) led to the discovery of significantly different transfection abilities that 
split the surfactants into two subgroups [201]. The 12-7NH-12 surfactant recorded the 
highest transfection efficiency and was significantly similar to the commercial 
Lipofectamine Plus reagent. The rest of the surfactants, including 12-3-12, gave 
significantly lower efficiencies. In advancing this initial work, additional gemini 
surfactants were generated through molecular design and synthesis, giving rise to an 
expanded gemini surfactant library. The expanded library of gemini surfactants can be 
grouped into three series; namely, m-3-m, m-7-m and m-7NH-m surfactants (Table 
3.1.2-1). The surfactants within any of the series vary only in the length or nature of 
their hydrocarbon tail while the difference between any two series occurs in both the tail 
length and spacer type. Thus, a different chemistry and architecture of the head–spacer 
region is encountered on moving from one series of gemini surfactants to the other. 
Transfection results for these gemini surfactants, altogether, would provide information 
on structure–activity correlations that are important to the delivery of nucleic acids by 
the surfactants. An insight into such structure–activity correlations will pave the way for 
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design of new and more effective compounds. As significant contribution to the 
development of non-viral gene delivery, transfection studies for the m-7-m surfactants 
and three of the m-7NH-m surfactants (those with m = 16, 18, 18:1) are being reported 
for the first time. 
5.3.2. Structure – Activity Relationship 
 The extensive investigation carried out for the 12-spacer-12 gemini surfactants 
allowed the transfection efficiencies recorded (in COS-7 cells) by these surfactants to be 
rationalized in terms of the surfactant molecular structure and properties of the resultant 
gemini surfactant–plasmid–DOPE complexes. In brief, the high transfection efficiency 
for the 12-7NH-12 surfactant is attributable to its ability to engage in close-matching or 
more favourable interactions with DNA phosphate groups, as well as its ability to induce 
the endosomal release of complexed DNA to allow nuclear entry and protein expression. 
This integrated ability is attributable to the trimethylene spacing between nitrogen 
centres and the more pH-sensitive imino group, both of which are important features for 
transfection [201; 263; 274]. Thus, quite expectedly, transfection results for the multi-
series gemini surfactants show the highest transfection efficiencies for the m-7NH-m 
surfactants, even though in this instance the use of PAM 212 cells led to a general 
reduction in the level of protein expression compared to COS-7 cells. This reduction in 
protein expression could account for the slightly wider difference in transfection 
efficiency between the m-7NH-m surfactant group (lower) and Lipofectamine Plus™ 
reagent (higher). The slight difference (found in PAM 212 cells), however, is 
statistically insignificant.  
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The distinctively higher transfection abilities for the m-7NH-m surfactants (Figure 
4.5.2.2-1) reinforce earlier indications of the special functionality conferred on these 
surfactants by the pH-active imino group (Section 5.2), and is consistent with recent 
reports [201; 263; 274]. First, the positive effect of the imino group is made manifest by 
the fact that the m-7-m surfactants, which in comparison lack only the imino group, 
resulted in rather low overall transfection. Second, even though the m-3-m surfactants 
also have trimethylene spacing between their nitrogen centres for close-matching 
interactions with DNA phosphates, they nonetheless recorded low transfection results. 
Between the m-3-m and m-7-m surfactants, the former recorded slightly higher (though 
statistically insignificant) transfection efficiency over the later (Figure 4.5.2.2-1). This 
emphasizes the important role of trimethylene spacings in the spacer for optimal gemini 
surfactant interaction with DNA as against the rather long heptamethylene spacing. The 
heptamethylene spacer, at the same time, is not long enough compared with, for 
instance, 16-methylene spacers, which are able to fold into the bilayer membranes, 
restoring the required optimal spacing and leading to enhanced transfections [132]. 
Published work on polyamine–DNA interactions supports this conclusion by showing 
that trimethylene and tetramethylene spacings are required for a tight binding interaction 
between polyamines and double helical DNA [261; 275; 276]. Such high affinity 
binding was later linked to higher transfection in CHO cells [277]. 
Also on the subject of interactions, recently published work has indicated that the 
use of dimethylene spacings weaken or perturb cationic liposome–DNA interactions. 
While such non-optimal transfection agent–DNA interactions have been shown to 
negatively affect (or, at the least, not to enhance transfection ability) [277], as found for 
both 12-5N-12 and 12-8N-12 herein, other reports have correlated similar significantly 
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weak transfection agent–DNA interactions to increased transfection [274]. But, as a 
contributory factor to reduced transfection ability, the 12-5N-12 and 12-8N-12 
surfactants have methyl group(s) on the tertiary amino functional group(s), for which the 
resulting steric hindrance further limits their interactions with DNA. The opposing 
reports with regards to the influence of non-optimal or weak transfection agent–DNA 
interactions on transfection efficiency clearly poses a question of what level of 
interactions is required for enhanced cellular gene transfer. That is, which of ‘high 
affinity binding’ or ‘loose/weak binding’ interactions are preferable? The use of 
amphiphile agents for gene delivery in part rest upon their ability to neutralize, condense 
and encapsulate DNA into nano-complexes, and release the DNA inside a cell at the 
needed time. Thus, while the need to neutralize, condense and encapsulate calls for a 
reasonable amount of ‘high affinity binding’, the need also to release DNA has led to the 
rationalization of high transfection efficiency in terms of weak interactions. For these 
reasons, emphasis in non-viral gene delivery is shifting toward both optimal ‘high 
affinity binding’ and incorporation of functional groups to help engineer DNA release 
once complexes are incorporated in a cell [52; 205] – as demonstrated in the use of the 
N-H group in the m-7NH-m surfactants. 
The difference in transfection between the three series of surfactants can be 
explained at yet another level using the pKa values. The importance of pKa is made more 
evident by the fact that m-7NH-m surfactants have amino groups that exhibit basic 
character while both the m-3-m and m-7-m surfactants possess no amino groups. The 
pKa values for the m-7NH-m surfactants, listed on Table 4.2.4-1, are all approximately 
5. Such low pKa values in relation to the final pH range of 7.6 ± 0.4 for the optimal 
transfection complexes (ρ+/- = 10:1) prepared for transfection imply that the excess 
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amino functional group in the finished complexes would remain unprotonated. The 
presence of such an unprotonated amino functional group further supports the 
proposition of assisted endosomal release of complexed DNA following entry of 
complexes into the cell [274]. Amino functional groups with low pKa values in 
polyethylenimine (PEI) have been suggested to have the capacity to buffer intracellular 
endosomal compartments after cellular uptake of complexes, thereby promoting osmotic 
shock of the endosomal membranes and release of DNA into the cytosol [239; 257]. 
In other words, the m-7NH-m surfactants have outperformed both the m-3-m and 
m-7-m surfactant groups by possessing a low pKa-conferred capacity to release DNA 
from endosomes following cellular uptake or endocytosis. The potential availability of 
unprotonated amino functional groups for this purpose is supported by the fact that the 
amino functional groups have pKa values (around 5) that are lower than both the pH of 
finished transfection complexes (found to be 7.6 ± 0.4) and the physiological pH of host 
cells (excluding cells’ endosomal compartments). It should, however, be pointed out 
that, among the 12-spacer-12 surfactants, both 12-8N-12 and 12-7N-12 had pKa values 
lower than 5 (implying greater buffering capacity). But these two were outperformed by 
the 12-7NH-12 surfactant either because the two surfactants are limited by the lack of 
suitable separation between the nitrogen centres (Table 5.1-1), the steric hindrance from 
the amino-containing methyl group or both factors. 
Of the overall dependence of transfection activity on the structural elements of the 
gemini surfactants investigated, the hydrophobic moiety accounted for a small to 
statistically insignificant portion of it. This is relative to the effect of varying the 
headgroup–spacer region as described above. Also, at the narrower level of alkyl tail vs. 
alkyl tail comparison, difference in transfection was insignificant in the majority of 
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cases. For both the m-3-m and m-7-m surfactants, the trend of increased transfection in 
response to the increase in the alkyl tail length, though evident and consistent with some 
reports [198], was insignificant. Increase in transfection was only statistically significant 
in the m-7NH-m surfactants, being slightly statistically higher for m = 16, 18 relative to 
m = 12, 18:1 (p < 0.01). The former pair was equivalently efficient as was the later. The 
occurrence of sharper differences in transfection in a number of cases has stemmed from 
comparisons of transfection agents having alkyl tails with a single digit number of C 
atoms with agents whose alkyl tails fall within the much more transfection-efficient 
range (12 to 18 C atoms) [210]. But, in general, the question of whether there is a best 
length of alkyl tail (saturated or unsaturated, asymmetric or not) has been answered with 
split experimental findings, ruling out any linear correlation between tail length and 
transfection [185; 278]. For instance, a study of phospholipids indicated that shorter 
alkyl tails allowed for better in vitro transfection, whereas longer tails were needed for 
better in vivo transfection [279]. In broader studies of collections of alkyl tails in the 
range C12 – C18/C18:1, each of them namely, C12 [280; 281], C14 [282; 283], C18  [73; 
210; 284] and C18:1 [52; 73; 282; 285] has emerged the best out of the rest in one study 
or the other. 
With regard to unsaturated alkyl tails, the 18:1-3-18:1 surfactant, made by 
incorporation of mono-unsaturated oleyl tails in the m-3-m template, yielded the highest 
transfection for that series, whereas 18:1-7NH-18:1 created from m-7NH-m template 
dropped in its series (Figure 4.5.2.2-1). This apparent paradox is placed in the context of 
recent reports: oleyl tails were found to perform less than the optimal C18 counterparts in 
studies of spermine-based gemini surfactants [210] and biodegradable pyridinium 
amphiphiles [284]; other studies involving carbohydrate-based and peptide-substituted 
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gemini surfactants as well as other amphiphile molecules have found oleyl tails to be 
more effective relative to their saturated analogues [52; 73; 282; 285]. Oleyl tails when 
they result in higher transfection are believed to do so through their enhancement of the 
membrane fluidity of transfection complexes, an effect correlated to endosomal escape 
[281]. On the other hand, the susceptibility of the double bond to oxidation, either during 
transfection complex preparation or during a storage duration, may constitute the 
potential to cause reduced transfection yield [185]. 
5.4. Transfection Complexes: Particle Characteristics vs. Transfection 
The presence of different forms of particle structure observed in transfection 
systems involving the m-7NH-m surfactants have been noted using TEM, Section 4.3.3. 
The observed heterogeneity may well indicate the polymorphic tendencies displayed by 
transfection complexes whereby they adopt a number of multiple structural phases 
including lamellar, hexagonal and cubic phases. A number of studies have been reported 
in which SAXS studies of DNA/gemini surfactant complexes revealed multiple 
structural phases and these phases were matched with different structural forms observed 
using TEM [205]. The positive correlation between structural polymorphism and higher 
transfection has already been underscored [272; 273]. For instance, the m-3-m 
surfactants (m = 12, 16, 18:1), which are known for their ability to form polymorphic 
complexes with DNA, are observed to mediate effective transfections both in this 
research and previously [272; 273]. In line with the link between polymorphism and 
effective transfection, it is reasonable to ascribe the increased transfection of the m-
7NH-m surfactants in part to their polymorphism, which is being proposed based on 
TEM studies (Figure 4.3.3-1). The proposition of polymorphism could, in future, be 
 134 
evaluated using SAXS studies and an examination of the SAXS scattering pattern in 
relation to electron micrographical studies for the m-7NH-m surfactant/DNA 
transfection systems. 
The increase in transfection efficiency observed for the amine-substituted m-7NH-m 
surfactants relative to the unsubstituted m-3-m and m-7-m surfactants is also in part 
related to the ability to undergo pH-induced structural transition. Unlike the m-3-m and 
m-7-m surfactants, the m-7NH-m surfactants displayed a structural change in response 
to a neutral to acidic pH transition for both the gemini surfactant-only aggregates or 
vesicles and the transfection complexes formed from these surfactants and DNA 
(Figures 4.3.1-1, 4.3.1-2). The occurrence of such structural change together with the 
increased transfection observed for the m-7NH-m surfactants is consistent with reports 
in which either vesicle-to-micelle [52] or lamellar-to-hexagonal [205] structural changes 
have been correlated with increased transfection. For the purpose of increasing 
transfection, these structural changes are believed to mediate the release of DNA from 
endosomes through the membrane perturbation or fusion that results from the change of 
structural conformation [52; 205]. The changes also reflect the ability of certain types of 
gemini surfactants to interface with and take advantage of the progressive acidification 
process associated with lysosomal/endosomal degradation through which cells conduct 
their internal natural recycling and foreign particle destruction [33]. 
The pH-induced structural changes for transfections systems prepared from the m-
7NH-m surfactants, described above, and the potential for this behaviour to cause the 
release of DNA trapped in endosomal compartments fit with proposed diagrammatic 
models [33; 205; 247; 286]. Such step-specific models (for endosomal release or escape) 
give precise illustration and throw more light on the overall process of DNA transfection 
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presented in Figure 1.3.4-1. Asokan and Cho in their recent report presented a simplified 
description of the release or escape of complexed DNA from endosomal compartments 
in terms of a shift of the compartmental pH to an acidic state by the action of cells’ 
internal machinery (Figure 5.4-1) [286]. 
 
 
 
 
Figure 5.4-1. Illustration of the proposed ‘endosomal release or escape’ of complexed 
DNA during cellular transfection with pH-sensitive gene delivery molecules.  
The release mechanism is summarized into two steps and explained as follows:  
 
In Step I, the endosomal compartment and its contents turn acidic, presumably as the 
cell prepares to naturally digest and/or recycle the internalized foreign material. 
Spontaneously, the surfactant-containing DNA complexes absorb protons through 
protonation of the m-7NH-m surfactants, which as found in pH-controlled particle size 
analysis (Figures 4.3.1-1, 4.3.1-2), results in a change of the original complex structure. 
The type of structural change depicted here is a vesicle-to-micelle transition, but the 
possible structural changes for complexes also include a potential lamellar-to-hexagonal 
transition. Both of these would cause a disruption to the endosomal membrane and 
trigger a dissociation of the DNA from the surfactants either immediately or 
subsequently. 
 
In Step II, the contents of the endosomal compartment including the DNA (bold black 
coils) are released into the cytosol through pores created in the disrupted endosomal 
membrane. The DNA is shown to have already dissociated from the micelles before the 
release, but the possibility for post-release dissociations have also been expressed [33], 
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and could readily occur for lamellar-to-hexagonal transitions. The release of freed DNA 
or surfactant-associated DNA into the cytosol allows the DNA to avoid imminent 
destruction through endosomal digestion. The step also brings DNA to the final phase of 
its journey, i.e., passage into the nucleus. Alternatively, the DNA can be directly 
involved in protein expression in the cytosol without the need for an additional transport 
into the nucleus. The two step mechansim was proposed by Asokan and Cho [286]. 
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Another characteristic that potentially indicates a change in the nature of 
transfection complexes, i.e., zeta potential, was observed to undergo a transition in 
response to acidification for the 12-7NH-12 surfactant. But the surfactants with longer 
alkyl tails lacked a clear transition in zeta potential, showing rather a decrease in zeta 
potential as a function of decreasing pH consistent with the expected decrease in 
hydroxide ion concentration (Figure 4.3.2-1). This nonetheless still allows the increased 
transfection efficiency for the m-7NH-m surfactants to be explained in terms of the pH-
induced changes in the complex structures that are inferred through acidification vs. size 
measurements (Figures 4.3.1-1, 4.3.1-2). 
5.5. Non-Transfectant-related Factors Affecting Transfection 
The complex multi-step process of DNA transfection is governed by not only the 
structural elements of delivery molecules (the transfectants) but also by biological as 
well as other factors. This is supported by the findings herein, including the fact that 
luciferase gene expression was time-dependent (Figure 4.5.2.1-1), rising to a peak at 24 
h after transfection and then declining. The transgene expression was also affected by 
the cell type (Figure 4.5.2.4-1) and the dose of gemini surfactant (Figure 4.5.2.2-1). This 
might suggest that simple relationships between transfection efficiency and any of these 
factors, particularly structure of delivery molecules, are not to be expected. But the 
implications of any set of variables, whether they arise regularly, circumstantially or 
both, can inform the development process of non-viral gene medications. With regard to 
the time-dependent decline of luciferase expression, future genetic medications working 
in a similar fashion can be applied repeatedly as already practiced for an overwhelming 
number of non-genetic medications. 
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The fact that COS-7 cells displayed higher transfectability (ability to be transfected) 
than PAM 212 cells might suggest that evolving non-viral gene medicines based on 
gemini surfactants will need to be specialized for use in specific cell types or range of 
cell types. In other words, one type of medication built with a certain kind of gemini 
surfactant vector might not be effective for application in all cell/tissue types or via all 
routes of administration. The need to specialize medications could also result from 
nucleic acids meant for delivery to the cell nucleus as against those meant for cytosolic 
delivery. Antisense oligonucleotides usually destined for cell cytoplasm complete their 
journey upon crossing the cell plasma membrane into the cytoplasm. But transfer of 
plasmid DNA to the nuclei calls for additional transport processes for the DNA to make 
it through the cytoplasm and across nuclear membrane into the nucleus.  
A scarcely investigated but potentially very important factor affecting the uptake of 
transfection complexes by cells is the size and morphology of the cells themselves. 
Understandably, the fact that the size and morphology of cells evolve as the cells grow 
in culture and cannot be routinely controlled limit investigations involving the 
exploitation of cell size and morphology as manipulatable variables. Furthermore, given 
a good level of control over the life mechanisms of living cells, it would be possible to 
artificially program or induce cell division to occur while cell transfection is being 
carried out. Cell division provides a special opportunity for increased nuclear entry of 
DNA during transfection, as there is transient opening of the cell nucleus. Thus, clearly, 
a step beyond the general lack of control over the above-mentioned cellular attributes, 
including cell division and the size and morphology naturally adopted by cells, could 
prove to be very important in cellular gene delivery. But in the meantime, examination 
of the natural size and morphologies adopted by cultured PAM 212 cells was carried out 
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in this research using stereological-TEM analysis (Figure 4.4-1). Cells on average 
measured 6 – 10 μm in diameter when taken as circular or spherical entities, and were 24 
– 40-fold larger than the transfection complexes (measuring 250 nm, maximum), which 
were presented to the cells for uptake. Some studies have recently reported that active 
uptake of complexes through endocytosis is achieved for complexes in the small size 
range of around 100 nm [287]. If small size of the complexes is required, then the 
herein-found size ratios, which confer relative small and large sizes to the complexes 
and cells, respectively, place the cells in a position to effectively engulf or endocytose 
the complexes. Such examination of size ratios could be continued in future transfection 
studies to obtain accumulated data for a more comprehensive cell-to-transfection 
complex size ratio analysis. 
5.6. Toxicological Evaluation 
The incorporation of amphiphile transfection agents, which in many cases are non-
natural and non-biodegradable, into cells through uptake of transfection complexes 
creates cell membrane pores and disrupts the cellular signalling mechanism by inhibition 
of protein kinase C [288]. Whether synthesized or developed from natural components 
and subunits, the efficacy of any molecular gene delivery system is particularly 
important when comparing its optimal gene delivery record with the cytotoxicity 
associated with it. Upon toxicological investigations, both the m-3-m and m-7-m 
surfactant groups (unsubstituted) were found to cause lower toxicities to cells relative to 
the imino-substituted m-7NH-m surfactants (comparison done under optimal 
transfection conditions: ρ+/- = 10:1, 24 h post-transfection evaluation, Figure 4.5.3-1). 
However, because of the level of similarity, no significant distinction (p > 0.05) was 
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observed between the m-3-m and m-7-m surfactants (which have closer similarity) or 
between either of the unsubstituted gemini surfactant groups and the m-7NH-m 
surfactants. Altogether, although the m-7NH-m surfactants emerged narrowly more 
toxic to cells, they transfected the cells at much higher efficiencies than their less 
efficient m-3-m and m-7-m counterparts. Thus, their kind of headgroup–spacer moiety 
yielded remarkably higher transfections without a correspondent increase in their 
cytotoxicity effects. This ranks them high in terms of good efficacy/toxicity balance. 
When viewed in the light of two other variables, which are the length of alkyl tail 
and level of gemini surfactant usage (i.e., concentration) the cytotoxicities either showed 
no correlation at all or correlated rather weakly. But in general the cytotoxicities varied 
insignificantly (p > 0.01) in response to both variables within the range investigated. In 
response to increase in gemini surfactant dose, cytotoxicities rose insignificantly in most 
of the cases. This trend is illustrated in Figure 4.5.3-2 using results for the m-7NH-m 
surfactants. For the gemini surfactant dose corresponding to ρ+/- = 10:1 (which yielded 
the best transfection for all surfactants) the cytotoxicity was insignificantly higher than 
for lower ρ+/- values. However the ρ+/- = 10:1 dose showed more than 50% greater 
transfection efficiency than the lower doses (Figure 4.5.2.2-1) was also significantly 
more efficient than previously reported doses exceeding ρ+/- = 10:1 [244]. Thus, the 
higher transfection for the ρ+/- = 10:1 dose coupled with its low dose-related toxicity 
makes it the optimum condition for transfection complex preparation using the 
investigated gemini surfactants. It was only at this dose that the m-7NH-m surfactants 
transfected cells at a level as high as Lipofectamine Plus™ (Figure 4.5.2.2-1), while 
maintaining a high level of cell viability comparable to Lipofectamine Plus™ (Figure 
4.4.3-1) (p < 0.01 in both cases). 
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5.7. Concluding Remarks 
The investigations conducted over the entire research and described in this thesis 
included the rational design and synthesis of novel gemini surfactants, and the fitting of 
these surfactants within a library of gemini surfactants (totaling 14 different compounds) 
for in vitro gene delivery studies. A significant amount of 1H NMR, ESI-MS and CH&N 
analytical data were generated that confirmed the targeted synthetic gemini surfactant 
products and their high-grade purities. Characteristics of the gemini surfactants that are 
important to gene delivery were determined; these include Krafft temperatures, CMC 
values, headgroup areas, pKa values and the pH-dependencies of size and zeta potential 
of the aqueous gemini surfactants. Transfection complexes, prepared from mixtures of 
gemini surfactants, plasmid and DOPE, were also analyzed to determine their size and 
zeta potential pH-dependencies, as well as their morphological attributes. Transfection 
studies, staged in two phases and involving two cell lines, were ultimately carried out 
using fresh transfection complexes. In brief, the m-7NH-m surfactants emerged as the 
most efficient in transfecting cells, and as potential or suitable candidates for non-viral 
gene delivery at high levels including in vivo. The results also demonstrate that the 
transfection efficiencies of the surfactants studied could be improved by stepwise 
optimization of the surfactant structures, including lengthening the alkyl tails from C12 to 
either C18 or C18:1. The specific conclusions of the research are given in Sections 5.7.1 to 
5.7.3. 
 142 
5.7.1. Important Structural Features Emerging from Transfection Studies 
The following specific conclusions can be drawn in relation to beneficial structural 
features: 
• The gemini surfactants built from chosen headgroup–spacer and hydrocarbon tail 
moieties and displaying various structures, exhibited controlled properties and also 
properties that varied naturally.  
• A strong correlation between structure of the gemini surfactants and their 
transfection ability is noted. Incorporation of amino functional groups generally 
accentuated transfection ability; however, the use of an N-H group showed a 
stronger impact than an N-CH3 group (12-7NH-12 better than 12-7N-12). This 
difference relates to limitations imposed by the N-CH3 group, which include reduced 
pH-activity, on one hand, and steric hindrance against optimal surfactant–DNA 
interactions, on the other hand.  
• Also, in relation to the impact of the gemini surfactant structure, optimal equilibrium 
distance (corresponding to tri-methylene separation) between adjacent nitrogen 
centres was also important, although the impact was found to be modest. Also, with 
both N-H group and optimal inter-nitrogen separation, transfection ability could still 
be enhanced by lengthening the alkyl tails from C12 to either C18 or C18:1. 
5.7.2. Morphology of Transfection Complexes or Nanoparticles 
The characteristics of transfection complexes derived from plasmid–gemini 
surfactant–DOPE mixtures constitute yet another dimension determining the level of 
transfection. Complexes capable of adopting polymorphic structural phases and which 
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undergo pH-induced structural transition demonstrated high transfection efficiencies. 
Endosomal release of DNA can be staged by both characteristics. Ability to exhibit both 
characteristics (e.g., 12-7NH-12-based complexes are both polymorphic and pH-
sensitive) led to higher transfection compared with the ability to exhibit only one 
characteristic (e.g., 12-3-12-based complexes are only polymorphic). 
5.7.3. Toxicological Effects 
Evaluated toxicological effects associated with the gemini surfactants show that the 
most efficient m-7NH-m surfactants imposed no higher toxicity on cells relative to the 
less efficient surfactants. Thus, the rational design of the m-7NH-m surfactants to 
enhance their transfection abilities also ensured that their toxicity to cells was kept 
minimal. These surfactants have thus emerged as suitable candidates for non-viral gene 
delivery at in vivo or higher levels. 
5.7.4. Future Directions of Research 
As indicated above, gene delivery abilities of the m-7NH-m surfactants could be 
further investigated in vivo, for instance using a mouse gene delivery model. The in vivo 
delivery could be targeted to the epidermal keratinocytes using topical administration 
since the model PAM 212 cell line used herein are themselves developed from murine 
epidermal keratinocytes primary cultures. Such an investigation will, in combination 
with the in vitro results presented herein, provide direction as to the next steps forward 
for designing efficient gemini surfactants for non-viral gene delivery. In the meantime, 
results at the in vitro level suggest that incorporation of additional imino (N-H) groups 
could make the resulting m-(NH)X+1-m surfactants more efficient transfection agents 
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since the use of a single imino group resulted in increased transfection for the m-7NH-m 
surfactants (Figure 5.7.4-1). The variable x is the number of additional imino groups 
separated by trimethylene spacings; x ≥ 1. Similarly, variations in length of hydrocarbon 
chain ranging from C12 to either C18 or C18:1 can be introduced. The gene delivery 
assessment of these further-designed surfactants could be complemented by evaluation 
of their toxicological effects. 
 
m-(NH)X+1-m surfactants 
• Simple schemes, quick 
and easy synthesis 
 Peptide-based gemini surfactants [73; 289] 
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Figure 5.7.4-1. Schematic difference between m-(NH)X+1-m (left) and peptide-based 
(right) gemini surfactants. 
The m-(NH)X+1-m surfactant structural template proposes the next level of molecular 
design of gemini surfactant structures within the framework of further increasing the 
transfection efficiencies demonstrated in this research. 
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Within the context of routine production of gene delivery molecules for practical 
application, it is important for these molecules to be produceable in sizeable quantites to 
meet demands of a possible pharmaceutical non-viral genetic medicine industry. This 
particularly requires that the current research of gene delivery molecules, including 
gemini surfactants, lead to the design of efficient but simple candidates for which 
optimal and large-scale industrial manufacture can be easily attained. Such optimal and 
large-scale manufacture is necessary for obtaining gemini surfactants with high-grade 
purity, as required for any pharmaceutical ingredient, and for reducing cost of 
production. Even though a number of complex molecular structures such as the peptide-
based gemini surfactant structure shown in Figure 5.7.4-1 have been demonstrated to fall 
into the same class or a higher class of transfection efficiency than the commercial 
transfection Lipofectamine Plus™ reagent [33; 73; 289], the synthesis of this surfactant 
falls within inherent limitations. In general, synthetic methods for generating compounds 
with multiple functional groups or moieties (such as the peptide-based gemini surfactant, 
Figure 5.7.4-1) are less efficient. As a comparative advantage, the m-7NH-m surfactants 
designed in this research are simple, allow quick and easy synthesis and yet yield 
transfection efficiencies as high as Lipofectamine Plus™. By expectation, this advantage 
should, at the minimum, hold for the m-(NH)X+1-m surfactants (Figure 5.7.4-1), with the 
possibility that these surfactants could prove to be better than Lipofectamine Plus™. 
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7. APPENICES 
 
Appendix A: Compound confirmation data for the gemini surfactants 
Table A-I: CH&N elemental analysis results for the gemini surfactants 
Calculated  Found – Averages Surfactant %C %H %N  %C %H %N 
12-spacer-12        
12-3-13a 59.2 10.9 4.5  58.3 10.9 4.4 
12-5N-12b 59.0 11.0 6.3  58.9 11.3 5.9 
12-8N-12b 59.3 11.1 7.7  58.6 11.3 7.1 
12-7N-12b 60.1 11.1 6.0  60.1 11.3 6.0 
12-7NH-12b 59.6 11.0 6.1  60.1 11.2 5.9 
        
m-3-m        
12-3-12a – Same sample as the 12-3-12 sample above 
16-3-16c 63.2 11.4 3.8  63.0 11.5 4.0 
18-3-18  64.80 11.63 3.51  63.71 11.56 3.55 
18:1-3-18:1d 65.13 11.18 3.53  64.84 11.00 3.65 
        
m-7-m        
12-7-12 61.39 11.19 4.09  59.81 11.30 3.99 
16-7-16 64.80 11.63 3.51  64.80 11.80 3.37 
18-7-18  66.17 11.81 3.28  65.30 11.88 3.25 
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Table A-I (con’t): CH&N elemental analysis results for the gemini surfactants 
Calculated  Found – Averages Surfactant %C %H %N  %C %H %N 
m-7NH-m        
12-7NH-12 59.55 11.02 6.13  60.23 11.39 5.89 
16-7NH-16 63.21 11.49 5.27  63.39 11.37 5.18 
18-7NH-18 64.69 11.68 4.92  62.32 11.47 4.96 
18:1-7NH-18:1 64.99 11.26 4.94  64.84 11.48 4.86 
Data for the superscript-bearing surfactants used in this research have been previously published: 
aFrom ref. [218; 236]  
bFrom ref. [219] 
cFrom ref. [222]  
dFrom ref. [223] 
Data for all other surfactants were obtained from analytical work carried out in this research. 
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Table A-II: 1H NMR data for the gemini surfactants 
Surfactant  Group   δ (ppm)  # of protons
12-spacer-12   
 12-3-12a  – Data have been previously published 
       
 12-5N-12b  – Data have been previously published 
       
 12-8N-12b  – Data have been previously published 
       
 12-7N-12b  – Data have been previously published 
       
12-7NH-12  N+-CH2-CH2-CH2-NH-  4.14-4.08  4 
  N+-CH2-CH2-(CH2)9-CH3 ,  
N+-CH2-CH2-CH2-NH- 
 3.46-3.40  8 
  N+-CH3   3.30  12 
  N+-CH2-CH2-CH2-NH-  2.64  4 
  -NH-  2.18  1 
  N+-CH2-CH2-(CH2)9-CH3  1.78  4 
  N+-CH2-CH2-(CH2)9-CH3  1.38-1.26  36 
  N+-CH2-CH2-(CH2)9-CH3  0.89-0.84  6 
m-3-m       
  16-3-16c  – Data have been previously published 
        
18-3-18  N+-CH2-CH2-CH2-N+  4.00-3.96  4 
  N+-CH2-CH2-(CH2)15-CH3   3.48-3.44  4 
  N+-CH3   3.30  12 
  N+-CH2-CH2-CH2-N+  2.82  2 
  N+-CH2-CH2-(CH2)15-CH3   1.82  4 
  N+-CH2-CH2-(CH2)15-CH3  1.40-1.26  60 
  N+-CH2-CH2-(CH2)15-CH3   0.89-0.84  6 
       
18:1-3-18:1d  – Data have been previously published 
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Table A-II (con’t): 1H NMR data for the gemini surfactants 
Surfactant  Group   δ (ppm)  # of protons
m-7-m       
12-7-12  N+-CH2-CH2-(CH2)3-CH2-CH2-N+  3.84-3.74  4 
  N+-CH2-CH2-(CH2)9-CH3   3.48-3.44  4 
  N+-CH3  3.33  12 
  N+-CH2-CH2-(CH2)3-CH2-CH2-N+  1.85  4 
  N+-CH2-CH2-(CH2)9-CH3  1.72  4 
  N+-CH2-CH2-(CH2)3-CH2-CH2-N+  1.56-1.50  6 
  N+-CH2-CH2-(CH2)9-CH3  1.38-1.20  36 
  N+-CH2-CH2-(CH2)9-CH3  0.89-0.85  6 
       
16-7-16  N+-CH2-CH2-(CH2)3-CH2-CH2-N+  3.92-3.86  4 
  N+-CH2-CH2-(CH2)13-CH3   3.44-3.38  4 
  N+-CH3  3.32  12 
  N+-CH2-CH2-(CH2)3-CH2-CH2-N+  1.88  4 
  N+-CH2-CH2-(CH2)13-CH3   1.72  4 
  N+-CH2-CH2-(CH2)3-CH2-CH2-N+  1.58  6 
  N+-CH2-CH2-(CH2)13-CH3  1.38-1.26  52 
  N+-CH2-CH2-(CH2)13-CH3  0.89-0.85  6 
       
18-7-18  N+-CH2-CH2-(CH2)3-CH2-CH2-N+  3.88-3.82  4 
  N+-CH2-CH2-(CH2)15-CH3   3.50-3.42  4 
  N+-CH3   3.35  12 
  N+-CH2-CH2-(CH2)3-CH2-CH2-N+  1.86  4 
  N+-CH2-CH2-(CH2)15-CH3   1.72  4 
  N+-CH2-CH2-(CH2)3-CH2-CH2-N+  1.58-1.52  6 
  N+-CH2-CH2-(CH2)15-CH3  1.36-1.20  60 
  N+-CH2-CH2-(CH2)15-CH3   0.89-0.85  6 
m-7NH-m       
16-7NH-16  N+-CH2-CH2-CH2-NH-  4.08-4.12  4 
  N+-CH2-CH2-(CH2)13-CH3  3.36-3.45  4 
  N+-CH3  3.32  12 
  N+-CH2-CH2-CH2-NH-  2.98  4 
  -NH-  2. 90  1 
  N+-CH2-CH2-CH2-NH-  2.19  4 
  N+-CH2-CH2-(CH2)13-CH3   1.74  4 
  N+-CH2-CH2-(CH2)13-CH3  1.35-1.25  52 
  N+-CH2-CH2-(CH2)13-CH3  0.88  6 
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Table A-II (con’t): 1H NMR data for the gemini surfactants 
Surfactant  Group   δ (ppm)  # of protons
18-7NH-18  N+-CH2-CH2-CH2-NH-  4.18-4.10  4 
  N+-CH3   3.40  12 
  N+-CH2-CH2-(CH2)15-CH3   3.30  4 
  N+-CH2-CH2-CH2-NH-   2.92-2.80  4 
  N+-CH2-CH2-CH2-NH-   2.58-2.48  4 
  -NH-  2.04  1 
  N+-CH2-CH2-(CH2)15-CH3   1.76  4 
  N+-CH2-CH2-(CH2)15-CH3   1.38-1.26  60 
  N+-CH2-CH2-(CH2)15-CH3   0.89-0.86  6 
       
18:1-7NH-18:1  -CH2-CH=CH-CH2-  5.40-5.30  4 
  N+-CH2-CH2-CH2-NH-  4.15-4.10  4 
  N+-CH3  3.50-3.45  12 
  N+-CH2-CH2-(CH2)5-CH2-CH=CH-  3.25-3.20  4 
  N+-CH2-CH2-CH2-NH-  2.70-2.60  4 
  N+-CH2-CH2-CH2-NH- , 
-CH2-CH=CH-CH2- 
 2.10-1.90  12 
  -NH-  1.90  1 
  N+-CH2-CH2-(CH2)5-CH2-CH=CH-  1.74-1.82  4 
  -(CH2)5-CH2-CH=CH-CH2-(CH2)6-  1.40-1.20  40 
  -CH=CH-CH2-(CH2)6-CH3  0.91-0.82  6 
Data for the superscript-bearing surfactants used in this research have been previously published: 
aFrom ref. [218; 236]  
bFrom ref. [219] 
cFrom ref. [222]  
dFrom ref. [223] 
Data for all other surfactants were obtained from analytical work carried out in this research.  
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Table A-III: Electrospray ionization mass spectroscopic (ESI-MS) data for the gemini 
surfactants 
  Results of analysis 
Surfactant 
(symbol) 
Gemini surfactant ion 
(without 2Br- ions) 
m/z Relative intensity (%) 
12-spacer-12    
12-3-12 124.09 0.64 
 234.27 100.00 
 241.27 0.84 
 248.29 0.18 
 250.27 0.39 
 
N+N+
C12H25C12H25  
Mass = 468.88 g mol-1 
254.29 0.30 
    
12-5N-12 107.07 0.07 
 135.16 0.09 
 219.56 0.05 
 255.79 100.00 
 262.31 1.07 
 
N N+N+
C12H25 C12H25  
Mass = 511.95 g mol-1 
280.27 0.05 
    
12-8N-12 234.27 1.19 
 241.27 0.06 
 255.79 0.19 
 262.30 0.07 
 284.31 100.00 
 291.31 0.88 
 299.31 0.28 
 
N
N N+
N+
C12H25
C12H25
 
Mass = 569.05 g mol-1 
344.37 0.32 
    
12-7N-12 185.72 0.24 
 236.27 0.82 
 255.80 0.06 
 262.79 0.17 
 269.80 100.00 
 
N
N+N+
C12H25C12H25  
Mass = 540.00 g mol-1 
276.79 0.13 
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Table A-III: Electrospray ionization mass spectroscopic (ESI-MS) data for the  
          gemini surfactants, (cont’d) 
  Results of analysis 
Surfactant 
(symbol) 
Gemini surfactant ion 
(without 2Br- ions) 
m/z Relative 
intensity (%) 
12-spacer-12    
12-7NH-12 178.73 0.07 
 202.67 0.26 
 262.81 100.00 
 284.85 0.07 
 
H
N
N+N+
C12H25 C12H25  
Mass = 525.98 g mol-1 346.91 0.03 
    
m-3-m    
16-3-16 123.10 0.76 
 217.11 2.83 
 262.80 0.34 
 290.33 100.00 
 346.89 0.20 
 433.21 0.94 
 
N+N+
C16H33C16H33  
Mass = 581.10 g mol-1 
455.18 0.57 
    
18-3-18 217.11 1.80 
 245.19 0.03 
 318.36 100.00 
 433.21 0.55 
 
N+N+
C18H37C18H37  
Mass = 637.20 g mol-1 
455.18 0.46 
    
18:1-3-18:1 262.80 3.25 
 269.81 0.91 
 316.34 100.00 
 325.88 2.04 
 
N+N+
C18H35C18H35  
Mass = 633.17 g mol-1 
346.39 5.82 
    
m-7-m    
12-7-12 124.08 0.07 
 214.09 0.06 
 262.30 100.00 
 269.80 0.33 
 
N+N+
C12H25 C12H25  
Mass = 524.99 g mol-1 
276.32 0.05 
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Table A-III: Electrospray ionization mass Spectroscopic (ESI-MS) data for the  
          gemini surfactants, (cont’d) 
  Results of analysis 
Surfactant 
(symbol) 
Gemini surfactant ion 
(without 2Br- ions) 
m/z Relative 
intensity (%) 
m-7-m    
16-7-16 124.09 0.92 
 262.81 1.26 
 318.37 100.00 
 325.36 1.42 
 
N+N+
C16H33 C16H33  
Mass = 637.20 g mol-1 
346.41 2.66 
    
18-7-18 262.80 2.13 
 325.87 2.49 
 332.38 0.64 
 346.40 100.00 
 
N+N+
C18H37 C18H37  
Mass = 693.31 g mol-1 
362.39 0.07 
    
m-7NH-m    
16-7NH-16 181.15 1.33 
 214.08 1.76 
 231.18 1.24 
 245.16 1.10 
 318.86 100.00 
 415.28 0.31 
 
H
N
N+N+
C16H33 C16H33  
Mass = 638.19 g mol-1 
431.49 0.46 
    
18-7NH-18 220.75 3.11 
 231.60 4.38 
 316.35 1.48 
 325.87 2.56 
 346.89 100.00 
 
H
N
N+N+
C18H37 C18H37  
Mass = 694.30 g mol-1 
473.04 1.70 
    
18:1-7NH-18:1 164.14 0.08 
 219.75 0.50 
 227.17 0.57 
 344.88 100.00 
 
H
N
N+N+
C18H35 C18H35  
Mass = 690.30 g mol-1 471.01 0.09 
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Appendix B: Gemini surfactant conductivity data 
Table B-I: Conductance vs. temperature data; TKrafft determination 
 
•16-7-16  •16-7NH-16  
Temperature 
(oC) 
Conductance
(μS) 
Temperature
(oC) 
Conductance 
(μS) 
14 539.62 17 960.34 
15 555.61 18 996.84 
17 586.86 19 1029.15 
19 620.86 21 1090.13 
20 638.92 23 1155.55 
22 674.88 25 1256.65 
24 718.76 27 1292.41 
26 848.72 29 1361.42 
28 893.76 31 1436.15 
30* 937.68 34 1550.15 
32* 980.12 37 1701.26 
35 1069.15 38* 1783.29 
37 1149.64 40 1830.95 
40 1194.15 42 1879.94 
45 1223.43 45 1981.14 
50 1249.66 47 2007.33 
  50 2050.44 
The astericks indicate temperature(s) surrounding the start and complete clarification the saturated gemini 
surfactant–water system. 
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Table B-I (con’t): Conductance vs. temperature data; TKrafft determination 
 
•18-7-18  •18-7NH-18  
Temperature 
(oC) 
Conductance
(μS) 
Temperature
(oC) 
Conductance 
(μS) 
10 6.33 11 26.32 
15 7.17 13 28.05 
18 7.82 15 29.86 
20 8.24 18 32.92 
22 8.73 20 35.33 
24 9.35 22 37.85 
27 10.88 24 41.44 
29 13.42 26 46.11 
32 32.54 28 53.96 
35 108.16 29 62.48 
37 280.91 30 66.66 
38 340.94 31 82.79 
39* 351.08 32 97.88 
40 359.53 33 114.10 
44 388.73 34 132.66 
45 395.47 35 161.88 
48 420.27 36 193.54 
50 440.02 37 223.48 
  38 251.78 
  39* 267.66 
  40 285.56 
  42 324.08 
  43 339.68 
  44 353.10 
  46 370.03 
  47 382.43 
The astericks indicate temperature(s) surrounding the start and complete clarification the saturated gemini 
surfactant–water system. 
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Table B-I (con’t): Conductance vs. temperature data; TKrafft determination 
 
•18-3-18  •18:1-3-18:1  
Temperature 
(oC) 
Conductance
(μS) 
Temperature
(oC) 
Conductance 
(μS) 
10 18.63 10 277.4753 
15 21.02 12 297.2669 
17 21.88 14 325.4621 
20 23.99 16 362.1394 
22 25.06 18 423.7918 
24 26.19 19 490.7063 
26 27.56 20 523.5353 
28 28.88 21 650.2173 
30 30.18 22 768.7313 
33 31.48 23 896.1202 
36 33.06 24 1041.887 
38 33.89 25 1271.375 
40 56.16 26 1520.027 
41 78.58 27 1755.17 
42 96.11 29* 1977.433 
44* 204.42 30 2102.152 
47* 222.37 31 2242.735 
48 225.03 33 2545.264 
49 233.81 34 2667.784 
50 251.28 35 2773.182 
52 269.22 37 2906.147 
54 278.93 38 3003.534 
55 286.41   
57 287.31   
The astericks indicate temperature(s) surrounding the start and complete clarification the saturated gemini 
surfactant–water system. 
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Table B-I (con’t): Conductance vs. temperature data; TKrafft determination 
 
•18:1-7NH-18:1  
Temperature 
(oC) 
Conductance 
(μS) 
10 188.79 
12 201.71 
15 243.66 
17 405.34 
18 511.84 
19 624.15 
21 735.13 
23 916.55 
25 1082.65 
27 1140.41 
29* 1306.42 
32* 1477.15 
34 1602.15 
37 1760.26 
38 1783.29 
40 1830.95 
42 1921.94 
44 1989.14 
46 2017.33 
47 2052.44 
The astericks indicate temperature(s) surrounding the start and complete clarification the saturated gemini 
surfactant–water system.  
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Table B-II: Specific conductance (κ) vs. concentrtion data; CMC determination 
•12-7-12  •16-7-16  
Conc. 
(mM) 
κ 
(μS cm-1) 
 Conc. 
(mM) 
κ 
(μS cm-1) 
0 2.62 0 3.18 
0.0397 13.90 0.0040 3.97 
0.0789 25.14 0.0079 4.85 
0.1176 36.97 0.0118 5.84 
0.1558 48.48 0.0156 6.87 
0.1935 59.78 0.0194 7.82 
0.2308 70.85 0.0231 8.89 
0.2675 81.36 0.0268 9.73 
0.3038 91.33 0.0304 10.53 
0.3396 101.80 0.0340 11.26 
0.3750 111.99 0.0375 11.93 
0.4444 131.68 0.0410 12.56 
0.5122 149.67 0.0444 13.13 
0.5783 167.46 0.0479 13.68 
0.6429 184.14 0.0512 14.21 
0.7059 200.61 0.0545 14.67 
0.8571 236.76 0.0578 15.14 
1.0000 259.93 0.0611 15.58 
1.1351 277.12 0.0643 15.99 
1.2632 291.58 0.0675 16.39 
1.3846 304.63 0.0706 16.78 
1.5000 316.20 0.0737 17.16 
1.6098 327.39 0.0767 17.52 
1.7143 337.54 0.0798 17.89 
1.8140 347.06 
1.9091 355.97 
2.0000 364.62 
2.0870 372.97 
2.1702 380.65 
2.2500 388.05 
2.4000 404.51 
2.5385 417.59 
2.6165 424.92 
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Table B-II (con’t): Specific conductance (κ) vs. concentrtion data; CMC determination 
 
•16-7NH-16  •18-3-18  
Conc. 
(mM) 
κ 
(μS cm-1) 
Conc. 
(mM) 
κ 
(μS cm-1)
0 3.93 0 5.58 
0.0040 5.35 0.0022 13.06 
0.0079 6.81 0.0065 14.90 
0.0118 8.31 0.0108 16.65 
0.0156 9.71 0.0150 18.04 
0.0194 11.29 0.0192 19.19 
0.0231 12.74 0.0233 20.20 
0.0268 14.18 0.0274 21.41 
0.0304 15.57 0.0314 22.43 
0.0340 16.88 0.0354 23.22 
0.0375 18.19 0.0393 24.00 
0.0410 19.38 0.0413 24.24 
0.0444 20.71 0.0451 24.73 
0.0479 21.77 0.0489 25.37 
0.0512 22.75 0.0526 25.64 
0.0545 23.68 0.0563 26.16 
0.0578 24.55 0.0600 26.49 
0.0611 25.34 0.0636 26.75 
0.0643 26.11 0.0672 27.21 
0.0675 26.88 0.0707 27.39 
0.0706 27.66 0.0742 27.87 
0.0737 28.39 0.0776 28.00 
0.0767 29.01 
0.0798 29.69 
0.0828 30.35 
0.0857 30.98 
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Table B-II (con’t): Specific conductance (κ) vs. concentrtion data; CMC determination 
 
 •18-7-18  •18-7NH-18  •18:1-7NH-18:1 
Conc. 
(mM) 
κ 
(μS cm-1) 
Conc. 
(mM) 
κ 
(μS cm-1)
Conc. 
(mM) 
κ 
(μS cm-1) 
0 4.23 0 10.87 0 2.01 
0.0020 4.61 0.0033 11.94 0.0033 18.10 
0.0040 5.99 0.0066 12.88 0.0066 33.33 
0.0059 7.04 0.0099 13.98 0.0099 48.54 
0.0079 8.20 0.0132 14.71 0.0132 63.09 
0.0098 9.34 0.0164 15.69 0.0164 77.12 
0.0118 10.55 0.0196 16.29 0.0196 90.83 
0.0137 11.82 0.0228 16.91 0.0228 103.94 
0.0156 12.85 0.0260 17.52 0.0260 116.85 
0.0175 13.79 0.0291 18.19 0.0291 127.27 
0.0194 14.92 0.0323 18.72 0.0323 138.86 
0.0212 16.01 0.0354 19.37 0.0385 162.55 
0.0231 16.86 0.0385 19.94 0.0446 183.67 
0.0268 18.55 0.0415 20.51 0.0506 203.59 
0.0304 20.07 0.0446 21.11 0.0566 222.46 
0.0340 21.27 0.0476 21.78 0.0625 240.41 
0.0375 22.51 0.0506 22.37 0.0683 258.03 
0.0444 24.61 0.0536 22.93 0.0741 274.73 
0.0512 26.51 0.0566 23.46 0.0798 291.46 
0.0578 28.36 0.0596 23.95 0.0854 307.12 
0.0643 30.20 0.0625 24.47 0.0909 322.10 
0.0706 31.74 0.0683 25.26 0.0964 336.85 
  0.0741 26.08 0.1018 351.47 
  0.0798 26.98 0.1071 365.82 
  0.0854 27.77 0.1124 380.01 
  0.0909 28.71  
  0.0964 29.58  
  0.1018 30.40  
  0.1071 31.24  
  0.1124 32.13  
  0.1176 32.89  
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Appendix C: Surface tension data for the gemini surfactants 
Table C: Log C vs. surface tension (γ) data; CMC determination 
•12-7-12 •16-7-16  
log C 
(C: mol L-1) 
γ  
(mN m-1) 
 
 
log C 
(C: mol L-1) 
γ  
(mN m-1) 
-3.88 57.31   -5.40 65.49 
-3.71 54.92   -5.23 60.61 
-3.59 53.17   -5.10 59.87 
-3.49 50.96   -5.01 55.98 
-3.41 49.64   -4.93 54.07 
-3.35 49.01   -4.86 51.85 
-3.30 47.65   -4.81 49.91 
-3.25 46.19   -4.71 48.91 
-3.20 45.36   -4.64 48.33 
-3.17 43.85   -4.57 47.81 
-3.13 43.28   -4.43 46.66 
-3.10 42.97   
-3.07 42.66   
-3.04 42.61   
-3.02 42.81   
-2.99 42.81   
-2.97 42.92   
-2.95 42.81   
-2.86 42.81   
 
 
•16-7NH-16    •18-3-18  
log C 
(C: mol L-1) 
γ  
(mN m-1) 
  log C 
(C: mol L-1) 
γ  
(mN m-1) 
-5.60 64.31   -5.18 60.19 
-5.48 63.18   -5.08 57.47 
-5.31 59.49   -5.00 55.50 
-5.18 56.78   -4.94 53.12 
-5.01 53.07   -4.88 50.85 
-4.89 50.43   -4.79 46.61 
-4.79 48.18   -4.71 42.45 
-4.72 47.60   -4.59 39.26 
-4.65 48.18   -4.49 38.18 
-4.60 47.91   -4.30 37.41 
-4.51 47.65   -4.20 36.55 
    -4.13 34.06 
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Table C (con’t): Log C vs. surface tension (γ) data; CMC determination 
•18-7-18 •18-7NH-18  
log C 
(C: mol L-1) 
γ  
(mN m-1) 
  log C 
(C: mol L-1) 
γ  
(mN m-1) 
-5.70 70.72   -5.78 67.32 
-5.40 65.98   -5.48 60.72 
-5.23 59.12   -5.30 57.89 
-5.10 57.95   -5.18 55.40 
-5.01 54.55   -5.08 52.86 
-4.93 52.38   -5.00 51.27 
-4.86 51.75   -4.94 49.22 
-4.81 51.43   -4.88 46.82 
-4.76 51.17   -4.79 46.61 
-4.71 49.96   -4.71 45.98 
-4.64 49.70   -4.64 45.30 
-4.52 48.33   -4.59 45.25 
-4.43 47.50   -4.54 44.94 
    -4.49 44.58 
    -4.41 44.16 
    -4.35 43.49 
    -4.30 42.92 
 
•18:1-7NH-18:1 
log C 
(C: mol L-1) 
γ  
(mN m-1) 
-4.88 65.71 
-4.71 63.08 
-4.59 57.68 
-4.49 56.35 
-4.41 54.23 
-4.35 53.01 
-4.30 52.59 
-4.25 52.64 
-4.20 52.54 
-4.17 52.28 
-4.13 51.91 
-4.07 52.06 
-4.02 51.80 
-3.97 51.64 
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Appendix D: COS-7 cell transfection and cytotoxicity results (supplemental data) 
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Figure D-I. Luciferase reporter gene expression in COS-7 cells measured as a function 
of the gemini surfactant:DNA charge ratio (i.e., the +/− charge ratio). 
The PGL complexes prepared with variable ρ+/- values including 10:1, 5:1, 2.5:1, 1:1 and 
0.5:1, featured the m-3-m surfactants. The resulting protein produced within the cells 
was quantified at 24 h-post transfection. n = 4, error bars = SD. 
 190 
 
 
0
20
40
60
80
100
120
10
:1
 (3
 n
m
ol
)
5:
1 
(1
.5
 n
m
ol
)
2.
5:
1 
(0
.7
5 
nm
ol
)
1:
1 
(0
.3
 n
m
ol
)
0.
5:
1 
(0
.1
5 
nm
ol
)
%
 V
ia
bl
e
P-12-3-12-L
P-16-3-16-L
P-18-3-18-L
P-18:1-3-18:1-L
 
 
Figure D-2. Dose-dependent toxicities for gemini surfactants in COS-7 cells.  
Cells were transfected with PGL complexes prepared using varying concentration of m-
3-m surfactants (i.e., complexes had values of ρ+/- ranging from 10:1 to 0.5:1. The 
numbers in parentheses next to each ρ+/- value represent the amount of surfactant used 
for preparing complexes based on a uniform plasmid dose of 0.2 µg). Cell viabilities 
were quantified after 24 h of transfection. The figure inset shows the level of 
cytotoxicity or motility in transfected cells (% Mortality = 100 - % cell viability).  n = 4, 
errors bars = SD. 
 
